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Introduction: Despite achieving normal epicardial coronary artery flow after primary 
percutaneous coronary intervention (P-PCI), a significant proportion of patients with acute ST 
elevation myocardial infarction has a poorer outcome because of microvascular coronary damage 
and/or dysfunction. Endothelial dysfunction may play a role in this microvascular coronary 
damage after STEMI, and its evaluation by peripheral arterial tonometry may be useful to predict 
the extent of microvascular coronary damage and the extent of myocardial infarction. 
Objectives: To evaluate the relation of early peripheral endothelial dysfunction, as measured by 
the reactive hyperemia index (RHI, obtained by peripheral arterial tonometry) and the index of 
microcirculatory resistance (IMR) immediately after P-PCI and to access the relation between RHI 
and IMR values and: 1) the extent of myocardial infarct evaluated by contrast enhanced cardiac 
magnetic resonance (ceCMR) and troponin release; 2) the extent of microvascular obstruction 
(MVO), evaluated by ceCMR and by other available indirect indicators; 3) late (3 months) left 
ventricular remodelling, measured by echocardiography. 
Methods: Observational, prospective cohort study. Patients with a first STEMI successfully treated 
with P-PCI, hemodynamically stable and without contra-indications for adenosine administration 
were included. After successful P-PCI, IMR was determined, using a pressure-wire. RHI was 
evaluated acutely and after 24 hours, using EndoPAT; endothelial dysfunction was defined as 
RHI<1.67, and RHI was also analysed by tertiles. Corrected TIMI frame count (cTFC) and TIMI 
myocardial perfusion grade (TMBG) were evaluated at the end of the procedure. Blood tests for 
cardiac biomarkers were collected on admission and on scheduled intervals during the first 48 
hours. ECGs were recorded before and immediately after P-PCI and at 90 and 180 minutes, for ST 
resolution evaluation. Left ventricular global and regional function were evaluated by 
echocardiography at baseline and at 3 months. ceCMR was performed on the 7-8th day post-MI. 
Results: 60 patients were included (48 males, mean age 59.6±12.7 years). In the first acute RHI 
values were higher than expected (mean 2.15±0.58) suggesting important technical pitfalls; no 
relation was found between this acute RHI and any of the infarct extent or microvascular 
obstruction indicators. Mean RHI values measured at 24 hours were 1.87±0.60. Patients with an 
RHI<1.67 on this second evaluation tended to have higher IMR (median 40.5 IQR 54.4 vs. median 
22.0 IQR 26.0, p=0.09), worse ST resolution, worse angiographic (cTFC and TMPG) results and had 
more MVO in the ceCMR (54.1% vs. 11.1%, p=0.03). They also had significantly larger infarcts as 
evaluated by peal TnI (p=0.024) and AUC TnI (p=0.012) and a tendency to have larger infarcts in 
the ceCMR. Left ventricular ejection fraction (LVEF) was lower and wall motion score index (WMSI) 
was higher in the first Echocardiogram in these patients.  IMR median values were 24 (IQR 33). 
IMR strongly correlated with MVO on the ceCMR (r=0.91, p<0.0001; ROC curve 0.723, CI95% 
0.500-0.896, p=0.018). Patients with IMR>24 had significantly worse ST resolution and 
angiographic indicators of microvascular dysfunction. IMR also correlated with infarct mass 
(r=0.70, p<0.001) and salvage mass (r=0.35, p=0.014) in the ceCMR. Patients with IMR>24 had 
significantly higher peak (p=0.013) and AUC (p=0.003) TnI. LVEF improved significantly only in 
patients with IMR<24 (p=0.01). IMR independent predictors were age, glucose and HbA1c.  
Conclusions: RHI measured in the acute phase of STEMI after P-PCI seems to be unfeasible. RHI 
measured 24h after the P-PCI is feasible and predicts infarct size and MVO, confirming endothelial 
dysfunction as an important mechanism in microvascular dysfunction in STEM patients. IMR is 






Introdução: Apesar da normalização do fluxo coronário epicárdico após intervenção coronária 
percutânea primária (ICP-P), uma proporção significativa dos doentes com enfarte agudo do 
miocárdio com elevação do segmento ST (EAMcST) têm piores resultados clínicos devido ao 
desenvolvimento de lesão ou disfunção microvascular coronária. A disfunção endotelial 
provavelmente desempenha um papel nesta lesão microvascular coronária e a sua avaliação por 
tonometria arterial periférica poderá ser útil para prever a extensão da lesão microvascular e a 
extensão do enfarte. 
Objectivos: Avaliar a relação da disfunção endotelial periférica precoce, avaliada pelo índice de 
hiperémia reactiva (IHR, obtido por tonometria arterial periférica) com o índice de resistência da 
microcirculação (IRM), medido imediatamente após a ICP-P e estimar a relação entre o IHR e o 
IRM e, 1) a extensão do enfarte, avaliada por ressonância magnética cardíaca com contraste 
(RMCc) e pela curva de libertação de Troponina I; 2) a extensão da obstrução microvascular 
(OMV), avaliada por RMCc e por outros indicadores indirectos; 3) a remodelagem ventricular 
esquerda tardia (aos 3 meses), avaliada por ecocardiografia. 
Métodos. Estudo observacional, prospectivo, de coorte. Foram incluídos doentes com um 
primeiro EAMcST, tratados com sucesso por ICP-P, hemodinamicamente estáveis e sem contra-
indicações para administração de adenosina. Depois da ICP-P, o IRM foi medido usando um fio de 
pressão. O IHR foi avaliado na fase aguda e novamente 24 horas depois da ICP-P. A disfunção 
endotelial foi definida como um IHR<1,67 e o IHR foi também analisado por tercis. Os indicadores 
angiográficos de reperfusão (contagem corrigida de frames e grau de perfusão miocárdica TIMI) 
foram avaliados no final da ICP-P. Foram colhidas análises na admissão e em horários definidos 
nas primeiras 48 horas para avaliação da Troponina I. Antes, imediatamente após e 90 e 180 
minutos depois da ICP-P foram registados electrocardiogramas, para avaliação da resolução das 
alterações do segmento ST. A função ventricular esquerda global e segmentar foi avaliada por 
ecocardiografia após a ICP-P e aos 3 meses. A RCMc foi efectuada ao 7-8º dia  após o EAMcST. 
Resultados: Foram incluídos 60 doentes (48 homens, idade media 59,6±12,7 anos). Na primeira 
avaliação, os valores de IHR foram muito superiores ao esperado (média 2,15±0,58), 
provavelmente por erros técnicos incontornáveis, não se relacionando com nenhum dos 
indicadores de extensão do enfarte ou de OMV. Na segunda avaliação, às 24h, os valores médios 
de IRH foram 1,87±0,60. Os doentes com IRH <1,67 tiveram tendencialmente valores mais 
elevados de IRM (mediana 40,5 IIQ 54,4 vs. mediana 22,0 IIQ 26,0, p=0,09), pior resolução do 
segmento ST, piores resultados nos indicadores angiográficos de OMV e maior probabilidade de 
ter OMV na RMNc (54,1% vs. 11,1%, p=0,03). Também tiveram enfartes de maior dimensão na 
avaliação pela TnI I máxima (p=0,004) e pela área sob a curva de TnI (p= 0,012). A fracção de 
ejecção do ventrículo esquerdo (FEVE) foi menor e o score de motilidade segmentar (SMS) maior 
nestes doentes. A mediana do IRM foi 24 (IIQ 33). O IRM correlacionou-se fortemente com a OMV 
avaliada na RMNc (r=0.91, p<0.001; curva ROC 0,723, IC95% 0,500-0,896, p=0,018). Nos doentes 
com IRM >24, a resolução do ST foi significativamente menor e os indicadores angiográficos de 
reperfusão foram significativamente piores. O IRM também se correlacionou com a massa de 
enfarte (r=0,70, p<0,001) e a massa de miocárdio salvo (r=0,35, p=0,014) na RMCc. Os doentes 
com IRM>24 tiveram valores significativamente mais elevados de TnI máxima (p=0,013) e ASC de 
TnI (p=0,003). A FEVE melhorou de forma significativa apenas nos doentes com IMR<24 (p=0,01). 
Os preditores independentes do IRH foram a idade, a glicemia na admissão e a HbA1c na admissão.  
Conclusões: Não parece ser possível avaliar de forma fidedigna o IHR na fase aguda do EAMcST 
após ICP-P. O IHR medido 24h após a ICP-P é mensurável de forma adequada e prevê a dimensão 
do enfarte e da OMV, confirmando a disfunção endotelial como um mecanismo importante na 
disfunção microvascular em doentes com EAMcST. O IRM correlaciona-se fortemente com a OMV 























1. The scope of the problem: microcirculatory dysfunction in 
patients with acute STEMI 
  
The interventional cardiologists that perform primary percutaneous coronary interventions have 
a common insecurity when they face a patient with an occluded coronary artery in the setting of 
an acute ST elevation myocardial infarction: what if opening the artery is not enough?  
This anguish can take several forms: either more immediate – like the no-reflow phenomenon, 
the inability to improve patient’s pain or the unexpected absence of ST resolution – or later – like 
unexpected severe left ventricular remodelling or left ventricular dysfunction in the follow-up, 
even after a successful and timely procedure. All these questions and fears seem to have a 
common ground, one we need to understand better in order to further improve STEMI patients 
outcomes: the coronary microcirculation. 
The diagnosis and treatment of acute ST elevation myocardial infarction (STEMI) has undoubtedly 
been the subject of intense investigation over the last decades. As a result, prompt 
implementation of both mechanical (primary percutaneous coronary intervention) and 
pharmacological (adjuvant anti-platelets and anticoagulants) approaches to reopen the occluded 
coronary artery is nowadays universally accepted as the treatment of choice to improve survival 
in STEMI patients.1,2  
Notwithstanding  all the improvements we have seen in primary PCI programs, with dramatic 
reductions in the time between symptom onset and the intervention, and despite a normal 
epicardial coronary artery flow is almost always achieved in a timely fashion after primary 
percutaneous coronary intervention (P-PCI), a significant proportion of patients (from 20% to 60%) 
has a poor outcome because of microvascular coronary damage.3,4 In fact, microvascular perfusion 
is often impaired after P-PCI, and reperfusion of the epicardial coronary artery will not always 
guarantee reperfusion at the myocardial tissue level5.  
The extent of this microvascular coronary dysfunction has been shown to be an important and 
independent contributor to subsequent changes in left ventricular geometry and performance.6,7 
Patients with impaired microvascular perfusion have larger infarcts, as evaluated by CK and 
troponin release, less electrocardiographic ST elevation resolution, larger long-term left 
ventricular wall motion abnormalities and lower left ventricular ejection fraction, and larger 
necrotic areas as evaluated by cardiac magnetic resonance. As a consequence of these, coronary 
microvascular dysfunction is associated with higher event rates, risk of progression to heart failure 
and mortality. 
The precise mechanisms underlying coronary microcirculation dysfunction before and after the 
restoration of epicardial blood flow are largely unknown and likely to be multifactorial. 
Understanding what happens in the microcirculation in the setting of a ST elevation myocardial 
infarction is thus very relevant.  Most research done on this matter, however, has focused on the 
changes occurring on microcirculation after the STEMI and very little is known about the effect of 




The recent development of invasive techniques for the precise evaluation of the coronary 
microcirculation (such as the  resistance – IMR) and of non-invasive methods for the evaluation of 
endothelial dysfunction (such as digital peripheral arterial tonometry - PAT) opens a new window 
of opportunity for the understanding of the pathophysiological processes occurring in coronary 
microvasculature in patients with STEMI.  
I have been deeply involved in the area of functional evaluation of coronary disease in the past 
few years, both locally8–13and at a national14 and international levels15–17 and I am currently 
involved in several trials evaluating new non-hyperaemic technologies for physiological 
assessment of intermediate lesions and/or new clinical indications. Therefore, both I and all the 
Interventional Cardiology Department in which I work are very familiar with the use of pressure-
wire technology, both for clinical and investigational purposes. 
On the other hand, I am also quite familiar with the PAT technology, following the creation of an 
Endothelial Function Laboratory by Prof. Victor Gil. This laboratory has conducted several studies, 
not only in coronary artery disease,18–21, but also in other clinical conditions, like rheumatologic 
diseases22, obesity23–25 or erectile dysfunction26, in which I had the opportunity to collaborate.   
Therefore, using these new invasive (IMR) and non-invasive (EndoPAT®) techniques with the 
intention to improve our understanding of the coronary microcirculation dysfunction in STEMI 
patients was a natural step.  
In the following pages, the evidence that supports this study will be presented, organized in six 
sections:  
 Section 2 is a short description of the normal coronary microcirculation. 
 
 Section 3 presents the changes thought to occur in acute STEMI and the prevailing 
theories on the role of microcirculation, with particular focus on the endothelial function 
and on the gaps in knowledge that led to the current study. 
 
 Section 4 outlines the tools available for evaluating coronary microvascular circulation. 
 
 Section 5 focus on the index of microcirculatory resistance the clinical evidence currently 
available.  
 
 Section 6 is dedicated to describing the tools available for endothelial function evaluation. 
 
 Section 7 further details non-invasive peripheral arterial tonometry (EndoPAT).  








2. The normal coronary microcirculation 
 
2.1. Anatomy and function of the coronary arterial system 
 
The coronary arterial system can be subdivided into three functional compartments: conductive 
vessels, pre-arteriolar vessels and arterioles.27–29 The coronary blood flow is driven by the pressure 
difference between the aortic sinus and the coronary sinus (or the right atrium pressure) across 
these three compartments: 
 Conductive vessels (corresponding to epicardial arteries) are the first compartment and 
in the absence of obstructive stenosis, they offer very little resistance to coronary blood 
flow (even at maximum hyperemia), serving mainly as conductance vessels. 
Approximately 60% of their wall thickness consists of the muscular media, which can 
respond to changes in aortic pressure and modulates coronary tone in response to flow-
mediated endothelium-dependent vasodilators, circulating vasoactive substances and 
neural stimuli.  
 The intermediate compartment is represented by pre-arterioles, which are resistive 
vessels connecting the conductive arteries to the arterioles. They are epicardial (extra-
myocardial) vessels and have a diameter in the range of 200 to 500 μm. These vessels 
react to changes in shear stress and intravascular pressure to preserve adequate perfusion 
pressure in the distal arteriolar bed, being responsible for approximately 25% of the total 
coronary vascular resistance. 
 The distal compartment consists of arterioles. They are smaller than 200 μm in diameter 
and are the main regulatory component of the coronary circulation, representing 
approximately 55% of the total coronary vascular resistance. Arterioles are usually 
subdivided in two categories, according to their diameter and the mechanism(s) that 
regulate their tone30: endothelium-dependent vasoreactivity prevails in the larger 
arterioles (100–200 μm) and translates flow-related stimuli into vasomotor responses, i.e. 
vasodilation with increase in flow and vice versa. Medium-sized microvessels (40–100 μm 
in diameter) react predominantly to intraluminal pressure changes sensed by stretch 
receptors located in vascular smooth muscle cells (myogenic control), i.e. they constrict 
when the intraluminal pressure increases and, conversely, dilate when the pressure 
decreases. Finally, the tone of the smaller arterioles (vessels less than 40 mm in diameter) 
is modulated by the metabolic activity of the myocardium. 
 
The arterioles are responsible for the process of coronary autoregulation31,32: coronary flow is 
regulated independently of the arterial perfusion pressure despite large variations in this 
pressure. Vasodilatation of the smaller arterioles is induced by increased metabolic activity, which 
leads to pressure reduction in the medium-sized microvessels and myogenic dilation, which, in 









Figure 1 – Coronary arterial 
circulation   
Conductive vessels and proximal 
prearterioles are most responsive to flow-
dependent dilation. Distal prearterioles are 
most responsive to changes in intravascular 
pressure (and are mainly responsible for 
autoregulation of coronary blood flow), 
whereas arterioles are most responsive to 
changes in the myocardial concentration of 
metabolites, and are mainly responsible for 
the metabolic regulation of coronary blood 
flow (Adapted from Camici et al33) 
 
 
These mechanisms effectively and efficiently allow the microcirculation to regulate myocardial 
perfusion both at rest and at different levels of myocardial metabolic demand.30 When pressure 
falls to the lower limit of autoregulation, coronary resistance arteries are maximally vasodilated 
by intrinsic stimuli, and flow becomes pressure-dependent, resulting in the onset of 
subendocardial ischemia. Resting coronary blood flow under normal hemodynamic conditions 
averages 0.7 to 1.0 mL/min/g and can increase four to fivefold during vasodilation.34 
 
2.2. Regulation of coronary vascular tone  
 
Coronary blood flow is adjusted to the metabolic needs of the myocardium by at least three 
essential regulators of coronary tone:  
 The metabolic vasodilatory system, through the production of adenosine and 
simultaneous opening of the ATP-dependent K+ channels within the myocardial cells (both 
potent vasodilators) in the presence of an increase in the oxygen consumption and 
metabolic demand35;  
 The neurogenic control system, through adrenergic activation of α-receptors, resulting in 
arteriolar vasoconstriction. Vasoconstriction mediated by α1-receptor acts mainly on the 




regulating the degree of vasoconstriction of the smaller resistance vessels.29 These 
influences are opposed by the vasodilatory effect of vascular β-receptor stimulation and 
metabolic mechanisms. Importantly, cholinergic stimulation, normally vasodilatory 
because it releases nitric oxide, becomes vasoconstrictive when the endothelium is 
damaged (see below). 
 The vascular endothelium, that acts both through vasodilation and vasoconstriction, 
playing a central role in the regulation of vascular tone, since it closely interacts with the 
two other systems involved: 
o Endothelial-dependent vasodilation is mediated by nitric oxide (which is a very 
short-lived vasodilating factor) and by the endothelium-dependent 
hyperpolarizing factor (EDHF), both secreted by healthy endothelial cells in 
response to i) vascular shear forces associated with increased coronary flow36; ii) 
adenosine (acting on endothelial ATP-dependent K+ channels37); iii)  or other 
agonists (e.g. released from platelets or cardiac nerves).  Prostacyclin, or 
prostaglandin I2 (PGI2), is also produced in the coronary endothelium of collateral 
vessels and causes tonic vasodilation. 
o Endothelial-dependent vasoconstriction is mediated by endothelin-1 which 
activates protein kinase C in vascular smooth muscle to produce coronary 
constriction and competes with endothelium-derived relaxing factors. This effect 
is enhanced in diseased atherosclerotic arteries with extensively damaged 
endothelium.38 
 
2.3. The vascular endothelium 
 
The vascular endothelium is a monolayer of cells covering the internal lumen of all blood vessels, 
separating the blood from the vascular wall and organ tissues. The vascular endothelium has 
different functions39:  
 It plays a crucial role in vascular tone and blood flow regulation (as described in the 
previous section);  
 It is an anti-coagulant surface, with an active role on platelet adhesion and aggregation, 
and on thrombosis.40 Under physiological conditions, the endothelium prevents thrombus 
formation through a number of mechanisms: thrombomodulin, protein S, heparin 
sulphate, and tissue factor pathway inhibitor are all endothelium-derived inhibitors of 
coagulation, whereas PGI2, NO, and surface-bound CD39 inhibit platelet aggregation.41 
 It regulates vascular permeability to plasma constituents between blood and tissues42;  
 It contributes to vascular homeostasis and repair.43 
Additionally, the endothelium also actively produces proinflammatory and anti-inflammatory 
molecules, and is the actual target for circulating inflammatory mediators that are synthesized 





3. Coronary microcirculation dysfunction  
 
3.1. Classification and mechanisms of coronary microcirculation dysfunction 
 
Coronary microvascular dysfunction has been widely studied in the last two decades, particularly 
in patients chest pain despite having normal coronary arteriograms (i.e. microvascular angina).   
In an attempt to summarize the mechanisms involved and its clinical translation, Camici and Crea 
proposed44 (and recently reviewed45) a classification for the different clinical types of coronary 
microvascular dysfunction (Table 1). Of the four types of microvascular dysfunction proposed, 
Types 3 (obstructive coronary artery disease) and 4 (iatrogenic) are the ones involved in patients 
with acute ST elevation myocardial infarction.  
The authors also put forward the main pathogenic mechanisms more likely to be involved in these 
types of coronary microvascular dysfunction (luminal obstruction by thrombotic debris, 
endothelial dysfunction, smooth muscular cell dysfunction and autonomic dysfunction).  
 
Table 1 – Classification of coronary microvascular dysfunction 
 Clinical Setting Main pathogenic mechanisms 
Type 1: In the absence of 


















Type 3: In obstructive CAD 
Stable angina 




Type 4: Iatrogenic 
PCI 
Coronary artery grafting 
Luminal obstruction 
Autonomic dysfunction 
Adapted from Camici and Crea.45 CAD: coronary artery disease; SMC: smooth muscle cells; PCI: percutaneous coronary intervention 
 
However, the exact role of each of the abovementioned mechanisms is difficult to identify, 
particularly in pathogenic processes. In fact, a substantial number of hypotheses for the 
pathophysiology of coronary microvascular dysfunction has  been proposed in the literature44,46 
including: 
 Structural changes:  
o Luminal obstruction, caused by microembolization in acute coronary syndromes 




o Vascular wall infiltration (e.g. in infiltrative diseases, like Anderson-Fabry 
cardiomyopathy) 
o Altered microvascular remodelling, through sclerosis of small arteries and 
arterioles with perivascular fibrosis, swollen endothelial nuclei in capillaries, and 
irregular lumina of small arteries.47 
o Vascular rarefaction and perivascular fibrosis (e.g. in aortic stenosis and arterial 
hypertension). 
 Functional changes: 
o Endothelial dysfunction, including the release of substances with opposing effects 
(such as endothelin, thromboxane A2, prostaglandin H2, and superoxide) and 
resulting in a shift from a net dilator response to a net constrictor response to a 
variety of stimuli. Endothelial dysfunction also involves a switch from a quiescent 
to an activated state promoting inflammatory responses, chemokine and 
adhesion molecule expression, and subsequent interaction with platelets and 
leukocytes.48 
o Smooth muscle dysfunction, as showed by a reduced coronary blood flow 
response to endothelium-independent vasodilators (e.g. adenosine, 
dipyridamole, papaverine) in patients with microvascular angina.49 
o Microvascular spasm and sympathetic dysfunction, mediated via both α1 and α2-
adrenoceptors in epicardial conduit arteries and microvessels50,51, e.g. after 
coronary revascularization. 
 Extravascular factors 
o Extramural compression (aortic stenosis, hypertrophic cardiomyopathy, arterial 
hypertension) 
o Reduction in diastolic perfusion time (aortic stenosis). 
However, these mechanisms could not be critically tested, establishing clear and accepted 
pathophysiological concepts. In fact, there is no adequate information on the relevance of 
individual mechanisms in general, let alone in individual patients. As such, the stratification of 
individual patients and the rational development of targeted strategies is underdeveloped, as 
recently acknowledged in the 2015 William Harvey Lecture on Basic Science at the European 
Society of Cardiology Congress in London46, dedicated to coronary microvascular dysfunction. 
  
3.2. Coronary microcirculation dysfunction in STEMI 
 
Despite the fact that primary PCI is highly successful in restoring epicardial coronary blood flow, 
when performed in a timely fashion, reperfusion at the myocardial level is not accomplished in a 
significant proportion of patients (from 20 to 60%, depending on the technique used for its 
evaluation5). The negative prognostic implications (both on the risk of left ventricle remodelling 
and on the risk of hard endpoints, including death) associated with coronary microvascular 
damage have been repeatedly confirmed, whatever non-invasive or invasive indicator of 




Table 2 – Main studies showing the prognostic impact of coronary microcirculation 
dysfunction on adverse remodelling and mortality after primary PCI 
Author,  
Year of publication 





Risk of adverse remodelling   
   Bax et al, 200452 Doppler-wire CFR 73 OR 0.28 (0.14-0.41) 
   Araszkiewicz  et al, 200653 TIMI myocardial perfusion grade 145 OR 3.15, 95% CI 1.35-7.31 
   Galiuto et al, 200854 Myocardial contrast Echo 110 OR 12.7, 95% CI 2.65-61.2 
   Lombardo et al, 201255 ceCMR 36 OR 3.1 95% CI 1.45-6.64 
   Faustino et al, 201656 Index of microcirculatory resistance 40 HR 0.562, P<0.002 
Risk of death   
   Van´t Hoof. 199857 TIMI myocardial perfusion grade 777 OR 2.6 95% IC 1.2-5.4 
   Morishima et al, 200058 TIMI flow 0 (no reflow) 120 OR 5.3, 95% CI 1.90-15 
   Yamamuro et al, 200259 Coronary flow velocity 169 HR 12.8, p<0.001 
   Henriques et al, 200360 TIMI myocardial perfusion grade 924 OR 4.7, 95% CI 2.3-9.5 
   Bolognese et al, 20047 Myocardial contrast Echo 124 OR 0.26, 95% CI 0.09-0.72 
   Sorajja et al, 20054 ECG 456 OR 7.1, 95% CI 1.52-33.3 
   Ndrepepa et al, 201061 TIMI flow 1406 OR 1.66, 95% CI 1.17-2.36 
   De Waha et al, 201062 ceCMR 438 OR 5.12 95% CI 1.09-24.06 
   Van de Hoef et al, 201363 Doppler-wire CFR 100 OR 4.09 95% CI 1.18-14.17 
   Fearon et al, 201364 Index of microvascular resistance 253 OR 3.95 95% CI 1.26-15.00  
CFR: coronary flow reserve; ceCMR: contrast-enhanced cardiac magnetic resonance;  
 
In spite of this, if evidence is weak and mainly theoretical in stable disease, the exact role and 
mechanisms of coronary microvascular dysfunction is even less clear in patients with acute 
coronary syndromes, and particularly in patients with acute ST elevation myocardial infarction.   
Traditionally, coronary microvascular dysfunction in this setting is seen as a consequence of the 
primary epicardial event and/or of the coronary reperfusion, either pharmacological 
(thrombolysis) or mechanical (primary PCI). However, an alternative explanation is that either pre-
existing or simultaneous coronary microvascular dysfunction may have by itself 
pathophysiological importance and contribute to the extension of the myocardial infarction, left 
ventricular remodelling and future events.65  
 
3.2.1. The “classical theory” – coronary microvascular dysfunction as a secondary 
phenomenon  
 
The classical theory, which assumes that coronary microvascular dysfunction is a 
consequence of myocardial infarction, has been the prevailing one in past decades. It is based 
on the hypothesis that ST elevation myocardial infarction is primarily a large epicardial vessel 
event, as a consequence of a plaque rupture, leading to thrombus formation and subsequent 
complete occlusion of the vessel.66 
This hypothesis was widely accepted, since it offered an explanation for the surprising 




acute infarction.67 According to this view, the coronary microcirculation is just an “innocent 
bystander” in the acute phase of the acute STEMI, becoming dysfunctional as a result of the 
occlusive event.65  
Several mechanisms were hypothesized for this secondary impairment of the coronary 
microcirculation in STEMI patients (in line with the classification described in Section 3.1 of 
this Introduction) and three are generally accepted as the most relevant: mechanical 
obstruction, endothelial dysfunction and reperfusion injury. 
1. Mechanical obstruction, by distal embolization of atherothrombotic debris, is the 
mechanism that seems more intuitive – frequently it is even visualized during primary 
PCI.  It was initially proposed based on animal studies with microspheres, injected in the 
coronaries and resulting in myocardial infarction.68 Clinically, this phenomenon was 
confirmed in autopsy studies in patients with unstable angina (in which intermittent 
fragmentation of thrombi, with peripheral embolization causing microembolic occlusion 
of small intramyocardial arteries associated with microinfarcts, was documented in 73% 
of cases69) and in patients who died after balloon angioplasty or thrombolysis 
(microemboli were observed in 81% of patients, and were associated with infarct 
extension, new myocardial infarction or new ECG abnormalities70). Iatrogenic 
embolization during primary PCI was also the hypothesis for the observed impairment in 
coronary microcirculation (assessed by correct TIMI frame count) in a study performed 
in STEMI patients evaluated by IVUS both before and after angioplasty with stent. In this 
study, the investigators showed that the decrease in plaque volume (assessed by IVUS) 
was significantly larger in patients with inadequate flow than in those with better 
reflow.71 More recently, in patients with STEMI treated by primary PCI, it was showed 
that distal embolization, confirmed visually by the operator, was associated with larger 
infarct size and more frequent transmural necrosis, evaluated by contrast enhanced 
CMR. These patients also had more often microvascular obstruction, as evaluated by 
first-pass enhancement ceCMR.72  
 
However, despite all this evidence and the easy-to-understand logic behind it, the clinical 
results with protection, thrombectomy and/or aspiration devices have been 
disappointing, as showed both by recent meta-analyses of randomized trials73,74 and by 
large registries.75 Currently, these devices are not recommended as routine treatment in 
patients with acute ST elevation myocardial infarction.1,2,76,77 Still, it must be acknowledge 
that the fact that these devices failed does not mean that distal embolization did not 
occur:  it may be that a significant amount of distal embolization occured before any type 
of medical or procedural intervention, yielding the myocardial microcirculation 
dysfunction and thereby limiting the therapeutic potential of these procedures.65  
 
2. Endothelial dysfunction, as described above, seems to be involved in microvascular 
dysfunction through several pathways in acute coronary patients. Thromboembolic distal 
embolization by itself results in release of vasoactive factors, but the coronary plaques 
also have the same potential, even without promoting distal mechanical obstruction. In 
fact, vasoactive factors, like endothelin-178–80 and tissue factor81, both potent 




experimental model in rat it was shown that rupture of atherosclerotic lesions induced 
rapid and marked increases in distal vascular resistance, without significant distal 
embolization.82 Accordingly, increased microcirculatory resistance has been 
demonstrated in patients with unstable angina83 and after balloon angioplasty of 
thrombotic lesions.84  Additionally, oxidative stress and ischemia per se may reduce the 
bioavailability of nitric oxide, further contributing to microvascular dysfunction.65 
 
3. Reperfusion injury is a controversial entity65,85, mainly because the experimental data 
that support its concept failed to prove in the clinical setting. Basically, it translates the 
pathological deleterious events that may occur as a result of the restoration of coronary 
flow, including changes in myocardial contractile performance (myocardial stunning), 
myocyte viability (infarction extension), arrhythmogenic threshold (reperfusion 
arrhythmias) and, again, endothelial function (vascular stunning).65,86 A number of 
pathophysiologic mechanisms have been postulated, including histological evidence of 
platelet and leukocyte accumulation and activation in the myocardial microcirculation, 
leading to thrombosis, vasoconstriction and release of free oxygen radicals, proteases, 
and pro-inflammatory mediators; as a consequence, there may be a reduction in nitric 
oxide bioavailability and activation of endothelin and of the local renin-angiotensin 
system. Additionally, complement activation leads to the release of histamine and to an 
increase in cell permeability, resulting in endothelial cell and myocyte swelling, 
interstitial oedema, and further stimulation of leukocyte adherence.65 
However, this evidence was obtained in experimental models, and the pharmacological 
interventions developed based on these results (including calcium channel blockers, 
glycoprotein IIb/IIIa inhibitors, nicorandil and anti-neutrophils antibodies) all failed to 
improve clinical results in patients.5,65,87 The only possible exception is adenosine, which 
showed promising results in some trials, despite failing in others.88,89 
 
The main limitation of this view of coronary microvascular dysfunction as a consequence of 
the myocardial infarction relates to the fact that the studies that support it were not designed 
to evaluate if the abnormalities were already present before or during the myocardial 
infarction, as opposed to after the event. Additionally, the plaque rupture theory has been 
challenged in recent years, with the finding that plaque rupture is much more common than 
previously thought and that most plaque ruptures remain clinically silent. The best evidence 
on this comes from the PROSPECT trial, in which 697 patients with acute coronary syndromes 
underwent three-vessel coronary angiography and intravascular ultrasonographic imaging 
(IVUS) after percutaneous coronary intervention. Subsequent major adverse cardiovascular 
events, over a median follow-up time of 3.4 years, were found to be equally attributable to 
recurrence at the site of culprit lesions and to nonculprit lesions.90 Additionally, in a substudy 
of PROSPECT including only nonculprit ruptured plaques (seen in 14% of patients with ACS), 







3.2.2. Primary coronary microvascular dysfunction in STEMI 
 
While systemic factors such as thrombotic-fibrinolytic balance and local factors such as 
collateral blood flow have to be taken into consideration, it is reasonable to propose the 
myocardial microcirculation as a potential modulating factor in patients with ST elevation 
myocardial infarction, assuming the presence not only of the vulnerable plaque but also of 
the vulnerable myocardium and its microcirculation65.  
If this is the case, we would expect coronary microvascular dysfunction to be present not only 
in the culprit artery, but also in other arteries not involved in the infarction. This was exactly 
what Uren and colleagues found in 13 patients with STEMI in which they performed positron 
emission tomography in the first week: coronary flow reserve was found to be decreased not 
only in the culprit, but also in non-culprit arteries.92 More recently, the same result was found 
in a larger cohort (n=100) of STEMI patients, in which coronary flow reserve was measured 
both in the culprit artery and in one reference vessel not related with the infarction, using a 
Doppler wire. The authors found that a reduced CFR in the non-culprit artery was related with 
worse outcomes after 10 years of follow-up, with a significant increase in total mortality 
(hazard ratio, 4.09; 95% confidence interval, 1.18–14.17; P=0.03).63 Similar results were also 
found in several studies in patients with angiographically normal or minimally diseased 
coronary arteries, in which lower CFR values (measured with a Doppler wire) were related to 
an increase in long-term events.93,94  
The presence of endothelial coronary dysfunction (as measured by the flow response to 
intracoronary infusion of acetylcholine) was also a predictor of events in patients without 
evidence of epicardial coronary lesions.95 Taken together, this evidence clearly suggest that 
the presence of myocardial microcirculatory dysfunction is a strong predictor of clinical 
outcome, including future acute coronary events (particularly myocardial infarction), even in 
the absence of hemodynamically significant epicardial disease. In other words, this data 
argue against microvascular coronary dysfunction as just a secondary phenomenon, 
suggesting that it may also play a role before and during events. 
Further data suggesting that there may be a coronary microvascular “milieu” that exposes 
patients to a higher risk of events comes from the studies linking inflammation and coronary 
artery disease.  In fact, widespread activation of neutrophils across the coronary vascular bed 
has been reported in patients with unstable angina, regardless of the location of the culprit 
stenosis.96 Additionally, C-reactive protein serum concentration has been identified as an 
independent predictor of a blunted coronary blood flow response to adenosine 
(endothelium-independent) and substance P (endothelium-dependent), in patients 
undergoing elective PCI97. Similarly, in patients with normal coronary angiograms, a 
significant inverse correlation was noted between C-reactive protein concentrations and 
myocardial blood flow responses to cold pressor testing by 13 N-ammonia and PET imaging98.  
However, the strongest data in favour of the primary coronary microvascular dysfunction 




known to improve microvascular function.99,100 In fact, several trials showed that previous 
treatment with statins:  
 Reduces the incidence and extent of myocardial injury in patients referred for elective 
PCI101; 
 Significantly reduces (by 74%) the incidence of no-reflow in STEMI patients treated 
with primary PCI102;  
 Reduces (by 20%) the risk of developing ST-segment elevation or evolving to full acute 
myocardial infarction in ACS patients103; 
 Improves clinical outcomes in patients with ACS, an effect that is completely abrogated 
if statins are prematurely discontinued after the onset of symptoms104. 
Taken together, this data suggest that a pre-existing transient or permanent microcirculation 
dysfunction may contribute to the development and prognosis of ACS, via reduction of 
coronary blood flow, leading to an alteration of shear stress and thereby aggravation of 
endothelial function on epicardial level as well as aggravation of thrombus formation.65 In 
this view, microvascular impairment and the consequent reduction of flow would be the 
primary factor and intracoronary thrombi would then develop after the onset of myocardial 
ischemia, as defended by William Roberts in his famous editorial published in 1974 in 
Circulation105, in which he stated that “coronary thrombosis is a consequence rather than the 
precipitating cause of acute myocardial infarction”.  
In summary, as Amir Lerman elegantly stated in his landmark paper “Microcirculatory dysfunction 
in ST-elevation myocardial infarction: cause, consequence, or both?”, while, with the available 
evidence, we cannot confirm which of these two theories is more correct, and assuming that both 
may be right to some extent, “if indeed microcirculatory dysfunction is ever demonstrated to be 
one of the major contributors to the evolution and not just the consequence of an acute myocardial 
infarction, this could substantially alter future research directions and approaches to therapy”.65 
 
3.3. Endothelial function: a core player throughout the continuum of coronary 
artery disease 
 
Whatever theory concerning microvascular coronary dysfunction in patients with ST elevation 
myocardial infarction is correct (cause, consequence or both), endothelial function seems to be 
always at the core of the proposed mechanisms.  
Indeed, as described in the previous sections, endothelial function plays a central role in 
microcirculation tone and blood flow regulation, thrombosis and coagulation, inflammation and 
vascular permeability, haemostasis and repair. Thus, it is not surprising to see current evidence 
suggesting that endothelial dysfunction occurs early in the process of atherogenesis and 
contributes to the formation, progression, and complications of the atherosclerotic plaque106: 
 In the early stage of atherosclerosis, several studies have shown that patients with 




dysfunction107–109 and that this endothelial dysfunction is an independent predictor of future 
cardiovascular events.110,111 In fact, endothelial dysfunction has been reported in relation 
with most risk factors for atherosclerosis, including hypertension112, diabetes113, 
hyperlipidaemia114, and ageing.115,116 However, the presence of endothelial dysfunction 
appears to have an incremental prognostic value, after control for these classical risk 
factors117–120, which may be explained by the fact that it reflects the overall burden of risk, 
including other so far unknown factors121.  
Conversely, as endothelial function is associated with risk factors, the absence of endothelial 
dysfunction appears to predict a particularly favourable state.122  
These observations strongly suggest that endothelial dysfunction is a common mechanistic 
link between risk factors and the development of atherosclerosis.123 Interestingly, endothelial 
dysfunction itself can cause myocardial ischemia, even in the absence of relevant coronary 
stenosis.124 
 
 In patients with established stable coronary artery disease, endothelial dysfunction, either 
measured in the coronary arteries by acetylcholine infusion125, or evaluated peripherally126, 
was associated with a worse prognosis.  
Even in patients with mild or non-obstructive coronary artery disease, the presence of 
endothelial dysfunction was independently associated with adverse cardiovascular events, in 
several studies performed with different methods.95,127–129 
 
 Finally, in patients with acute coronary syndromes, endothelial function, measured in the 
peripheral circulation, has been shown to be an independent predictor of events130, and 
subsequent normalization of endothelial function in these patients predicts a lower risk.131,132  
Similarly, in patients with ST elevation myocardial infarction treated with primary 
angioplasty, peripheral endothelial dysfunction was associated with larger infarctions as 
measured by troponin peak levels18 and endothelial function improvement six months after 
the event also correlated with lower end-diastolic left ventricular volumes.133  
 
Importantly, in most studies performed in all phases of the atherosclerotic process (risk factors -> 
stable disease -> acute coronary syndromes), endothelial function was evaluated peripherally by 
non-invasive techniques (see Section 6), as a surrogate for coronary endothelial dysfunction. In 
fact, endothelial dysfunction appears to be a systemic vascular process that not only mediates the 
development of the atherosclerotic plaque but may also modulate its clinical course.  
 
4. Methods for the evaluation of microcirculation in patients 
with acute ST elevation myocardial infarction 
 
Currently, no technique allows direct visualization of the coronary microcirculation in vivo in 
humans.  However, since coronary microcirculation dysfunction may result from functional and 
not necessarily structural abnormalities (or represents a combination of both mechanisms), even 




in humans in vivo, it would still be an incomplete evaluation. Therefore, microcirculatory function 
is indirectly assessed using several invasive and noninvasive techniques that enable the 
measurement of parameters that (under normal circumstances) are strongly dependent on the 
functional integrity of the coronary microcirculation.  
Consistent with its primary hemodynamic function, functional techniques for the assessment of 
the coronary microvasculature rely on the measurement of coronary blood flow, which changes 
mainly as a result of alterations in vascular tone. Although there are several imaging techniques 
that allow estimating coronary blood flow, at present, the most definite evaluation of the coronary 
microcirculation remains invasive. 
In the following pages, the most used invasive and non-invasive techniques for the evaluation of 
microvascular coronary circulation in patients with acute ST elevation myocardial infarction are 
described in short. The index of microcirculatory resistance, used in this study, will be detailed in 
Section 5.   
 
4.1. Non-invasive methods  
 
4.1.1. ECG ST resolution 
 
ECG ST-segment resolution is a simple, cheap and validated tool to evaluate acutely 
microvascular perfusion134 and has been used for several years in fibrinolysis and primary 
angioplasty trials.3,4  
After primary PCI, incomplete ST resolution has been related to coronary microvascular 
obstruction and worse clinical outcome.135 Different methods have focused on the 
assessment of multiple leads or single leads showing maximum ST elevation at baseline and 
a consensus is still lacking about which leads to analyse, the optimal timing of 
electrocardiogram analysis, and whether standard ECG or continuous ECG monitoring is 
preferable.  
Assessment of single lead ST resolution showing maximum ST elevation at baseline seems to 
be as accurate as the sum of ST resolution measurements.136,137  
Additionally, residual ST-segment elevation was found to be an independent marker of 








4.1.2. Imaging techniques 
 
Positron emission tomography (PET) is a well-established non-invasive technique for the 
assessment of coronary blood flow140,141, as it allows the determination of absolute regional 
myocardial blood flow at rest and in response to various stimuli. Myocardial blood flow 
measurement using PET is achieved by continuous monitoring of the radioactivity emitted by 
an intravenously administered tracer, in the circulation and the myocardium. The kinetics of 
radiotracer uptake in the myocardium are derived from time-activity curves in the left 
ventricular cavity and the myocardium; fitting these time-activity curves with an operational 
equation provides accurate estimates of myocardial blood flow. Importantly, however, it may 
lack sensitivity and specificity for the diagnosis of coronary vasomotor dysfunction and, in 
general, is unable to differentiate between epicardial and microvascular abnormalities.142  
 
Myocardial contrast echocardiography (MCE) uses ultrasound to visualize contrast 
microbubbles with a rheology similar to that of red blood cells that freely flow within patent 
microcirculation while lack of intra-myocardial contrast opacification is due to microvascular 
obstruction that predicts functional recovery after STEMI.54 It has proven to be a useful tool 
for identifying patients with the no-reflow phenomenon after interventional or thrombolytic 
treatment for STEMI.54,143–145 However, it has several limitations: moderate spatial resolution, 
operator dependency, and incomplete left ventricular coverage with suboptimal visualization 
of the lateral wall, and semi-quantitative assessment of coronary microvascular obstruction. 
 
Contrast enhanced cardiac magnetic resonance (ceCMR) allows multislice imaging with high 
tissue contrast and high spatial resolution, enabling accurate quantification of coronary 
microvascular dysfunction and obstruction, and infarct size. Coronary microvascular 
dysfunction and obstruction appear as an absence of gadolinium enhancement during first 
pass and lack of gadolinium enhancement within a necrotic region (late gadolinium hyper-
enhancement). Coronary microvascular obstruction evaluated by ceCMR correlates with 
MCE, and other angiographic and invasive indexes146 and is an independent predictor of 
adverse clinical outcome, alone or adjusted by other factors, such as infarct size and left 
ventricular ejection fraction.62,147–150 
 
Other imaging modalities, including CT-derived coronary flow reserve and hybrid positron 
emission tomography-computed tomography are still mainly investigational and have not 
been widely used in STEMI patients.  
Finally, periungueal capillaroscopy is a simple and reliable non-invasive technique allowing 
evaluation of cutaneous microcirculation. However, it has been used mainly in patients with 
Raynaud’s phenomenon and in patients with connective tissue diseases, and there is no 





4.2. Invasive methods  
 
4.2.1. Angiographic indexes 
 
Invasive TIMI flow, TIMI frame count and TIMI myocardial perfusion grade have all been 
proposed in the evaluation of microcirculation after acute ST elevation myocardial infarction. 
 The thrombolysis in myocardial infarction (TIMI) score grading system describes the 
rate of blood flow in the epicardial vessels, ranging between no flow at all (Grade 0) 
to a normal flow rate (Grade 3)152,153 (for more details, see Population and Methods, 
Section 3.4.1 - TIMI flow grade, page 89). TIMI flow <3 is a marker of both coronary 
microvascular obstruction and of larger infarct size and has been shown to affect 
prognosis both at short and long-term follow-up.58 However, the value of this index 
is limited, since coronary microvascular obstruction may occur in nearly 35% of 
patients with TIMI 3 flow.146 
 
 The corrected TIMI frame count (cTFC) index corresponds to the number of frames 
required for contrast medium to reach a standardized distal landmark (see 
Population and Methods, Section 3.4.2 - Corrected TIMI frame count, page 89). It 
further stratifies the prognosis of patients with TIMI flow 3 and correlates with 
invasive assessment of coronary flow reserve.154 
 
 The TIMI myocardial perfusion grade (TMPG) and the myocardial blush grade 
(MBG), assess the intensity of the radio-opacity of myocardial tissue after an 
epicardial coronary injection of contrast medium (MBG), as well as its wash-out rate 
(TMPG). An intense myocardial blush and fast wash-out of contrast medium indicate 
optimal microvascular reperfusion.60,155 Both are scored on a scale of 0–3, the latter 
indicating optimal perfusion (see Population and Methods, Section 3.4.3 - TIMI 
myocardial perfusion grade (TMPG), page 90). A MPG grade 0–1 can be observed in 
up to 50% of patients with TIMI flow grade 3.57  
Using both TIMI flow and TIMI myocardial perfusion grade156, coronary microvascular 
obstruction can be defined as a TIMI flow grade <3 or a TIMI flow grade 3 with a TMPG/MPG 
0 to 1. 
 
4.2.2. Doppler wire-derived coronary blood flow reserve  
 
Coronary flow reserve (CFR) represents the extent to which the coronary circulation can 
increase myocardial blood flow in response to exercise or a hyperaemic stimulus. It is 




assumes that maximal vasodilatation is achieved by abolishing coronary vasomotor tone, by 
intravenous administration of endothelium-independent vasodilators (mostly adenosine).  
CFR evaluates simultaneously the epicardial and microcirculatory compartments of the 
coronary tree, although, theoretically, in the absence of epicardial vessel disease CFR reflects 
microvascular function.157 
Invasive evaluation of CFR was first performed with a Doppler guidewire, positioned into the 
distal part of the coronary artery. With the sensor at the tip of this wire, coronary flow 
velocity at rest and during hyperaemia can be measured, and the ratio of maximum to 
baseline coronary flow velocity can be calculated.158  
However, this technique has several problems, including frequent guidewire positional 
changes (motion of the patient, or breathing), which disturbs the Doppler signal and limit the 
feasibility of the procedure to less than 70% of all arteries.159  Other technical pitfalls that can 
hamper signal acquisition include obstruction of the guiding catheter, inaccurate calibration, 
turbulent flow, and signal loss.160 
Still, in patients with ST elevation myocardial infarction, CRF evaluated with a Doppler wire 
was shown as a good prognostic marker for LV function recovery after anterior myocardial 
infarction treated with primary PCI.52,161 More recently, the prognostic value of microvascular 
function as determined using Doppler wire for predicting long-term cardiac mortality was 
assessed in both infarct-related and reference coronary arteries in patients immediately after 
primary PCI for ST-segment elevation myocardial infarction. During follow-up (median 11 
years), a CFR <2.1 in a reference vessel was associated with a fourfold increased risk of long-
term cardiac mortality, whereas a target-vessel CFR <1.5 was associated with an increase in 
short-term (but not long-term) risk of cardiac mortality.63 
 
4.2.3. Pressure wire-derived coronary blood flow reserve  
 
In an attempt to overcome the limitations of the Doppler wire, thermodilution-derived CFR 
was introduced. For this technique, a pressure wire is used to measure temperatures, and 
CFR is calculated using the principle of thermodilution: by giving short manual injections of 3 
cc saline at room temperature into the coronary artery, thermodilution curves are generated 
and mean transit times at hyperemia and baseline can be calculated. Because coronary flow 
is inversely proportional to the mean transit time of a bolus of cold saline needed to travel 
down the coronary artery, CFR can be easily calculated using the ratio of mean transit times.  
With this technique, successful measurement of CFR can be performed in 95% of patients.159 
CRF measurements performed this way correlated well with standard CFR, both in 
experimental model and in humans.158,162  
However, CFR (measured both by Doppler-wire or pressure-wire) varies with age and sex in 
healthy humans163,164, making it impossible to define a clear cut-off value below which 




under resting conditions is dependent on determinants of myocardial oxygen demand 
(namely heart rate, contractility and ventricular load) and CFR being the ratio of peak 
hyperaemic-to-resting flow, it is therefore affected by these same determinants, a fact that 
can also affect the reproducibility of the ratio.165 
CFR it is also significantly influenced by epicardial vessel disease and thus does not distinguish 
epicardial from microcirculatory disease.158 For all these reasons, CFR alone is not a good tool 
for evaluating the microcirculation in ST elevation myocardial infarction patients.  
 
4.2.4. Index of microcirculatory resistance 
 
To overcome the limitations of CFR and allow for the isolated evaluation of the 
microcirculatory coronary compartment, a new index, the index of microcirculatory 
resistance (IMR) was developed.166 The IMR is based on the assumption that microvascular 
resistance (that provides an independent assessment of microcirculatory function) can be 
calculated by dividing the distal coronary pressure by absolute coronary flow. According to 
the methodology previously described for CFR, IMR can be calculated as the distal coronary 
pressure divided by the inverse of the hyperaemic mean transit time (a correlate to absolute 
flow), measured simultaneously with the coronary pressure wire. 
The fundaments, methodology and clinical evidence for this technique will be further 
developed in Section 5.  
 
4.2.5. Doppler and Pressure combined indexes – hyperaemic  microvascular 
resistance index (hMR) and zero-flow pressure (Pzf) 
 
Recently, a single dual sensor wire (Doppler and pressure) was made available (Combo Wire, 
Volcano Therapeutics), allowing for the simultaneous measurement of phasic distal pressure 
and flow velocity.  With this wire and dedicated software, and using measurements 
performed at baseline and at hyperaemia induced by adenosine, both hMR (defined as the 
ratio of average coronary distal pressure and average instantaneous peak velocity during 
hyperaemia) and Pzf (which is the distal coronary pressure when theoretically the flow in a 
coronary artery would cease; since it is not possible to measure this directly, as in vivo 
coronary flow does not cease under normal circumstances, Pzf is extrapolated from pressure-
velocity loops167) can be measured.  
The reproducibility of repeated hyperaemic resistance parameters derived from distal 
pressure and velocity measurements was confirmed in patients with stable angina.168 In 
patients with acute STEMI, a few studies were performed, with promising results: In 2003, 
Shimada and colleagues169 studied Pzf using a Doppler wire and assessing arterial pressure 




that Pzf correlated with viability evaluated by PET. In 2007, it was confirmed that Pzf values 
are increased after myocardial infarction.170 More recently hMR, Pzf, and Doppler coronary 
flow reserve were measured with the combo Doppler-pressure wire in patients after anterior 
STEMI. All measures correlated with peak creatinine kinase-myocardial and CMR measures 
of infarct size, and Pzf was found to be higher in those with >75% infarct transmurality.171 In 
2015, hMR and Pzf were found to be related to microvascular injury (assessed by ceCMR) and 
myocardial perfusion (evaluated with PET).172 In the same year, another study compared Pzf, 
hMR and IMR, and suggested that the former was a better predictor of the extent of 
myocardial infarction (assessed with ceCMR) than the latter two.173 There is only one study 
reporting clinical outcomes in STEMI patients treated with primary PCI, and it also confirmed 
hMR as a strong predictor of a combined endpoint of death and hospital admission for heart 
failure.174 However, unlike other wire-based techniques, hMR and Pzf have not been 
validated in animal or human models. Furthermore, there are concerns that hMR 
measurement may not be accurate in patients with severe epicardial stenosis, since it does 
not account for collateral flow (and hence may lead to an overestimation of true 
microvascular resistance in the presence of a severe stenosis).  
 
5. The index of microcirculatory resistance (IMR) 
 
5.1. Definition and evaluation of IMR 
 
The IMR is a measurement of the minimum achievable microcirculatory resistance in a target 
coronary artery territory and thus it provides a quantitative assessment of the microvascular 
integrity. Unlike CFR, which provides a combined assessment of both the epicardial and the 
microvascular beds, IMR enables a specific quantitative assessment of the status of the 
microvascular coronary circulation (Figure 2).  
 
Figure 2 – Schematic of physiological assessment (FFR, CFR and IMR) using a coronary pressure 

















IMR measurement was made possible by the development of a wire with both pressure and 
temperature sensors on its tip.158,175 The distal sensor of the wire measures pressure and 
temperature and the shaft of the wire can be used as a second thermistor.  
By injecting room-temperature saline down a coronary artery, an indicator-dilution curve is 
obtained (according to the decrease in temperature) and the mean transit time (𝑻𝒎𝒏) can be 
determined. 𝑻𝒎𝒏 has been shown to strongly correlate inversely with absolute flow and 
therefore provides an easily measurable surrogate, both in vitro, in animal models158 and in 
humans.162 
According to Ohm’s law, the resistance (𝑹) in a given circuit is related to the pressure gradient 





In the coronary microcirculation, the pressure gradient (∆𝑷) is determined by distal pressure 
(distally in the epicardial vessel) minus venous pressure; at maximal hyperaemia, however, venous 
pressure can be assumed to be zero, implying that ∆𝑷 approximates distal pressure (Pd), 
measured with the pressure-wire.  
Similarly, at maximal hyperemia, absolute flow (𝑸) has been shown to have a linear relationship 
with the inverse of flow velocity (𝟏 𝑻𝒎𝒏⁄ ). Therefore, the microcirculation resistance can be 
derived from the simplified formula176:  




Or, to make it even simpler, 
𝑰𝑴𝑹 = 𝑷𝒅 ∗  𝑻𝒎𝒏 
 
Importantly, IMR is derived from the assumption that, at peak hyperaemia, the variability of 
resting vascular tone and hemodynamic will be eliminated, and the minimum microvascular 
resistance will be achieved.  
In the presence of a severe epicardial stenosis, myocardial flow is the composite of both the 
coronary and collateral flows. Accordingly, distal coronary pressure decreases to a lesser degree, 
given the contribution of collaterals – this in turn will produce an overestimation of IMR if not 
corrected for collateral flow. Therefore, to calculate the true IMR (IMRtrue) in this setting, a more 
complex formula has been developed, which includes measurement of the coronary wedge 
pressure as a measure of collateral pressure.177 However, in the absence of significant collateral 
flow, it is reasonable to use IMR as a surrogate for IMRtrue, avoiding the measurement of coronary 
wedge pressure.  
IMR evaluation was validated in animals and showed a strong correlation with true microvascular 




pressure and flow drop in the presence of an epicardial stenosis).166 This was also validated in 
humans.177,178  
Despite the relatively complex theoretical background, IMR is easy to evaluate and a very 
reproducible measurement.179 A dedicated console, equipped with dedicated software for IMR 
evaluation makes the procedure simple and easy to learn. The complete description of the 
procedure is given in detail in Population and Methods, Section 3.5 – Index of microcirculatory 
resistance (IMR), page 90.  
It is a safe technique to perform in STEMI patients180 and has been used in several studies 
(described in the next section). 
 
5.2. Clinical evidence on the use of IMR in STEMI patients 
 
The evaluation of coronary microcirculation involvement and its consequences in patients with 
acute STEMI treated with primary angioplasty is a logical application of IMR. Indeed, several 
studies were performed in ST elevation acute myocardial infarction patients, immediately after 
the primary PCI. These studies, summarized in Tables 3-6, showed that IMR is related with: 
 Left ventricular remodelling (either evaluated by wall motion score index, improvement 
in left ventricular volumes or improvement in left ventricle ejection fraction) between the 
acute phase and follow-up, using either echocardiography or contrast enhanced cardiac 
magnetic resonance (ceCMR), 
 Infarct size, measured either by the amount of cardiac biomarkers released, by single-
photon emission computed tomography  (SPECT) or by ceCMR, 
 The presence of microvascular obstruction, evaluated by ceCMR, and 
 Myocardial viability, assessed by positron emission tomography (PET). 
 
Additionally, recent evidence suggests that IMR measured immediately after the primary PCI in 
STEMI patients is a strong and independent predictor of major events, including death (Table 5). 
Although almost all of these studies were unicenter and small (the majority included less than 50-
60 patients), their results, coming from different groups of investigators, are remarkably 
consistent. Therefore, in the last years, IMR has also been used as a tool to evaluate both 
pharmacological strategies (like IIb/IIIa inhibitors, nicorandil or nitroprusside) and devices (like 
thrombus aspirators or distal protection devices) in the treatment of STEMI patients (Table 6).  
Finally, IMR has been widely used in stable patients, for several indications176,181: as an adjuvant 
of FFR in patients with equivocal clinical presentation and intermediate coronary stenosis182, in 
patients with probable microvascular angina183, to evaluate drugs184–186 or devices187, to assess the 
impact on microcirculation of percutaneous revascularization188,189, and in other specific clinical 
conditions (apical ballooning syndrome190, assessment of steam cell therapy191,192, transplant 
arteriopathy193 etc.). However, to the date, there are no studies relating IMR to endothelial-































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6. Methods for the evaluation of endothelial function 
 
When the endothelial function is altered, any of its functions could be impaired. Yet, for practical 
reasons, the current standard is to measure endothelial function by studying of its vasomotor 
regulation function. It is also customary to use the generic term “endothelial function” as an 
equivalent for endothelium-dependent vascular reactivity.  
The first demonstration of endothelial dysfunction in atherosclerotic coronary arteries using 
intracoronary infusion of acetylcholine and quantitative coronary angiography dates back to 1986 
by Ludmer and colleagues.194 Later, less invasive techniques were developed using mainly the 
forearm circulation as a surrogate for coronary arteries.195–197  
All approaches have their advantages and disadvantages and it is important to keep in mind that 
different vascular beds are examined. The basic principle, however, is similar: healthy arteries such 
as the coronary or brachial arteries dilate in response to reactive hyperaemia (flow-mediated 
vasodilatation) or after pharmacological stimuli, including intra-arterial infusion of endothelium-
dependent vasodilators such as acetylcholine, bradykinin, or serotonin, via release of NO and/or 
other endothelium-derived vasoactive substances.198,199 In disease states, such endothelium-
dependent dilatation is reduced or absent. Impaired endothelial-independent function, on the 
other hand, is associated with structural vascular alterations and alterations in smooth muscle 
cells rather than changes in the endothelium.  
A comprehensive assessment of the coronary microcirculation requires information on both the 
endothelium-dependent and independent coronary microcirculatory responses. CFR and IMR 
(described in the previous section), which require maximal hyperaemia, obtained primarily 
through adenosine vasodilator action on vascular smooth muscle cells, are potentially an 
incomplete measurement of coronary microcirculatory function, due to their inability to 
distinguish between endothelium-dependent and independent microcirculatory responses. In 
fact, the poor correlation between adenosine derived CFR and coronary endothelium-dependent 
microvascular function has been already demonstrated200.  
In the following pages, the main techniques available for the evaluation of both coronary and 
peripheral endothelial dysfunction are briefly described. EndoPAT, used in the current study, will 
be further detailed in Section 7. 
 
6.1. Invasive evaluation of coronary endothelial function 
 
6.1.1. Epicardial Endothelial Function 
 
The first studies of endothelial function in vivo evaluated endothelium-dependent reactivity of 




endothelium-independent vasodilator nitroglycerin were infused into the coronary arteries, 
followed by angiographic measurements of coronary vessels diameter. In patients with 
coronary atherosclerosis, acetylcholine infusion resulted in paradoxical vasoconstriction of 
epicardial vessels in contrast to coronary vasodilation observed in patients without 
documented cardiovascular disease. A normal vasodilator response to nitroglycerin suggests 
that a defect in endothelial vasodilator function, and not in smooth muscle cell reactivity, is 
responsible for the abnormal acetylcholine-induced coronary vasorelaxation. 
In addition to endothelium-dependent pharmacological agents (like acetylcholine, bradykinin 
or substance P), increase in blood flow can be used to investigate the responsiveness of 
coronary arteries. For this purpose, endothelium-independent agents (such as adenosine and 
papaverine, which act primarily on the coronary microvasculature to induce its vasodilation 
and thereby increase blood flow) can be used, resulting in an increase in shear stress, 
endothelial nitric oxide release and consequent proximal (epicardial) arterial vasodilation 
(flow-mediated dilation). By infusing either adenosine or papaverine into the midportion of the 
coronary artery of interest, followed by the angiographic measurement of its diameter, at the 
site proximal to the infusion, flow mediated dilation can be assessed in the coronary 
vasculature.201,202 
Finally, more “physiological” stimuli can be used, such as the cold pressor test and dynamic 
exercise. In the cold pressor test, sympathetic activation is achieved by immersing a patient’s 
hand and forearm in a slurry of iced water, followed by intracoronary blood velocities 
measurements and quantitative angiography.203 The supine dynamic exercise test has been 
performed using a bicycle ergometer with continuous hemodynamic monitoring and obtaining 
repeated coronary angiograms at baseline (before exercise), at peak exercise, after exercise, 
and after intracoronary nitroglycerin infusion.204 
 
6.1.2. Coronary microvascular function 
 
The just described angiographic evaluation of changes in epicardial vessel diameter after 
infusion of acetylcholine (or other pharmacological agents) or flow mediated dilation 
(induced by adenosine or papaverine) primarily evaluates large coronary conduit vessels.  
This assessment does not reflect the functional status of the coronary microcirculation that 
determines vascular resistance and, thus, blood flow to the myocardium. Endothelial function 
of the coronary microvasculature can be assessed by measuring changes in coronary blood 
flow, as described in Section 4 of this chapter.  
This method involves placement of a Doppler wire into a coronary artery and measuring 
blood flow velocities after the infusion of endothelium-dependent (acetylcholine) and 
endothelium-independent (adenosine or papaverine) agents. Relative changes in coronary 
blood flow can be calculated by multiplying changes in mean coronary blood flow velocity by 
changes in the estimated vessel cross-sectional area (determined by quantitative 




therefore rarely used outside a research setting. A pressure wire-based thermodilution 
technique was also validated for this200, but its use both in clinical and reearch settings is also 
limited.   
 
6.2. Non-invasive evaluation of peripheral endothelial function 
 
Although measurements of the acetylcholine-induced and flow-mediated variations in coronary 
artery diameter allow the direct assessment of endothelial function in coronary arteries, several 
limitations restrict their widespread use. The invasive nature of these studies confines their use 
to patients undergoing coronary angiography for clinical reasons, but also limits the possibility of 
repeated evaluations.  
Furthermore, measurements of coronary diameter, used in the assessment of endothelial 
function of large epicardial vessels, as well as in calculating changes in blood flow, are limited by 
the accuracy of coronary angiography and may pose technical difficulties in patients with 
atherosclerosis. Finally, and most importantly for the current study, this may not be a safe test to 
perform in acute patients, since the acetylcholine induced vasoconstriction would aggravate the 
ischemia and increase the risk of severe complications.   
Alternatively, endothelial function can be assessed non-invasively by measuring vasodilator 
responses to interventions known to stimulate endothelial release of nitric oxide. Several 
methodologies have been developed to measure endothelial vasomotor function in humans 41,205, 
including ultrasound flow-mediated dilatation (that evaluates the change in brachial artery 
diameter), pulse wave analysis (change in augmentation index), pulse contour analysis (change in 
reflective index) and pulse amplitude tonometry (change in pulse amplitude). 
Importantly, impaired endothelial responses, characteristically found in coronary arteries of 
patients with cardiovascular risk factors, have also been confirmed in different peripheral 
circulatory territories in these patients.206–208 This has led to the concept of a generalized nature 
of endothelial dysfunction and has facilitated endothelial function testing in more accessible 
vascular beds. 
 
6.2.1. Plethysmography of the forearm circulation 
 
With this technique (which is actually semi-invasive, since it requires an arterial puncture), a 
catheter is placed into the brachial artery, and drugs are infused, in small concentrations, 
directly into the forearm circulation. Blood flow is measured noninvasively, by means of strain 
gauge plethysmography.41  
It allows quantification of endothelium-dependent and endothelium-independent 




limited systemic effects, allowing the contralateral limb to serve as an internal control. The 
results are expressed as the ratio of the changes in flow measured in both arms and are 
reproducible.209 The technique is well suited to measure differences in blood flow to various 
stimuli or inhibitors in a single patient. However, because of different initial arterial 
pressures, forearm blood flow, different sizes of the forearm, and other factors, comparisons 
between groups or serial studies in the same patient are of limited value.210 
 
6.2.2. Flow-mediated dilation (FMD) of brachial artery 
 
The technique measures the ability of the arteries to respond with endothelial NO release 
during reactive hyperaemia (flow mediated) after a 5-minute occlusion of the brachial artery 
with a blood pressure cuff inflated, either above the antecubital fossa or on the forearm, to 
suprasystolic pressure (usually to ≥50 mm Hg above systolic pressure).  
Two-dimensional images of the brachial artery and Doppler signals are acquired at baseline, 
before cuff inflation, and for 1 minute after cuff release (time of maximum vasodilation). FMD 
is the change in poststimulus diameter, usually expressed as a percentage of baseline 
diameter. In most studies, subjects are given a systemic vasodilator (usually a single dose of 
sublingual nitroglycerin) as a parallel experiment to assess endothelium-independent 
vasodilation41. 
Peripheral endothelial function as assessed by FMD correlates with coronary artery 
endothelial function.206,208  
However, although the principle of this technique seems simple, its application is technically 
challenging. Study preparation, image acquisition and site selection, sphygmomanometer 
probe position, cuff occlusion time, accurate use of edge-detection software, and correct 
characterization of the FMD response are crucial.211,212  
This technique is therefore highly dependent on the skills of the examiner. High-quality 
ultrasound images are essential for accurate analysis, typically requiring several months of 
hands-on training by experienced individuals, as well as continuous performance of the 
technique, to maintain optimal quality and consistency of the data. 
 
6.2.3. Pulse wave analysis – applanation tonometry  
 
Applanation tonometry is a method that involves positioning a tonometer over the maximal 
arterial pulsation of the artery under study (typically a superficial artery, such as a radial, 
brachial, and femoral) to minimally flatten or applanate the arterial wall. This normalizes the 
circumferential stresses in the arterial wall thereby allowing accurate recording of the 




within the tonometer.213 The pulse-waveform shape obtained provides information about 
arterial compliance (including the augmentation index, a ratio between the pulse pressure at 
the second systolic peak and the pulse pressure at the first systolic peak, which is commonly 
used as a measure of arterial stiffness) and about endothelial function (by measuring the 
changes in the peripheral pressure waveform in response to β-2 adrenergic stimulation).214,215 
However, this technique has rarely been used to investigate endothelial dysfunction in clinical 
settings.  
 
6.2.4. Peripheral (pulse) arterial tonometry  
 
In addition to applanation tonometry, pulse wave amplitude of the peripheral 
microvasculature can be assessed by measuring changes in digital pulse volume using a finger 
photopletysmograph (pulse contour analysis).216  
Reactive hyperemia peripheral artery tonometry is a recent development of this technique, 
which uses plethysmography to record digital volume changes accompanying pulse waves.217 
Its fundaments and clinical evidence will be further detailed in the next section.  
 
6.2.5. Laser Doppler flowmetry of the skin 
 
Laser Doppler flowmetry (LDF) is a technique that enables the monitoring of skin 
microvascular blood flow.218 The assumption is that the response observed in the cutaneous 
circulation is a window towards the responses that would be observed in other vascular 
beds.219 During LDF, the original beam of coherent light changes in contact with moving 
tissues (red blood cells) and a photodiode measures the emerged beam. The fraction of 
shifted light depends on the concentration of moving red blood cells, whereas the magnitude 
of the frequency broadening depends on their average velocity.220 
LDF has been used to evaluate endothelial function of the skin microvasculature using 
postocclusive hyperemia, local thermal hyperemia, and acetylcholine iontophoresis. Despite 
being noninvasive and, therefore, attractive for routine clinical and research use, these 
techniques have certain limitations. Firstly, because the skin is a critical thermoregulatory 
organ, there are extreme variations in basal blood flux, which, in turn, dictate the need to use 
maximal vasodilatation (by either local warming of the skin or local sodium nitroprusside 
infusion) to normalize submaximal flux values. Secondly, poor interassay and intra-assay 
reproducibility and lack of standardization (e.g., site of the skin measurement) limit within-
patient and across-studies comparisons. Thirdly, and most importantly, recent insights into 
the mechanisms of the postocclusive hyperemia and acetylcholine-mediated dilatation 
indicate that these phenomena are not primarily NO mediated, suggesting that they might 




metabolic and endothelial vasodilators (independent from NO). Therefore, rather than 
representing specific markers of endothelial function, these tests provide a more global form 
of assessing microvascular function.41  
 
6.2.6. Biochemical biomarkers 
 
Markers of coagulation/thrombosis 
The plasma levels of several procoagulant mediators have been shown to increase with 
endothelial damage, suggesting that they could represent reliable markers of endothelial 
dysfunction. Furthermore, a change in the production of these molecules by the endothelium 
could directly contribute to atherotrombotic disease. These markers include, among others, 
von Willebrand factor, tissue plasminogen activator (t-PA) and PAI-1. However, prospective 
epidemiological studies aiming to evaluate the association between plasma levels of different 
hemostatic markers and the risk for cardiovascular disease are relatively sparse and often 
have inconclusive results.41 
 
Markers of inflammation 
Strong evidence suggests that atherosclerotic risk factors are often associated with systemic 
inflammation, which is a key player in the development and progression of atherosclerosis.106 
C-reactive protein, in particular, has emerged as a potential marker for cardiovascular risk. It 
can be measured with several standardized, validated, and inexpensive high-sensitivity 
assays and is the only biomarker ready for clinical use, adding predictive value above the 
currently established risk factors, both in stable and unstable patients.41 However, it is 
affected by several mechanisms and factors, which limits its use as a marker of endothelial 
function. 
 
Other markers of endothelial dysfunction 
Asymmetrical dimethylarginine (ADMA) and oxidized low-density lipoprotein (oxLDL) are two 
other markers which have been investigated as indicators of endothelial function. However, 
despite initial promising results, suggesting an association with cardiovascular disease and 
risk, both had more recent conflicting  results and there are doubts if they represent reliable 
substitutes for direct endothelial function measurement.211 
Endothelial microparticles and bone-marrow derived endothelial progenitor cells have also 
been widely investigated as markers of endothelial dysfunction, with promising results, but 
they remain mostly investigational tests.211 
Finally, baseline plasma levels of several cellular adhesion molecules (CAMs), including 
intercellular adhesion molecule-1 and E-selectin, have been shown to be associated with 




disease, elevated circulating vascular cell adhesion molecule-1 and intercellular adhesion 
molecule-1 values were also predictors of adverse outcome. However, the results from other 
large studies indicated that, after adjustments for other cardiovascular risk factors, the 
association of CAMs with coronary heart disease is not statistically significant.41 
 
 
7. Peripheral (pulse) arterial tonometry (EndoPAT) 
 
7.1. Principle and methodology 
 
Reactive hyperemia peripheral artery tonometry uses plethysmography to record digital volume 
changes accompanying pulse waves.217 On the basis of this principle, a finger pneumatic 
plethysmographic cuff, providing a ‘‘beat to beat’’ blood flow volume assessment by recording 
finger (peripheral) arterial pulsatile (PAT) volume changes, was developed by Itamar Medical, and 
made commercially available under the name EndoPAT 2000® (Figure 9, page 95).  
It consists of a fingertip plethysmograph capable of sensing volume changes in the digit with each 
arterial pulsation. The fingertip probe has a rigid external casing containing inflatable chambers 
and the uniformly applied pressure field across the finger prevents venous pooling and partially 
unloads arterial wall tension (Figure 10, Page 96). Volume changes in the fingertip are recorded 
digitally as pulse amplitude that can be tracked over time. 
Endothelial function testing with PAT is based on the same physiological mechanisms as the FMD 
technique, inducing transient ischemia in the upper limb as a stimulus for reactive vasodilatation: 
 A pressure cuff is placed around the arm and inflated above systolic pressure after a 
baseline recording 
 The cuff is then deflated after 5 minutes to induce reactive hyperemia in one arm (a main 
advantage of the system is that the contralateral arm serves as an internal control). 
 The ratio between hyperaemic and baseline pulse volume analysis (PAT ratio) is 
normalized for the same ratio in the contralateral arm, thus obtaining the reactive 
hyperemia index (RHI), or its natural logarithm (L_RHI).221  
This index is a validated marker of endothelial function – a value below 1.67 (or ≤0.51 for L_RHI) 
is considered suggestive of endothelial dysfunction. The reproducibility of the procedure was also 
clearly established.222–224  
The technical details of the EndoPAT procedure are further detailed in Section 3.9 of the Methods 
Chapter (Page 95). 
Unlike flow-mediated dilation evaluation, the PAT technique is operator-independent, and the 




7.2. Clinical evidence on the use of  EndoPAT in coronary artery disease 
 
The role of EndoPAT in the evaluation of patients with coronary artery disease is supported by the 
study performed by Bonetti and colleagues, in which they showed that a lower PAT hyperaemic 
response is significantly correlated with the presence of coronary endothelial dysfunction 
measured by acetylcholine response207 in patients undergoing coronary angiography. This study 
confirms previous evidence endorsing the concept of a generalized nature of endothelial 
dysfunction206,208 and supports the use of endothelial dysfunction evaluated by EndoPAT as a 
surrogate for coronary endothelial dysfunction.  
Additionally, EndoPAT has been evaluated in different stages of coronary artery disease: 
 In patients without known/suspected coronary artery disease, PAT hyperaemic ratio is 
progressively lower with increasing burden of cardiovascular risk factors225–227 and several 
studies confirmed that endothelial dysfunction evaluated with EndoPAT is related both to  
the risk of developing coronary disease and the risk of cardiac events. In fact, as described 
in Section 3.3 above and also confirmed with this technique, the presence of endothelial 
dysfunction appears to have an incremental prognostic value, after control for these 
classical risk factors, which may be explained by the fact that it reflects the overall burden 
of risk and significantly predicts the risk of cardiovascular events.  
 
The main prognostic studies performed with EndoPAT to evaluate the risk of events in 
patients without coronary artery disease are presented in Table 7.  
 
 In patients with known stable coronary artery disease, endothelial dysfunction evaluated 
by EndoPAT was related with the risk and severity of the disease and to  the characteristics 
of coronary plaques (Table 8).  
 
EndoPAT was also used to evaluate the effect of enhanced external counter pulsation in 
patients with stable angina and refractory complaints.   
 
Additionally, three long-term studies performed with EndoPAT confirmed its additional 
and independent value in predicting events in patients with coronary artery disease (Table 
9). 
 
 Finally, in patients with acute coronary syndromes and ST elevation myocardial 
infarction, evidence with EndoPAT includes studies predicting the risk of in-stent 
restenosis, initial patency of the culprit artery, angiographic severity of the coronary 
artery disease and the extension of infarction in STEMI patients (Table 10). These two last 
studies were performed in our centre, and they will be further described below, since they 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































7.2.1. Severity of coronary artery disease and endothelial dysfunction evaluated by 
peripheral arterial tonometry19 
 
With the purpose of evaluating the prevalence of endothelial dysfunction by severity of 
coronary artery disease, 231 patients referred for diagnostic angiography and 39 control 
subjects, were evaluated by peripheral arterial tonometry (EndoPAT) in our department. The 
severity of coronary artery disease was defined as the number of vessels with disease (lesions 
>70%).  
Of the 231 patients, 92 (39.8%) had no relevant disease (“normal” coronaries), 78 (33.8%) 
had 1 vessel disease, 37 (16.0%) had 2 vessel disease and 24 (10.4%) had 3 vessel disease. 
Mean RHI values in the control group were 2.10±0.63. In catheterised patients, RHI was 
progressively lower as CAD severity increased: 1.98±0.46, 1.86±0.46, 1.85±0.43 and 
1.60±0.39, respectively in patients with “normal” coronaries, 1, 2 and 3 vessels disease 
(p=0,003). Since patients with 1 and 2 vessels had similar RHI results, they were merged in 
one group for the analysis performed (Figure 3, Table 11). 
 
Table 11 – Patient characteristics according to the severity of coronary artery disease  
a presented as N (%); b Presented as mean±standard deviation: c p-value for the comparison normal coronaries vs. 1-2 vessel 
disease vs. 3 vessel disease: One-Way ANOVA for continuous variables and Chi-Square for categorical variables. d p=0.002 (One-
Way ANOVA; Controls vs. normal coronaries vs. CAD) 
 
Three vessel disease was more prevalent in male patients (in the unadjusted analysis). 
Patients with multivessel disease also tended to be older and more often diabetics. The other 




1-2 vessel  
disease 
3  vessel  
disease 
P value c 
Patients a 39 92 (39.8%) 115 (49.8%) 24 (10.4%) - 
Reactive hyperemia index b 2.08 ± 0.63 1.98 ± 0.46 d 1.85 ± 0.45 1.60 ± 0.39 0.001 
Physical characteristics      
   Age (years)  b 39.5± 12.8 59.5 ± 13.7 † 60.3 ± 13.7 64.2 ± 13.1 ns 
   Male gender a 17 (40.5%) 44 (47.8%) †† 87 (75.7%) 20 (83.3%) <0.001 
   Body mass index  b 25.4 ± 5.6 27.2 ± 4.1 † 27.2 ± 4.4 28.3 ± 3.9 ns 
   Heart rate  b 66.2 ± 9.2 65.0 ± 11.7 † 65.6 ± 11.2 69.1 ± 14.4 ns 
   Systolic blood pressure b 114.1 ± 14.4 121.7 ± 17.3 † 116.7 ± 20.8 118.4 ± 22.6 ns 
Risk Factors a      
Diabetes  0 (0.0%) 13 (14.2%) 28 (24.3%) 8 (33.3%) ns 
Hypertension  6 (14.3%) 66 (72.5%) 77 (67.0%) 18 (75.0%) ns 
Dyslipidaemia  12 (28.6%) 48 (52.2%) 54 (47.0%) 14 (58.3%) ns 





Figure 3 – Reactive hyperemia index according to the severity of the 




In the univariate analysis, comparing 3-vessel disease with 1 or 2-vessel disease, RHI and non-
ST acute coronary syndrome as indication for the angiography (vs. ST elevation myocardial 
infarction) were the strongest predictors of the severity of disease (Table 12). 
However, when this analyses was adjusted (for age, gender, previous diabetes mellitus or 
dyslipidaemia, BMI and waist circumference), only RHI was independently associated with 
the diagnosis of 3 vessel disease (Table 13).   
 
 
Table 12 – Univariate analysis of predictors of 3 vessel disease in the population with 
documented coronary artery disease 




Univariate analysis 1-2 Vessels 3 Vessels RR 95% CI P value 
Reactive hyperemia index 1,85±0,45 1,60±0,39   0,014 
nST-ACS (vs STEMI) 44,3% 70,8% 2,54 1,12-5,73 0,016 
Gender (male) 75,7% 83,3% 1,61 0,51-5,11 0,301 
Dyslipidaemia 47,0% 58,3% 1,58 0,65-3,85 0,215 
Diabetes mellitus 24,3% 33,3% 1,55 0,60-4,02 0,251 
Hypertension 67,0% 75,0% 1,48 0,54-4,03 0,304 
Age (per year) 60,3±13,6 64,2±13,1   0,193 




Table 13 – Multivariable analysis of predictors of 3 vessel disease in the 
population with documented coronary artery disease 
Multivariate analysis RR 95% CI P value 
RHI (each unit) 0,18 0,04-0,73 0,016 
Gender (male) 3,27 0,86-12,4 0,082 
Presentation  = nST ACS 2,27 0,78-6,63 0,132 
Dyslipidaemia 1,29 0,46-3,61 0,630 
Diabetes mellitus 1,23 0,42-3,60 0,708 
Waist circumference (each cm) 1,03 0,99-1,07 0,106 
Age (each year) 1,02 0,98-1,06 0,431 
nST-ACS: non-ST acute coronary syndrome; 
 
Based on these results, we conclude that endothelial dysfunction assessed by PAT is related 
with the severity of coronary artery disease. Therefore, we hypothesized that endothelial 
function may have a continuous role in the atherogenic process and, consequently, its 
noninvasive evaluation might be useful not only to predict the risk of CAD, but also in patients 
with disease already established.  
 
7.2.2. Endothelial dysfunction evaluated by peripheral arterial tonometry is related 
with peak TnI values in patients with ST elevation myocardial infarction 
treated with primary angioplasty18 
 
This study was published in Microvascular Research. A copy of the complete published paper 
can be found in the Appendix.  
In summary, our purpose was to evaluate the impact of endothelial dysfunction on peak 
Troponin I (TnI) values, as a surrogate for the extension of myocardial infarction, in patients 
with ST elevation myocardial infarction treated with primary angioplasty.  
Fifty-eight patients (mean age 59.0±14.0 years, 46 males) were included. Endothelial function 
was assessed by reactive hyperaemia index (RHI) as determined by PAT. Patients were 
divided in two groups according to the previous reported RHI threshold for high risk (1.67). 
The extension of myocardial necrosis was evaluated by peak TnI levels.  
RHI median value was 1.78 (IQR 0.74); 25 patients had endothelial dysfunction (RHI<1.67). 
The two groups had no significant differences in age, gender, main risk factors and pain-to-
balloon time.  
Patients with an RHI<1.67 had significant larger infarcts: TnI 73.5 ng/mL (IQR 114.42 ng/mL) 
versus TnI 33.2 ng/mL (IQR 65.2 ng/mL); p=0.028. Significant differences were also found in 
peak Creatine-kinase and its Mb fraction (Figure 4, Table 14). On multivariate analysis, the 






Figure 4 – Peak Troponin I values according to the presence of endothelial dysfunction 
(RHI<1.67) in patients with ST elevation myocardial infarction treated with primary PCI 
 
Importantly, the presence of endothelial-dependent dysfunction was related to peak TnI 
values even when other factors that affect the extension of myocardial infarction (e.g. age, 
risk factors, pain-to-balloon time, culprit artery and Killip class at admission) were taken into 
account. Therefore, since endothelial-dependent function plays a crucial role in vascular tone 
and coronary blood flow regulation, we hypothesized that endothelial dysfunction can play a 
role not only in the development of coronary artery disease, but also in the 
pathophysiological processes occurring in the microcirculation before and during STEMI.  
 
Table 14 – Cardiac enzymes peak values, according to the presence of endothelial 
dysfunction (RHI<1.67) 




RHI ≥ 1.67 
(n=33) 
P value 
Peak TnI (ng/mL) 50.3 (68.1) 73.5 (107.1) 35.2 (64.3) 0.028 †  
Peak CK  (UI/L) 1.586 (1.938) 1.909 (2.181) 1.227 (1.758) 0.045 † 
Peak CK-Mb  (UI/L) 252 (240) 303 (312) 224 (186) 0.032 † 







8. Summary of the evidence underlying this research – evaluation 
of endothelial dysfunction in the early acute phase in STEMI 
patients 
 
Primary angioplasty is a very effective treatment for ST elevation myocardial infarction and major 
improvements were obtained with dedicated primary PCI programs that significantly reduced 
ischemic times. However, despite a normal epicardial coronary artery flow is almost always 
achieved after primary PCI in a timely fashion, a significant proportion of patients has a worse 
outcome due to microvascular malperfusion.  
The negative prognostic implications (both on the risk of left ventricle remodelling and on the risk 
of hard endpoints, including death) associated with coronary microvascular damage has been 
repeatedly confirmed, with several invasive and non-invasive indicators. However, it is not clear if 
this microvascular dysfunction is a consequence of myocardial infarction (by distal embolization 
of thrombi, secondary endothelial dysfunction and/or reperfusion injury) or if it is part of the 
pathophysiological process that leads to and aggravates myocardial infarction.  
Endothelial function seems to be at the core of all the events occurring in myocardial infarction 
patients. In fact, there is accumulating evidence that endothelial dysfunction is not just a risk 
factor and precursor of coronary artery disease, but it also plays a central role leading to acute 
coronary syndromes and ST elevation myocardial infarction. It is therefore licit to speculate that 
previous endothelial dysfunction or a blunted reaction of the endothelial mechanisms during ST 
elevation myocardial infarction may be a central component of coronary microvascular 
dysfunction in these patients and, as a consequence, a determinant of microvascular reperfusion, 
infarction extension and left ventricle remodelling.  
Ideally, this hypothesis would best be proved if endothelial function evaluation had been 
performed before the myocardial infarction, which evidently is not possible. Actually, most studies 
evaluating endothelial function in acute coronary syndrome patients were performed relatively 
late (several days or weeks) after the onset of the event. As such, the worse results documented 
in patients with endothelial dysfunction may just be a consequence of larger and more 
complicated infarcts.  
In fact, endothelial function testing is particularly challenging in acute patients: the unpredictable 
nature of the acute event onset, the unstable condition of the patient and the early dramatic 
impairment in microvascular function make it difficult to obtain and interpret data concerning 
vascular reactivity in this context.  
Still, measuring endothelial function as early as possible after the onset of the ST elevation 
myocardial infarction could help clarify this question. Assuming peripheral endothelial function 
(which is much more easy to measure) as a surrogate of coronary endothelial function, we would 
expect, if the above theory is true, worse acute endothelial dysfunction, worse microvascular 
reperfusion and worse left ventricle remodelling in patients with larger infarctions. This is the 




The recent availability of a non-invasive, reproducible and non-operator dependent technique for 
endothelial function evaluation – peripheral arterial tonometry (EndoPAT®), together with the 
development of a new invasive tool for the assessment of coronary microcirculation – the index 
of microcirculatory resistance – opened new opportunities to try to understand what is happening 
























Study Hypothesis  
 
The study´s main hypothesis is: In patients with acute ST elevation myocardial infarction treated 
with primary PCI, endothelial dysfunction (evaluated by peripheral arterial tonometry) is related 
to the extent of microvascular damage and, consequently, to the extent of myocardial necrosis. 
 
Based on this hypothesis, the study primary aim is to evaluate the relation between endothelial 
dysfunction (evaluated with EndoPAT) and coronary microvascular dysfunction (evaluated by IMR 
immediately after primary revascularization).  
 
Secondary aims include both confirming IMR and evaluating endothelial dysfunction (as 
measured by peripheral arterial tonometry) as predictors of microvascular dysfunction and 




Study Outcome Measures  
 
The primary outcome measure is the IMR value. Since there are no clearly defined values for 
abnormal endothelial function in coronary artery disease patients, two pre-specified evaluations 
of this primary outcome measure were defined: 
 
1. IMR value in patients with endothelial dysfunction according to the prevailing threshold 
defined for EndoPAT (RHI  <1.67 versus ≥1.67)  
2. IMR value in patients according to the tertile of RHI  
 
Secondary outcomes of the study are: 
 
1. The relation between RHI values and  
a) The extent of myocardial necrosis, evaluated by troponin release (in the first 48 
hours), echocardiographic parameters (both measured acutely and at 3 months) and 
ceCMR; 
b) The extent of microvascular reperfusion indicators, including angiographic indicators 
(cTFC and TMPG), ECG (ST resolution), and ceCMR (microvascular obstruction). 
 
2. The relation between IMR values and 
a) The extent of myocardial necrosis, evaluated by troponin release (in the first 48 
hours), echocardiographic parameters (both measured acutely and at 3 months) and 
ceCMR;  
b) The extent of microvascular reperfusion indicators, including angiographic indicators 





























1. Type and Location of the Study 
  
Observational, prospective, single centre, cohort study, performed in the Cardiology Department 




All patients admitted to Hospital Prof. Doutor Fernando da Fonseca with a first acute ST elevation 
myocardial infarction, treated with primary angioplasty, were considered for inclusion in the 
study, according to the inclusion and exclusion criteria defined below. 
 
2.1. Inclusion Criteria 
 Age > 18 years. 
 First ST elevation acute myocardial infarction, defined by: 
- Chest pain lasting at least 20min and /or 
- ST segment  elevation of at least 1 mm in two or more contiguous leads 
 Pain to balloon time < 6 hours (or between 6 and 12 hours if clearly with ongoing pain) 
 Primary PCI performed with success on the culprit lesion (with no significant residual 
stenosis, independently of the final TIMI flow) in a native coronary artery. 
 Informed consent obtained  
 
2.2. Exclusion Criteria 
 Patients presenting with left bundle-branch block and patients with implanted pacemaker 
– excluded since ST resolution could not be evaluated. 
 History of previous of myocardial infarction (either ST elevation or non ST elevation MI) –
excluded in order to reduce the bias in the ceCMR and in the microvascular tests. 
 Patients with clear retrograde circulation to the infarct related artery (Rentrop ≥2). 
 Killip class IV (cardiogenic shock) on presentation or during the primary PCI procedure 
 Patients with known myocardial diseases (such as hypertrophic cardiomyopathy or 
restrictive cardiomyopathies) and patients with severe left ventricular hypertrophy (wall 
thickness > 15 mm) – were excluded in order to reduce the bias in the ceCMR and in the 
microvascular tests. 
 Previous coronary artery bypass surgery. 




 Long QT syndrome, 2nd or 3rd degree heart block and sick sinus syndrome (due to the risk 
of severe bradycardia/arrhythmias induced by adenosine) 
 Patients in atrial fibrillation (if ceCMR was to be performed) or with other arrhythmias 
considered by the investigator as serious enough to contra-indicate the use of adenosine 
immediately after the primary angioplasty. 
 Severe asthma or chronic pulmonary obstructive disease (due to the risk of bronchospasm 
induced by adenosine) 
 Previous severe reaction to adenosine or any other contraindication to adenosine, including 
systolic blood pressure < 90 mmHg or bradycardia deemed to be significant by the operator. 
 Presence of any serious non-cardiac disease associated with a life expectancy of less than 
12 months  




Since there were no clearly defined “normal” values both for RHI and IMR in patients with acute 
myocardial infarction, sample calculation was a difficult task to accomplish. Our previous work 
with EndoPAT in patients with ST elevation myocardial infarction18, showed that RHI values lower 
than 1.67 are associated with larger infarcts (measured by peak troponin I release). Values lower 
than 1.67 were present in approximately 30% of patients (unpublished data), which translates into 
an “exposed/non-exposed” ratio of 2.3. In patients with RHI lower than 1.67, approximately 70% 
had larger infarcts (peak troponin I > 50 ng/dL).  
Using the OpenEpi sample size calculator (Kelsey method) 228, for a two-sided significance level (α) 
of 0,05, a power (1-β, % chance of detecting) of 80 and assuming a proportion with disease (larger 
infarcts) in patients with RHI > 1.67 (“non-exposed”) of 30%, the sample size would be 58 patients 
(18 “exposed” + 40 “non-exposed”).  
 
 
3. METHODS  
 
3.1. Clinical information  
 
Data concerning patient physical characteristics (age, gender, weight, height, body mass index, 
waist circumference), major risk factors (high blood pressure, diabetes, dyslipidaemia, smoking 
habits) and previous coronary/non-coronary atherosclerotic history (previous angina, previous 
percutaneous revascularization were collected in all patients included. Data on previous drug 




3.2. Primary Percutaneous Coronary Intervention  
  
Primary percutaneous coronary angioplasty was performed according to the recommended 
standards. The time of symptoms onset, time of hospital admission and time of first coronary 
intervention (thrombus aspiration, balloon dilation or stenting, whichever was first) was recorded, 
in order to allow the determination of ischemic times:  
 “pain-to-hospital”: time between the onset of symptoms and the first medical contact; 
 “hospital-to-balloon”: time between the first medical contact and the first coronary 
intervention; and, 
 “pain-to-balloon”: time between symptom onset and the first coronary intervention.  
 
The treatment strategy (thrombus aspiration, direct stenting versus balloon pre-dilatation, 
balloon post-dilatation, type and number of stents, dose of non-fractionated heparin, use of GP 
IIb/IIIa inhibitors, dose and timing of clopidogrel, etc.) was left to the discretion of the primary 
operator. All these technical parameters were collected.  
After the primary PCI, patients were admitted to the Intensive Cardiac Unit and offered standard 
care for patients with acute STEMI, including recommended pharmacological therapy (aspirin, 
clopidogrel/ticagrelor, beta-blockers, ACE inhibitors and statins), according to Portuguese229 and 
European1 guidelines.  
 
3.3. Coronary angiography and area-at-risk scores 
 
Angiography was performed according to usual procedures, by one of the 4 senior operators of 
the Interventional Cardiology Unit of Hospital Prof. Doutor Fernando da Fonseca. All operators 
were largely experienced in treating patients with acute ST elevation myocardial infarction.  
The severity of coronary artery disease was evaluated by the Syntax Score.230 Lesion segments 
were classified (as in the Syntax Score) based on the 16 segment definition proposed by the 
American Heart Association and modified for the ARTS I and II trials.230 
The presence of collateral flow to the culprit artery was evaluated, using the Rentrop collateral 
flow classification231: 
 Grade 0: None 
 Grade 1: Filling of side branches of the artery to be dilated via collateral channels without 
visualization of the epicardial segment; 
 Grade 2: Partial filling of the epicardial segment via collateral channels; 





Patients with a Rentrop flow 3 or 4 in the infarct related artery were not included, in order to 
reduce the bias in IMR measurement in this territory.  
For each lesion, the area-at-risk was calculated, according to the segment involved and using two 
different scores: the APPROACH score and the BARI score.  These 2 scores have been widely 
validated in clinical practice.232–235 
 
3.3.1. Modified APPROACH Score 
 
The Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease  
(APPROACH) score236 is  an angiographic score in which the left ventricle is divided into 
regions according to the percentage of myocardium supplied by a vessel or its branches. The 
area-at-risk for a given lesions is calculated taking into account the location of the culprit 
lesion, dominance and size of the secondary branches. The modified APPROACH score232 




Figure 5 – Modified APPROACH score for evaluating the area-at-risk  






3.3.2. BARI Score 
 
The Bypass Angioplasty Revascularization Investigation Myocardial Jeopardy Index (BARI) 
score was developed based on angiographic data from the BARI trial.237 It assigns a score to 
all terminal arteries (terminal portion of the left anterior descending, left circumflex, and 
right coronary artery, as well as the ramus, diagonals, obtuse marginals, posterior descending 
and posterolateral branches) based on their length and calibre according to specific criteria. 
A value of 0 represents an almost insignificant vessel size, whereas a value of 3 defines a 
large-size artery with a length of two thirds the distance between the base and cardiac apex. 
Right ventricular marginals and posterior descending artery septal branches are not taken 
into account. The final score is obtained by dividing the resulting value from the infarct-
related artery by the overall score of all arteries supplying the LV, which finally permits 
estimation of the percentage of myocardial muscle at risk.  
 
An example of the calculation of both the APPROACH and BARI scores for a given patient is 
presented in Figure 6. The patient had a STEMI due to a proximal left anterior descending artery 
(LAD) occlusion. Since there was a reperfused diagonal branch of medium importance, the area-
at-risk according to the APPROACH score (Figure 5) was 44.5%. For the BARI score, all left and 
coronary artery branches were classified from 1 to 3, according to their importance. The total 
value of branches distal to the occluded proximal LAD (total 11 points, corresponding to: distal 
LAD = 3 points, major diagonal branch = 3 points, 2 minor diagonal branches = 1 point each, 3 
septal branches = 1 point each) was divided by the total points of the patient (26), resulting in an 
area-at-risk of 42.3%.  
 
 
Figure 6 – Area-at-risk calculation according to the APPROACH and BARI scores 




3.4. TIMI Flow, corrected TFC and TIMI myocardial perfusion grade 
 
At the end of the primary PCI procedure, a final run of images of the culprit artery was registered, 
at 30 frames per second, in order to measure TIMI flow, TIMI frame count and TIMI perfusion 
grade. If necessary, the view was adjusted, so that the culprit vessel territory was not 
superimposed. The duration of cine filming was prolonged at least 3 cardiac cycles, to make sure 
that the entire washout phase was included. These three measures of flow were analysed offline 
by an operator blinded to other evaluations of the patient. 
 
3.4.1. TIMI flow grade 
 
TIMI flow grade was classified according to the standard definition152: 
 TIMI 3 (complete reperfusion): Anterograde flow into the terminal coronary artery 
segment through a stenosis is as prompt as anterograde flow into a comparable segment 
proximal to the stenosis. Contrast material clears as rapidly from the distal segment as 
from an uninvolved, more proximal segment. If there are difficulties in reproducibly 
assessing myocardial flow relative to other vessels, the modified definition of TIMI grade 
3 flow153 can be used (opacification of the distal coronary artery within three cardiac 
cycles) 
 TIMI 2 (partial reperfusion): Contrast material flows through the stenosis to opacify the 
terminal artery segment. However, contrast enters the terminal segment perceptibly 
more slowly than more proximal segments. Alternatively, contrast material clears from 
a segment distal to a stenosis noticeably more slowly than from a comparable segment 
not preceded by a significant stenosis. 
 TIMI 1 (penetration with minimal perfusion): A small amount of contrast flows through 
the stenosis but fails to fully opacify the artery beyond.  
 TIMI 0 (no perfusion): No contrast flow through the stenosis. 
 
3.4.2. Corrected TIMI frame count  
 
The corrected TIMI frame count (cTFC) was measured as the number of frames required for 
epicardial contrast to reach standardized distal landmarks, as previously described.154 The 
first frame used for TIMI frame counting was defined as the frame in which a column of dye 
touched both borders of the coronary artery and moved forward, and the last frame was 
defined as the frame in which dye begins to enter (but does not necessarily fill) a standard 





The standard distal landmarks for each epicardial vessel were: 
 The first branch of the posterolateral artery for the right coronary artery; 
 The most distal branch of the obtuse marginal branch beyond the culprit lesion in the 
circumflex system; and, 
 The distal bifurcation in the left anterior descending coronary artery. These frame 
counts were corrected for the longer length of the left anterior descending coronary 
artery by dividing the TFC by 1.7, to arrive at the corrected TIMI frame count (cTFC). 
  
3.4.3. TIMI myocardial perfusion grade (TMPG)  
 
TIMI myocardial perfusion grade (TMPG) was classified according to the standard 
definition155: 
 Grade 3 TMPG: Normal entry and exit of dye from the microvasculature: There is a 
ground-glass appearance (“blush”) or opacification of the myocardium in the 
distribution of the culprit lesion that clears normally, and is either gone or mildly or 
moderately persistent at the end of the washout phase (approximately three cardiac 
cycles), similar to an uninvolved artery. Blush that is of only mild intensity throughout 
the washout phase but fades normally is also classified as grade 3. 
 Grade 2 TMPG: Delayed entry and exit of dye from the microvasculature: There is a 
ground-glass appearance (“blush”) or opacification of the myocardium in the 
distribution of the culprit lesion that is strongly persistent at the end of the washout 
phase (i.e., dye is strongly persistent after three cardiac cycles of the washout phase 
and either does not diminish or only minimally diminishes in intensity during 
washout).  
 Grade 1 TMPG: Dye slowly enters but fails to exit the microvasculature: There is a 
ground-glass appearance (“blush”) or opacification of the myocardium in the 
distribution of the culprit lesion that fails to clear from the microvasculature, and dye 
staining is present on the next injection (approximately 30 sec between injections).  
 Grade 0 TMPG: Failure of the dye to enter the microvasculature: Either minimal or 
no ground-glass appearance (“blush”) or opacification of the myocardium in the 
distribution of the culprit artery, indicating lack of tissue-level perfusion.  
  
3.5. Index of microcirculatory resistance (IMR) 
 
The index of microcirculatory resistance was measured immediately after successful P-PCI. All 




The measurements were made with a 0.014 mm Certus pressure-wire, together with a 




Figure 7 – The Certus Pressure-wire, with a pressure and temperature sensor, and the 
RadiAnalyzer Xpress (St. Jude Medical®) 
 
The procedure was done as previously defined238:  
 The coronary pressure wire was calibrated outside the body, and equalized to the 
pressure reading from the guide catheter with the pressure sensor positioned at the 
ostium of the guide catheter, after intracoronary administration of 1-2 ml of nitroglycerin; 
 After calibration and equalization, the pressure wire was advanced to the distal two-thirds 
of the culprit vessel.  
 Three ml of room-temperature saline were injected down the culprit vessel 3 times at 
rest, and the resting transit times, which are inversely proportional to flow, were recorded 
and averaged (Figure 8).  
 Maximal hyperemia was induced using intravenous adenosine, 140 g/kg/min. 
 Three millilitres of room-temperature saline were again injected down the culprit vessel, 
and the hyperaemic transit times were recorded and averaged (Figure 8).  
 The mean aortic and distal coronary pressures were recorded during peak hyperemia.  
 The IMR was defined as distal coronary pressure divided by flow during peak hyperemia 
and calculated by dividing the mean distal coronary pressure by the inverse of the 
hyperaemic transit time, or, more simply, by multiplying the mean distal coronary 
pressure by the hyperaemic transit time (these values were given automatically by the 
RadiAnalyzer console).   
Coronary flow reserve (CFR), defined as the mean resting transit time divided by the mean 






Figure 8 – Example of baseline and hyperaemic thermodilution curves  
(IMR = mean hyperaemic transit time x distal pressure = 0.20 x 89 = 17.8) 
 
3.6. Laboratory Tests 
 
On admission (before P-PCI), a blood sample was collected, for evaluation of: 
 Cardiac biomarkers (creatine kinase [CK], creatine kinase-MB [CK-Mb], troponin I [TnI]) 
 Other relevant risk markers in myocardial infarction (N-terminal pro b-type natriuretic 
peptide [NT-Pro-BNP], high-sensitivity C-reactive protein [hs-CRP], complete blood count, 
glucose, glycated haemoglobin [HbA1c], creatinine). 
 
Blood samples were also collected every 6 hours for the first 24 hours after admission (i.e., 0, 6, 
12, 18, 24), and every 12 hours thereafter until 48 hours after admission (i.e., 36 and 48 hours), in 
order to determine the peak CK, CK-Mb and TnI values and to calculate the areas under the curve 
(AUC) for these markers, as previously described.239 Troponin I values were used to quantify the 
extent of the myocardial infarction. In order to account for lesion location, these values (AUC of 
TnI and peak TnI values) were indexed to area-at-risk scores (BARI and modified APPROACH 
scores).  
The following laboratory tests were used: 
 Troponin I: sandwich chemiluminescent immunoassay based LOCI™ technology, with a 
Dimension Vista™ Intelligent Lab System (Siemens Healthcare DiagnosticsTM). 
 Creatine kinase: NAC activated, with a Dimension Vista™ Intelligent Lab System (Siemens 
Healthcare DiagnosticsTM). 
 Creatine kinase-Mb fraction: Immunoinhibition, enzymatic, with a Dimension Vista™ 
Intelligent Lab System (Siemens Healthcare DiagnosticsTM). 
 NT-pro-BNP: sandwich chemiluminescent immunoassay based LOCI™ technology, with a 
Dimension Vista™ Intelligent Lab System (Siemens Healthcare DiagnosticsTM). 
 hs-CRP: Immunonephelometric, fixed-time kinetic, with a Dimension Vista™ Intelligent 




 Creatinine: Alkaline picrate, fixed-time kinetic with a Dimension Vista™ Intelligent Lab 
System (Siemens Healthcare DiagnosticsTM). 
 Glucose: Hexokinase, with a Dimension Vista™ Intelligent Lab System (Siemens Healthcare 
DiagnosticsTM). 
 HbA1c: High performance liquid chromatography, with ADAMS A1C HA-8180V 
 
3.7. ECG ST segment resolution 
 
Twelve-lead ECGs were performed: 
 Immediately before P-PCI (baseline ECG), 
 Immediately after the end of the procedure (post-PCI ECG), 
 90 minutes after reperfusion (90-min ECG), and  
 180 minutes after reperfusion (180-min ECG). 
In the baseline ECG, the following baseline measurements were performed: 
 Total ST elevation: the sum of ST elevation in all leads, measured 20 milliseconds after the 
end of the QRS complex, with the PR segment as reference baseline, in leads I, aVL, and 
V1–V6 for anterior, and leads II, III, aVF, and V5–V6 for non-anterior myocardial 
infarction.240 
 Total ST deviation: the sum of ST deviation in all leads, measured 20 milliseconds after the 
end of the QRS complex.139 
 ST elevation in the lead with maximal ST elevation: measured the same way as described 
above.135,136   
In the 3 post-revascularization ECGs (post-PCI, 90-min and 180-min), reperfusion was evaluated 
through the following ST resolution parameters, in comparison with the baseline ECG: 
 Percentage of total ST-segment-elevation resolution. 
 Percentage of total ST-segment-deviation resolution. 
 Percentage of maximal ST-segment-elevation resolution in the lead showing the 
maximum elevation in the baseline ECG. 
 Sum of residual ST-segment-elevation. 
 Sum of residual ST-segment-deviation. 









3.8. Echocardiographic Evaluation 
 
A transthoracic echocardiogram was performed within 12 hours of presentation and a follow-up 
exam was scheduled approximately 3 months after the acute event.  
The exams were performed using a commercially available ultrasound system (Vivid 7 GE 
Healthcare, with a M4S GE probe). Measures were performed offline with EchoPAC version 113 
GE Healthcare by two observers.  
Parameters were measured several times and then averaged. To minimize bias, operators 
performing the measurements were blinded to the invasive (including IMR) and non-invasive 
(including EndoPAT) results. 
The following echocardiographic parameters were evaluated in both exams:  
 Left ventricular end-diastolic, end-systolic volumes and left ventricular ejection fraction 
(measured in apical 4-chamber and 2-chamber views), using a semiautomatic border 
detection based on feature tracking imaging241; 
 Wall motion score index (WMSI), by 2D imaging, according to the European Society of 
Echocardiography’s Recommendations, using the 17-segment model on a 1–5 scale: 1-
normal, 2-hypokinesia, 3-akinesia, 4-dyskinesia, 5-aneurysmal. The final WMSI was 
calculated by adding the points for each segment (a lower score implies better left 
ventricular function)242; 
 Left atria volume (indexed to body surface area) by 2D imaging; 
 E/A ratio in the mitral inflow, obtained by pulsed-wave Doppler-echocardiography with 
the sample volume between mitral leaflet tips during diastole; 
 Ratio of early diastolic mitral inflow velocity to early diastolic mitral annular velocity (E/e´), 
using mitral annulus velocities obtained from the media of septal and lateral annulus by 
tissue Doppler imaging;  
 Global longitudinal strain (GLS), assessed using speckle-tracking analysis with automated 
function imaging. Peak longitudinal strain was defined as the change in length of the 
myocardium from end-diastole to end-systole and expressed as a percentage: longitudinal 
strain (%) = (L end-systole - L end-diastole)/L end-diastole x 100%, where L is the length of 
the region of interest. GLS was obtained from 2D grey scale images of the apical four-
chamber, two-chamber, and long-axis view with optimized frame rate (50–90 
frames/sec). Software identified the endocardial border, and myocardial motion was 
automatically tracked in each imaging view. In segments with poor tracking, the observer 
readjusted the endocardial trace line until a better tracking was achieved. The mean of 
the peak systolic longitudinal strain values from the 17 left ventricle segments was 
calculated to determine left ventricular GLS. 





3.9. Digital peripheral arterial tonometry (EndoPAT) 
 
Noninvasive measurements of endothelial function were done with EndoPAT 2000 (Itamar 
Medical®, Caesarea, Israel; Figure 9). The system includes a fingertip plethysmograph capable of 
sensing volume changes in the digit with each arterial pulsation.  
Measurements were performed in a thermoneutral environment, after admission to the Intensive 
Cardiac Intensive Care Unit, immediately after the primary PCI.  
As described below (see point 1.4, under Results), after an interim analysis of the results, patients 
also did a second evaluation 24 hours after the first, using the same methodology. 
 
 
Figure 9 – The EndoPAT 2000 
 
The protocol was the same followed in previous studies.222 Briefly, a complete digital peripheral 
arterial tonometry (PAT) endothelial function test includes three phases: baseline, occlusion, and 
hyperemia: 
 A blood pressure cuff is placed on one upper arm (study arm), while the other arm serves 
as a control (control arm).  
 A PAT probe is positioned on one finger of each hand and set by the computer to inflate 
to 10 mm Hg below diastolic pressure or 70 mm Hg (the lower value is selected). 
Recordings are taken simultaneously from both fingers throughout the study. The 
response in the control finger not experiencing hyperemia can be used to adjust for 
systemic effects (Figure 10).  
 After baseline data acquisition, the blood pressure cuff is inflated on one arm to 
suprasystolic pressures for 5 minutes. During the occlusion period, signals are absent from 




 After cuff release, pulse amplitude increases in the hyperaemic finger. The pulse 
amplitude recordings are digitized and analysed by an automated, proprietary algorithm. 
Average pulse amplitude is calculated for each 30-second intervals after cuff occlusion for 
up to 5 minutes.   
 As a measure of reactive hyperemia, the pulse amplitude tonometry is then calculated as 
the ratio of the average amplitude of the PAT signal over a 1-min time interval starting 1 
min after cuff deflation divided by the average amplitude of the PAT signal of a 3.5-min 
time period before cuff inflation (baseline).  
 Subsequently, PAT index values from the study arm are normalized to the control arm. All 
these data are analysed by a computer in an operator-independent manner, to get the 
reactive hyperemia index (RHI) and its logarithmic transformation (L_RHI). 
In patients with two exams, the same study arm (left or right) was used in both tests.  
 
 
Figure 10 – EndoPAT procedure 
 
3.10. Contrast Enhanced Cardiac Magnetic Resonance 
 
Cardiac magnetic resonance was performed in a subset of patients on the 7-8th day post-MI.243, 
using a 1.5-T magnetic resonance imaging system (Avanto, Siemens Medical System, Erlangen, 
Germany) equipped with a dedicated cardiac software package and 8 available independent 




After the acquisition of localizing images, long- and short-axis cine images were obtained, using 
retrospectively ECG-gated breath-hold segmented K-space balanced steady-state free precession 
pulse sequence (trueFISP) technique. The short-axis cine scans of 6-mm slices were used to 
determine the left ventricular mass, volume, and function (in-plane resolution 1.6x1.6mm; gap 
2mm). STIR technique, a triple-IR black-blood turbo spin echo pulse sequence was used for 
oedema quantification (area at risk). 
 
A bolus of contrast medium (gadopentetate dimeglumine - Magnevist, Schering AG, Berlin, 
Germany) was injected at a dose of 0.2 mmol/kg.  Early enhancement images for microvascular 
obstruction assessment were obtained by acquiring an inversion-recovery segmented gradient 
echo T1-weighted sequence with a high inversion time (approximately 500 ms), 2-4 min after 
gadolinium injection. Delayed enhancement images were then obtained by acquiring an inversion-
recovery segmented gradient echo T1-weighted sequence, 10 to 15 min after the bolus.  
 
All post-processing and analyses of the left ventricular mass, volume, function, area at risk, 
myocardial infarct size, and presence of microvascular obstruction were performed using CVI 42 
Version 5 Software (Circle Cardiovascular Imaging Inc, Calgary, Canada) by a cardiologist 
experienced in CMR and blinded to all clinical and invasive physiological data.  
 
Area-at-risk was manually quantified on short-axis STIR sequences slices, delineating higher 
intensity areas (no threshold definition) at each slice, with subsequent computation for mass 
estimation. Infarct size was also assessed manually by planimetry on each short-axis slice, 
delineating the hyperenhanced area, including areas of hypoenhancement surrounded by the 
hyperenhanced area, the latter being considered microvascular obstruction. Infarct size, as a 
percentage of left ventricular mass, was computed from the sum of hyperenhanced pixels from 
each of the 10 short-axis images divided by the total number of pixels within the left ventricular 
myocardium multiplied by 100% (21)244. Microvascular obstruction mass was also manually 
quantified as the sum of hypoenhanced pixels at delayed enhancement sequences as better 
spatial resolution was found when compared for early enhancement sequences245.  
 
 
4. STATISTICAL ANALYSIS 
 
Continuous variables are presented as mean ± standard deviation (normal distribution) or as 
median and interquartile range (non-normal distribution); categorical variables are presented as 
frequencies.  
All analysis of categorical dependent variables (i.e., RHI<1.67 vs. >1.67, IMR<24 vs >24, etc.) were 
performed using independent sample T-Test for continuous variables with a normal distribution, 
Mann-Whitney Test, for continuous variables with a non-normal distribution and Chi-square for 




Analysis according to RHI tertiles was performed using one-way ANOVA for continuous variables 
with a normal distribution and Kruskal-Wallis for continuous variables with non-normal 
distribution. 
Analysis of IMR or RHI as continuous variables were performed using Pearson’s correlation for 
continuous variables with a normal distribution and Spearmans’s rho correlation for continuous 
variables with a non-normal distribution 
The analysis of IMR predictors was adjusted for confounding variables by linear regression 
analyses, including the variables identified as relevant on univariate analysis and also all variables 
considered clinically relevant.  
For paired comparisons, paired sample T test, Wilcoxon or signs test was used, as indicated.  
Statistical tests and corresponding p-values were two-sided and a p value <0.05 was considered 
as statistically significant.  IBM SPSS version 21.0 was used for all statistical analyses. 
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1. Population included 
 
Between June 2012 and June 2015, a total of 543 ST elevation myocardial infarction patients 
treated by primary percutaneous coronary intervention were admitted to Hospital Prof. Doutor 
Fernando da Fonseca. Of these, 60 patients fulfilled all the inclusion criteria, accepted to 
participate in the study and were considered eligible for the procedure, according to the operator.  
The flowchart of patient inclusion is presented in Figure 11Error! Reference source not found..  
 




1.1. Main epidemiological characteristics 
 
Of the 60 patients included, 48 (80.0%) were male. Mean age was 59.6±12.7 years (58.5±12.0 for 
male and 63.9±14.7 for female patients). The histogram for age is presented in Figure 12. Half of 
the patients had a previous history of dyslipidaemia and one fourth were diabetics. The main risk 
factors in the population included are presented in Figure 13. Mean body mass index (BMI) was 
27.5±4.0 kg/m2 (28.0±3.8 kg/m2 for males and 25.4±4.2 kg/m2 for females). Mean waist 
circumference was 99.2±12.2 cm (100.2±12.0 for male and 92.5±12.6 cm for female patients). 
 
 
Figure 12 – Age distribution of patients 
included 
 
Figure 13 – Prevalence of main risk factors  
 
Most patients had no history of coronary artery disease: only 9 patients (15.0%) had previous 
angina complaints and 2 (3.3%) had previously undergone coronary angiography and 
percutaneous coronary intervention.  Accordingly, only 6 patients (10.0%) were on anti-platelet 
(aspirin or clopidogrel) therapy. Statins were used by 9 patients (15.0%). ACE 
inhibitors/angiotensin antagonists, beta-blockers and calcium channel antagonists were being 
used, respectively, by 23 (38.3%), 4 (6.7%) and 4 (6.7%) patients prior to hospital admission.   
 
1.2. Angiographic and angioplasty-related characteristics 
 
1.2.1 Out-of-hospital and in-hospital time delays 
 
The median time between the onset of symptoms and the first medical contact (“pain-to-door” 
time) was 130 minutes (IQR 126 minutes). The median time between the first medical contact 












median total ischemic time (time between the onset of symptoms and first balloon dilation, or 
“pain-to-balloon” time) was 209 minutes (IQR 148 minutes).  
 
1.2.2 Angiographic data 
 
The culprit artery was the left anterior descending artery (LAD) in 28 patients (46.7%), the left 
circumflex artery (LCx) in 13 patients (21.7%) and the right coronary artery in 19 patients 
(31.7%). Multivessel disease (classified as lesions >70% in major coronary arteries) was present 
in 25 patients (41.7%). The median Syntax score was 15.5 (IQR 10.0).  
TIMI flow on the first injection was 0 (no flow beyond the point of occlusion) or 1 (faint 
coronary flow beyond the occlusion with incomplete filling of the distal coronary bed) in 50 
patients (83.8%).  
 
1.2.3 Area-at-risk scores 
 
Mean APPROACH and BARI scores were similar: 28.5%±6.6% and 28.0%±6.3%, respectively, 
with a slight tendency for higher areas with the APPROACH score. Correlation between the 2 
scores was very high (R=0.90, p<0.001), suggesting that both scores perform similarly well in 
identifying the area at risk for each lesion location (Figure 14). 
 
 
Figure 14 – Correlation between APPROACH and BARI scores in identifying the area-at-risk 




1.2.4 Angioplasty procedure 
 
All patients received intravenous non-fractionated heparin and both aspirin (intravenous) and 
clopidogrel/ticagrelor (oral). Intracoronary nitrates were also administrated in all patients, 
since it is mandatory for the IMR measurement. Fourteen patients (23.3%) received 
intravenous abciximab during angioplasty.  
Mechanical thrombectomy (aspiration) was performed in 26 cases (43.3%).  Stents were 
implanted in 57 (95.0%) and a direct stenting technique was used in 25 (41.7%), with balloon 
post-dilation in 28 (38.3%). 
 
1.2.5 Angiographic  indicators of microvascular perfusion 
 
A normal (TIMI 3) flow was obtained in all patients. Corrected TIMI frame count (cTFC) and 
TIMI myocardial perfusion grade (TMPG) were measured in all patients immediately after the 
P-PCI. cTFC median value was 17.0 (IQR 7.0). A normal 3 TMPG was obtained in 37 patients 
(61.7%).  Patients with lower TMPG had, as expected, higher cTFC values (Figure 15). 
 
 
Figure 15 – Corrected TIMI frame count, according to TIMI myocardial perfusion grade 






1.3. Index of microcirculatory resistance (IMR) 
 
IMR was measured in all patients. Median IMR value was 23.9 (IQR 32.9). An IMR value higher 
than 40 was measured in 21 patients (35.0%).  
Two examples of IMR measurements are presented in Figure 16. 
 Example 1 corresponds to a young 28 years old male patient with an inferior 
myocardial infarction, due to a proximal RCA occlusion, revascularized (pain-to-balloon 
time) 155 minutes after symptoms onset. His IMR was 17.  
 Example 2 corresponds to a 75 years old female patient, with an inferior myocardial 
infarction revascularized 192 minutes after symptoms onset; she had a proximal LCx 
occlusion successfully revascularized and her IMR after the procedure was 76.  
 
 






1.4. Endothelial function (EndoPAT) 
 
The first EndoPAT evaluation was performed immediately after the P-PCI in all patients. Since 
these were seriously ill patients, with an acute ST elevation myocardial infarction, endothelial 
dysfunction (defined as an RHI< 1.67) was expected to be present in a majority of patients. 
However, when the first 20 patients were included, an interim analysis showed that exactly the 
opposite was apparently happening, since RHI values in these first patients were actually higher 
than the ones we previously reported, both in normal and in coronary artery disease patients.18,20 
Following this interim analysis, it was decided to perform a second EndoPAT evaluation 24 hours 
after the first. This second EndoPAT exam is available in 38 patients.  The mean values of the 
reactive hyperaemia index (RHI) and logarithmic RHI (L-RHI) are presented in Table 15, together 
with the percentage of patients with endothelial dysfunction (RHI<1.67). When only patients with 
2 EndoPAT evaluations were considered (n=38), RHI measured in the first EndoPAT (2.16±0.52) 
was similar to the total population (n=60, 2.15±0.58), suggesting this subgroup with 2 evaluations 
is similar to the whole sample population.  
 




1st EndoPAT in patients 





RHI a 2.15±0.58 2.16±0.52 1.87±0.60 0.006  
Endothelial dysfunction (RHI<1.67)b 11 (18.3) 6 (15.8) 16 (42.1) 0.011  
L_RHI a 0.73±0.28 0.74±0.24 0.61±0.25 0.006  
a Presented as mean±standard deviation; b Presented as N(%). C p-value for the comparison between first and second EndoPAT only in 
patients with 2 evaluations; paired samples T-Test for continuous variables and Chi-square test for categorical variables; RHI: reactive 
hyperaemia index; L_RHI: logarithmic RHI. 
 
In patients with 2 EndoPAT evaluations, RHI values were significantly lower in the second 
evaluation (1.87±0.60 vs. 2.16±0.52, p=0.006). Accordingly, the number of patients with 
endothelial dysfunction (RHI<1.67) increased from 15.8% to 42.1% (p=0.011). 
Another important question, as shown in the boxplot of RHI values in the first EndoPAT (Figure 
17) is that there were 6 outliers – one extremely low value (0.64, in a female patient with vasculitis 






Figure 17 – Reactive hyperaemia index (RHI) values on the 1st EndoPAT (complete cohort) 
 
When these extreme values were excluded from the analysis (Figure 18, Table 16), mean value of 
RHI was naturally lower (2.08±0.42).  
 
 





Importantly, the same observations described above for the complete cohort were confirmed in 
this “purified” population: 
 When only patients with 2 EndoPAT evaluations were considered (n=35), RHI measured 
in the first EndoPAT (2.06±0.41) was similar to the one measured in the global population 
(n=54, 2.08±0.42). 
 In these patients with 2 EndoPAT evaluations, RHI values were significantly lower in the 
second evaluation (1.81±0.56 vs. 2.06±0.41, p=0.018), and the number of patients with 
endothelial dysfunction (RHI<1.67) increased from 15.8% to 45.7% (p=0.01). 
In this population, values of RHI on the second EndoPAT evaluation did not correlate well with 
values on the first EndoPAT (r=0.260, p=0.131). Among the 6 patients with endothelial dysfunction 
(RHI<1.67) on the first EndoPAT, 3 (50.0%) evolved to normal endothelial function on the second 
one.  On the other hand, 13 of the 29 patients (44.8%) with a normal endothelial function on the 
first EndoPAT ended up with endothelial dysfunction (RHI<1.67) on the second evaluation. 
Although patients with endothelial dysfunction (RHI<1.67) on the second EndoPAT had a tendency 
for lower RHI values on the first evaluation (1.92±0.36, vs. 2.17±0.42), this difference was not 
statistically significant (p=0.07). Altogether, this data suggests that the first EndoPAT results are 
apparently not related to the second EndoPAT results.  
 




1st EndoPAT in patients 





RHI a 2.08±0.42 2.06±0.41 1.81±0.56 0.018  
Endothelial dysfunction (RHI<1.67)b 10 (16.7) 6 (15.8) 16 (45.7) 0.01  
L_RHI 0.70±0.20 0.70±0.20 0.59±0.24 0.006  
a Presented as mean±standard deviation; b Presented as N(%). C p-value for the comparison between first and second EndoPAT only in 
patients with 2 evaluations; paired samples T-Test for continuous variables and Chi-square test for categorical variables; RHI: reactive 
hyperaemia index; L_RHI: logarithmic RHI. 
 
Two examples of EndoPAT measurements are presented in Figure 19.  Panel A corresponds to a 
patient with normal reactive hyperaemic response (RHI 2.14), with an increase of signal amplitude 
after unilateral cuff occlusion (bottom graph), corrected with contralateral finger signal (top 
graph). Panel B corresponds to a patient with an abnormal response (RHI 1.40) with a blunted 






Figure 19 - Examples of peripheral endothelial function measured by digital pulse amplitude 
with endothelial peripheral arterial tonometry 
 
 
1.5. Laboratory tests 
 
1.3.1 Laboratory tests on admission 
 
A blood sample was collected on admission in all patients. Among others, glucose, HbA1c, 
creatinine, high sensitive C-reactive protein and NT-pro-BNP were measured, along with 
cardiac enzymes (see below). In a few cases, not all are available. Median values are presented 
in Table 17.  
 
Table 17 – Admission laboratory values 
Test Available in Median (IQR) Median ± standard deviation 
Creatinine (mg/dL) 60 0.90 (0.31) 0.95±0.30 
hs-CRP (mg/dL) 59 0.44 (0.59) 0.78±0.93 
Glucose (mg/dL) 56 133.5 (61.0) 158.8±85.5 
HbA1c 49 5.7 (1.1) 6.4±1.9 
NT-pro-BNP (pg/mL) 54 137.5 (255.6) 334.0±728.5 
 
1.3.2 Cardiac enzymes 
 
Peak values and the area under the curve of creatine kinase (CK), Mb fraction of creatine kinase 
(CK-Mb) and Troponin I (TnI), measured on admission and at 6, 12, 18, 24, 36 and 48 hours are 




presented in Table 18. In order to account for the area-at-risk for each lesion, these values 
were indexed to APPROACH and BARI scores. 
 
Table 18 – Total and indexed values for maximal and AUC values of cardiac biomarkers 
Test Total 
Indexed  Correlation 
APPROACH BARI R p value a 
Creatine Kinase (UI/L) 
   Peak value 2370±1539 692±568 673±516 0.989 <0.001 
   AUC 43398±24921 12645±9171 12296±8282 0.987 <0.001 
Mb Fraction of Creatine Kinase (CK-Mb) 
   Peak value 255±141 74±48 72±46 0.981 <0.001 
   AUC 4291±1834 1232±622 1208±612 0.975 <0.001 
Troponin I (ng/mL)      
   Peak value 117±82 34±27 33±25 0.994 <0.001 
   AUC 1938±1283 565±441 548±405 0.993 <0.001 
a Spearman correlation between APPROACH and BARI indexed values; AUC – area under the curve 
 
 
1.6. ECG ST segment resolution 
 
ECGs were performed in all patients, before and immediately after the P-PCI, and 90 and 80 min 
after the procedure. Total ST elevation, total ST deviation and ST elevation in the lead with largest 
ST-segment-elevation, along with the respective percent resolution, are presented in Table 19. 
 
Table 19 – ECG parameters before and after primary PCI 
 
Pre-PCI 
Post-PCI 90 min 180 min 
 Residual % resolution Residual % resolution Residual % resolution 
Total ST elevation 9.5(11.6) 3.3 (6.0) 74.5 (39.0) 1.5 (4.0) 79.5 (32.0) 1.5 (3.0) 84.5 (33.0) 
Total ST deviation 13.3 (17.5) 4.8 (6.0) 73.5 (44.0) 2.0 (4.0) 82.5 (33.0) 1.5 (4.0) 88.0 (26.0) 
ST max lead a 3.0 (3.9) 1.0 (2.0) 68.0 (47.0) 0.5 (2.0) 77.5 (34.0) 0.5 (2.0) 83.0 (33.0) 
Values expressed as median (Interquartile range), in mV; a ST in lead with initial largest ST elevation. 
 
Classical ECG criteria suggesting reperfusion (i.e., ST resolution >70% of the changes observed in 




minutes (Table 20). Remarkably, in this group of patients with adequate (final TIMI 3 flow) and 
relatively early reperfusion, about 1/5 maintained significant ST changes, suggesting 
microcirculatory damage.   
 
Table 20 – ST resolution >70% in ECGs performed after the primary PCI 
 Post-PCI 90 min 180 min 
Total ST elevation 34 (56.7) 41 (68.3) 49 (81.7) 
Total ST deviation 32 (53.3) 41 (68.3) 46 (76.7) 
ST max lead a 29 (48.3) 33 (55.0) 41 (68.3) 
Values expressed as number (%); a ST at lead with initial largest ST elevation. 
 
1.7. Echocardiographic evaluation 
 
The first (acute) echocardiographic evaluation was not performed in 3 patients, due to unplanned 
logistic restrictions. In the remaining 57 patients:  
 In 6 cases, the echo was performed, but the images are not available due to errors in the 
DICOM files; 
 In 4 patients the quality of the images was considered inappropriate for analysis; 
 The remaining 47 patients were included in the morphological (2D) analysis; 
 From these, only 40 had images with enough quality for the speckle tracking imaging 
analysis.  
The second (3 month) echocardiographic evaluation was not performed in 4 patients, which were 
lost for follow-up or missed the schedule date for the exam. In the remaining 56 patients:  
 In 2 cases, the exam was performed, but the images are not available due to errors in the 
DICOM files; 
 The remaining 54 were included in the morphological (2D) analysis; 
 From these, only 51 had images with enough quality for the speckle tracking imaging 
analysis.  
In 45 patients, both exams were available, and 35 of these had images with enough quality for the 
speckle tracking imaging analysis to be performed.  
Main results of both exams are presented in Table 21 (2D measurements) and Table 22 (Doppler 
and 2D speckle tracking imaging). Between the two exams, significant improvements were 
documented in LVEF, WMSI, E/A ratio and GLS (analysis performed only for patients with 2 exams).  
Importantly, when comparing mean values in patients with and without the 2 exams, results were 





Table 21 – 2D measurements in first (acute) and second (3 months) echocardiographic exams 









Patients w/ 2 echos 
(n=45) 
LVEdV (ml) a 105.8±24.2 105.4±24.8 109.7±26.4 109.8±27.8 0.18 
LVEsV (ml) a 54.7±12.7 54.1±12.5 52.9±18.8 53.0±19.6 0.60 
LVEF (%) a 47.9±6.7 48.3±6.0 52.6±7.1 52.6±6.7 0.001 
WMSI b 1.41 (0.35) 1.41 (0.35) 1.24 (0.35) 1.24 (0.35) <0.001 
LA Volume (ml/m2) a 34.8±12.2 34.3±11.8 39.1±15.4 39.8±16.6 0.005 
a Presented as mean±standard deviation; b Presented as median (interquartile range); C p-value for the comparison between the first 
and the second echo only in patients with 2 evaluations; paired samples T-Test for variables with normal distribution and Wilcoxon 
test for variables with non-normal distribution. LVEdV – left ventricular end diastolic volume; LVEsV – left ventricular end systolic 
volume; LVEF – left ventricular ejection fraction; WMSI – wall motion score index. LA – left atria 
 
Table 22 – Doppler and 2D speckle tracking measurements in first (acute) and second (3 
months) echocardiographic exams 









Patients w/ 2 echos 
(n=35) 
Doppler measurements     
   E/A ratio a 1.00±0.34 0.99±0.34 1.20±0.56 1.14±0.51 0.022 
   E/e’ ratio a 9.00±2.71 9.00±2.84 8.83±3.29 8.89±3.58 0.82 
2D speckle tracking imaging     
   GLS a -13.54±2.28 -13.88±2.09 -15.77±3.11 -15.67±3.10 <0.001 
a Presented as mean±standard deviation; b p-value for the comparison between the first and the second echo only in patients with 2 
evaluations; paired samples T-Test for variables. GLS – global longitudinal strain  
 
 
1.8. Contrast enhanced cardiac magnetic resonance (ceCMR) 
 
Of the 60 patients included in the study: 
 4 refused to perform the ceCMR, mainly because of claustrophobia; 
 3 did not perform the exam due to logistic limitations; 
 2 did the exam, but images were lost; 
 2 did the exam, but the quality of the images was considered inadequate for evaluation; 




The exam was performed 8.8 days (6-13) after the primary PCI. Oedema was present in all but 1 
patient. Microvascular obstruction was identified in 13 patients (26.5%) and complete transmural 
necrosis was found in 23 (46.9%). 
Figure 20 depicts three examples of ceCMR exams, with one case of extensive no-reflow, one case 
of transmural infarction and one of subendocardial infarction.  
 
 
Figure 20 – Three examples of ceCMR 
Left column images depict myocardial oedema (area at risk) as assessed by t2-weighted stir (short tau inversion 
recovery) sequences; the column in the centre shows early enhancement acquisition with a long time of inversion for 
microvascular obstruction detection; right column shows delayed enhancement sequences for infarct mass estimation. 
Patient A: large area at risk (between arrows) with extensive no-reflow (yellow arrow), clearly depicted across a 
transmural antero-septal infarction (short yellow arrow); Patient B: lateral oedema (between arrows) with absence of 
no-reflow despite the presence of a transmural infarction (*); Patient C: antero-septal oedema (between arrows), 







2. Outcome measures - summary 
 
The primary outcome measures were, as stated above, the IMR values according to the presence 
of endothelial dysfunction (RHI<1.67) and to RHI tertiles. Since a second EndoPAT measurement 
was performed, these 2 outcomes will be presented for each EndoPAT exam. Additionally, analysis 
of RHI as a continuous variable will also be presented for each EndoPAT evaluation. So, in 
summary, primary outcomes measures will be presented as follows: 
First EndoPAT  
1. IMR values in patients with and without endothelial dysfunction (RHI<1.67) in the first 
EndoPAT (Section 3.1). 
2. IMR values according to RHI tertiles in the first EndoPAT (Section 3.2). 
3. Relation of RHI as a continuous variable in the first EndoPAT to IMR values (Section 3.3). 
Second EndoPAT  
4. IMR values in patients with and without endothelial dysfunction (RHI<1.67) in the second 
EndoPAT (Section 4.1). 
5. IMR values according to RHI tertiles in the second EndoPAT (Section 4.2). 
6. Relation of RHI as a continuous variable in the second EndoPAT to IMR values (Section 
4.3). 
 
Secondary outcome measurements included the impact or relation between RHI and IMR and the 
extent of myocardial necrosis and microvascular reperfusion, evaluated by several different 
methods. These results will be presented as follows: 
First EndoPAT 
1. Impact of the presence of endothelial dysfunction (RHI<1.67) in the first EndoPAT on the 
extent of myocardial infarction, evaluated by troponin release, echocardiographic 
parameters and ceCMR (Section 5.1). 
2. Impact of the presence of endothelial dysfunction (RHI<1.67) in the first EndoPAT on 
microvascular reperfusion indicators, including angiographic indicators (cTFC and TMPG), 




3. Impact of the presence of endothelial dysfunction (RHI<1.67) in the second EndoPAT on 
the extent of myocardial infarction, evaluated by troponin release, echocardiographic 
parameters and ceCMR (Section 6.1). 
4. Impact of the presence of endothelial dysfunction (RHI<1.67) in the second EndoPAT on 
microvascular reperfusion indicators, including angiographic indicators (cTFC and TMPG), 




Index of microcirculatory resistance (IMR) 
5. Relation between IMR and patient baseline characteristics (Section 7.1) 
6. Impact of the presence of coronary microvascular damage as evaluated by an IMR>24 
(median value) on the extent of myocardial infarction, evaluated by troponin release, 
echocardiographic parameters and ceCMR (Section 7.2). 
7. Relation between the presence of coronary microvascular damage as evaluated by an 
IMR>24 (median value) on microvascular reperfusion indicators, including angiographic 
indicators (cTFC and TMPG), ECG (ST resolution) and ceCMR (microvascular obstruction) 






3. Primary outcome – IMR and RHI values on the first EndoPAT 
 
3.1. IMR values in patients with and without endothelial dysfunction (RHI<1.67) on 
the first EndoPAT 
 
Endothelial dysfunction, as evaluated by an RHI<1.67, was present in 11/60 patients (18.3%) in 
the first EndoPAT evaluation.  In the following pages, the main patients characteristics according 
to the presence of endothelial dysfunction will be shortly described, followed by the IMR analysis.  
 
3.1.1. Main characteristics of patients according to the presence of endothelial 
dysfunction (RHI<1.67) 
 
Table 23 summarizes the main characteristics of patients with and without endothelial 
dysfunction (RHI<1.67) in the first EndoPAT evaluation.  
 
Table 23 – Main characteristics of patients according to the presence of endothelial 




Endothelial dysfunction (RHI<1.67) 
p value c 
No (n=49) Yes  (n=11) 
Physical characteristics     
   Age (years) a 59.6±12.7 59.7±13.4 59.1±9.5 0.89 _ 
   Male gender b 48 (80.0) 39 (79.6) 9 (81.8) 0.80 d 
   BMI a 27.5±4.0 27.5±4.0 27.4±4.2 0.94 _ 
   Waist circumference a 99.2±12.2 98.9±12.0 100.8±14.0 0.68 _ 
Risk Factors and previous coronary disease b 
   Hypertension  43 (71.7) 34 (69.4) 9 (81.8) 0.21 d 
   Diabetes  15 (25.0) 10 (20.4) 5 (45.5) 0.18 d 
   Dyslipidaemia 30 (50.0) 25 (51.0) 5 (45.5) 0.74 _ 
   Active smoking 26 (43.3) 17 (34.7) 9 (81.8) 0.01 d 
   Previous angina 9 (15.0) 7 (14.3) 2 (18.2) 0.89 d 
   Previous revascularization 2 (3.3) 1 (2.0) 1 (9.1) 0.80 d 
Previous medication b     
   Aspirin 5 (8.3) 3 (6.2) 2 (18.2) 0.50 d 
   Clopidogrel 1 (1.7) 1 (2.1) 0 (0.0) 0.42 d 
   ACEi/ARBs 23 (38.3) 17 (35.4) 6 (54.5) 0.41 d 
   Beta-blockers 4 (6.7) 1 (2.1) 3 (27.3) 0.04 d 
   Nitrates 1 (1.7) 0 (0.0) 0 (0.0) - 
   Statins 9 (15.0) 6 (12.5) 3 (27.3) 0.44 d 
a Presented as mean±standard deviation; b Presented as number (%); c Independent t-test for continuous variables, Chi-Square for 





Patients whit endothelial dysfunction were more frequently active smokers (81.8% vs. 34.7%, 
p=0.01), but there were no other significant differences in physical characteristics or in other 
risk factors between the two groups. Patients with endothelial dysfunction were more likely to 
be on beta-blocker treatment, but the numbers were too small (1 vs. 3 patients) to allow for 
any valid conclusion. There were no other significant differences in previous treatment, 
including anti-platelets and statins.   
Blood tests on admission, including creatinine, NT-pro-BNP, hsCRP, glucose and HbA1c, were 
also similar between both populations (Table 24). 
 
Table 24 – Laboratory results on admission according to the presence of endothelial 




Endothelial dysfunction (RHI<1.67) 
p value c 
No (n=49) Yes  (n=11) 
Creatinine (mg/dL) b  0.90 (0.31) 0.90 (0.35) 0.89 (0.16) 0.51 
NT-pro-BNP (pg/mL) b 137.5 (255.5) 137.5 (256.3) 191.3 (265.8) 0.99 
hsCRP (mg(dL) b 0.44 (0.59) 0.40 (0.58) 0.50 (1.11) 0.46 
Glucose (mg/dL) b 133.5 (61.0) 131.0 (60.0) 139.0 (64.0) 0.77 
HbA1c (%)b 5.7 (1.1) 5.7 (0.7) 5.7 (1.4) 0.91 
a Presented as mean±standard deviation; b Presented as median (interquartile range); c Independent t-test for continuous variables 
with a normal distribution, Mann-Whitney test for continuous variables with a non-normal distribution.  
 
 
3.1.2. Angiography and angioplasty variables according to the presence of 
endothelial dysfunction (RHI<1.67) 
 
There were no significant differences in ischemic (pain-to-balloon) or hospital-to-balloon times 
between patients with and without endothelial dysfunction. Main angiographic characteristics, 
including culprit artery, presence of multivessel disease, Syntax score and initial TIMI flow were 
also similar in both groups (Table 25).  
The area-at-risk, measured both by the APPROACH and BARI scores, was also similar. 
Finally, treatment options (use of mechanical aspiration, stent implantation technique and use 







Table 25 – Ischemic times and angiographic characteristics according to the presence of 




Endothelial dysfunction (RHI<1.67) 
p value d 
No (n=49) Yes  (n=11) 
Pain-to-balloon time (min)c 209 (148) 210 (156) 174 (128) 0.52 x 
Door-to-balloon time (min) c 78 (45) 76 (49) 80 (59) 0.37 x 
Culprit artery b     
       Left anterior descending 28 (46.7) 24 (49.0) 4 (36.4) 
0.95 e        Left circumflex 13 (21.7) 10 (20.4) 3 (27.3) 
       Right coronary artery 19 (31.7) 15 (30.6) 4 (36.4) 
Multivessel disease b 25 (41.7) 22 (44.9) 3 (27.3) 0.54 e 
Syntax score c 15.5 (10.0) 15.5 (11.0) 16.5 (9.0) 0.72 x 
Area at risk scores a     
       APPROACH score 28.5±6.6 28.1±6.9 30.2±5.5 0.33 x 
       BARI score 27.7±6.3 27.4±6.4 30.6±5.4 0.13 x 
Initial TIMI flow 0-1 b 50 (83.3) 41 (83.7) 9 (81.8) 0.77 e 
a Presented as mean±standard deviation; b Presented as number (%); c Presented as median (interquartile range); d Independent 
t-test for continuous variables with a normal distribution, Mann-Whitney test for continuous variables with a non-normal 
distribution, Chi-Square for categorical variables; e Yates correction 
 
 
Table 26 – Angioplasty treatment options according to the presence of endothelial 




Endothelial dysfunction (RHI<1.67) 
p value b 
No (n=49) Yes  (n=11) 
Mechanical aspiration 26 (43.3) 21 (42.9) 5 (45.5) 0.86 
Balloon pre-dilatation 35 (58.3) 29 (59.2) 6 (54.5) 0.96 
Stent implantation 57 (95) 46 (93.9) 11 (100.0) 0.94 
Balloon post-dilatation 23 (38.3) 20 (40.5) 3 (27.3) 0.62 
Abciximab treatment 14 (23.3) 9 (18.4) 5 (45.5) 0.13 
a Presented as number (%); b Chi-Square test, with Yates correction 
 
 
3.1.3. IMR according to the presence of endothelial dysfunction (RHI<1.67) 
 
IMR median values did not differ (and actually tended to be lower) between patients with and 
without endothelial dysfunction on the first EndoPAT evaluation (Figure 21, Table 27). 
There was also no difference in the prevalence of microvascular coronary damage, whether 
this was defined as an IMR >24 (median value) or an IMR >40 (value published in the literature 
as prognostic marker in STEMI patients). Finally, coronary flow reserve (CFR) values were also 




Table 27 – Invasive hemodynamic measurements according to the presence of endothelial 




Endothelial Dysfunction (RHI<1.67) 
p value d 
No (n=49) Yes  (n=11) 
IMR c 23.9 (32.9) 24.0 (31.2) 16.0 (37.3) 0.17 
   IMR < 24 (median) b 30 (50) 23 (46.9) 7 (63.6) 0.32 
   IMR < 40 b 21 (35) 31 (63.9) 8 (72.7) 0.55 
Coronary flow reserve c 1.1 (0.8) 1.1 (0.8) 1.2 (2.0) 0.45 
Basal SBP a 111.4±28.3 108.7±28.1 122.5±27.6 0.15 
Basal DBP a 61.5±13.8 60.3±14.3 66.2±10.3 0.21 
Hyperaemic  SBP a 91.6±22.5 91.0±23.6 94.2±18.2 0.68 
Hyperaemic  DBP a 51.3±13.2 50.1±13.2 56.2±12.3 0.63 
Aortic pressure a 65.3±15.7 64.1±16.0 69.8±14.2 0.13 
Distal pressure a 71.8±23.1 69.5±22.8 81.1±22.8 0.29 
a Presented as mean±standard deviation; b Presented as number (%); c Presented as median (interquartile range); d Independent 
t-test for continuous variables with a normal distribution.  Mann-Whitney test for continuous variables with a non-normal 
distribution. Chi-Square for categorical variables 
 
 
Figure 21 – Boxplot of IMR values according to the presence of endothelial dysfunction 
(RHI<1.67) on the first EndoPAT evaluation 
 
In summary, there were no significant differences in IMR values in patients with and without 
RHI<1.67 on the first EndoPAT evaluation. With the exception of active smoking and previous 
beta-blocker therapy, endothelial dysfunction also did not relate to any patient baseline 
characteristics, including age, risk factors, blood tests on admission, coronary anatomy or 




3.2. IMR values according to RHI tertiles on the first EndoPAT  
 
According to the defined protocol, RHI was divided in tertiles: 
 Tertile 1 (n=20): RHI< 1.92  
 Tertile 2 (n=20): RHI 1.92 – 2.30  
 Tertile 3 (n=20): RHI> 2.30. 
In the following pages, the main patient characteristics according to RHI tertiles will be shortly 
described, followed by the IMR analysis in these groups. 
 
3.2.1. Main characteristics of patients according to tertiles of RHI 
 
Table 28 summarizes the main characteristics of patients according to RHI tertiles on the first 
EndoPAT evaluation.  There were no significant differences in any of the analysed variables, 
including physical characteristics, risk factors and previous pharmacological treatment. Blood 
tests results on admission were also similar (Table 29). 
 











Tertile 3  
(n=20) 
Physical characteristics 
   Age (years) a 59.6±12.7 58.9±11.6 58.8±15.1 61.0±11.4 0.83 x 
   Male gender b 48 (80.0) 16 (80.0) 15 (75.0) 17 (85.0) 0.89 d 
   BMI a 27.5±4.0 27.6±3.93 28.4±4.02 26.5±3.99 0.33 x 
   Waist circumference a 99.2±12.2 100.4±14.1 102.4±13.4 99.2±12.2 0.25 x 
Risk factors and previous coronary disease b 
   Hypertension  43 (71.7) 16 (80.0) 13 (65.0) 14 (70.0) 0.56 x 
   Diabetes  15 (25.0) 6 (30.0) 5 (25.0) 4 (20.0) 0.77 x 
   Dyslipidaemia 30 (50.0) 9 (45.0) 10 (50.0) 11 (55.0) 0.82 x 
   Active smoking 26 (43.3) 12 (60.0) 7 (35.0) 7 (35.0) 0.18 x 
   Previous angina 9 (15.0) 4 (20.0) 2 (10.0) 3 (15.0) 0.86 d 
   Previous 
revascularization 
2 (3.3) 1 (5.0) 1 (5.0) 0 (0.0) 0.94 d 
Previous medication b 
   Aspirin 5 (8.3) 2 (10.0) 1 (5.0) 2 (10.0) 0.97 d 
   ACEi/ARBs 23 (38.3) 9 (45.0) 7 (35.0) 7 (35.0) 0.79 x 
   Beta-blockers 4 (6.7) 3 (15.0) 1 (5.0) 0 (0.0) 0.44 d 
   Statins 9 (15.0) 4 (20.0) 3 (15.0) 2 (10.0) 0.88 d 
a Presented as mean±standard deviation; b Presented as number (%); c One-way ANOVA for continuous variables, Chi-Square 
















Tertile 3  
(n=20) 
Creatinine (mg/dL) b  0.90 (0.31) 0.90 (0.17) 0.90 (0.40) 0.96 (0.36) 0.62 
NT-pro-BNP (pg/mL) b 137.5 (255.5) 162.0 (269.0) 113.0 (170.5) 131.5 (298.0) 0.64 
hs-CRP (mg(dL) b 0.44 (0.59) 0.64 (0.71) 0.29 (0.35) 0.44 (0.95) 0.10 
Glucose (mg/dL) b 133.5 (61.0) 122.0 (54.0) 141.5 (60.0) 131.0 (61.0) 0.63 
HbA1c (%)b 5.7 (1.1) 5.5 (0.9) 5.8 (1.9) 5.7 (2.3) 0.44 
a Presented as mean±standard deviation; b Presented as median (interquartile range); c One-way ANOVA for continuous variables 
with a normal distribution, Kruskal-Wallis test for continuous variables with a non-normal distribution.  
 
 
3.2.2. Angiography and angioplasty variables according to RHI tertiles 
 
There were no significant differences in pain-to-balloon or hospital-to-balloon times in RHI 
tertiles groups. Main angiographic characteristics, including culprit artery, presence of 
multivessel disease, Syntax score and initial TIMI flow were also similar (Table 30). 
 











Tertile 3  
(n=20) 
Pain-to-balloon time (min)c 209 (148) 223 (149) 201 (179) 200 (102) 0.85 x 
Door-to-balloon time (min)c 78 (45) 82 (45) 67 (55) 76 (43) 0.43 x 
Culprit artery b      
       Left anterior descending 28 (46.7) 10 (50.0) 8 (40.0) 10 (50.0) 
0.99 e        Left circumflex 13 (21.7) 4 (20.0) 5 (25.0) 4 (20.0) 
       Right coronary artery 19 (31.7) 6 (30.0) 7 (35.0) 6 (30.0) 
Multivessel disease b 25 (41.7) 11 (55.0) 8 (40.0) 6 (30.0) 0.28 x 
Syntax score c 15.5 (10.0) 16.0 (9.0) 11.8 (12.0) 15.8 (7.0) 0.95 x 
Area at risk scores 
       APPROACH score a 27.8 (2.0) 27.8 (4.0) 27.8 (4.0) 27.8 (2.0) 0.63 x 
       BARI score a 27.7±6.3 29.3±7.3 28.0±5.7 26.7±6.0 0.46 x 
Initial TIMI flow 0-1 b 50 (83.3) 17 (85.0) 19 (95.0) 14 (70.0) 0.23 e 
a Presented as mean±standard deviation; b Presented as number (%); c Presented as median (interquartile range); d One-way 
ANOVA for continuous variables with a normal distribution, Kruskal-Wallis test for continuous variables with a non-normal 
distribution, Chi-Square for categorical variables; e Yates correction 
 
The area-at-risk, measured both by the APPROACH and BARI scores, was also similar in the 
three tertiles. Finally, treatment options (use of mechanical aspiration, stent implantation 















Tertile 3  
(n=20) 
Mechanical aspiration 26 (43.3) 8 (40.0) 8 (40.0) 10 (50.0) 0.76 x 
Balloon pre-dilatation 35 (58.3) 12 (60.0) 12 (60.0) 11 (55.0) 0.93 x 
Stent implantation 57 (95) 19 (95.0) 19 (95.0) 19 (95.0) 0.67 c 
Balloon post-dilatation 23 (38.3) 7 (35.0) 8 (40.0) 8 (40.0) 0.93 x 
Abciximab 14 (23.3) 8 (40.0) 2 (10.0) 4 (20.0) 0.17 x 
a Presented as number (%); b Chi-Square test; c Yates correction 
 
 
3.2.3. IMR according to RHI tertiles 
 
IMR median values did not differ between tertiles of RHI. The number of patients with coronary 
microvascular dysfunction (IMR>24 or IMR>40) was also similar in the three groups. All other 
invasive measurements were similar across RHI tertiles (Table 32). 
 











Tertile 3  
(n=20) 
IMR a 23.9 (32.9) 19.4 (35.0) 40.5 (31.2) 23.3 (30.3) 0.26 
   IMR < 24 (median) b 30 (50) 9 (45.0) 13 (65.0) 8 (40.8) 0.25 
   IMR < 40 b 21 (35) 6 (30.0) 10 (50.0) 5 (25.0) 0.22 
Coronary flow reserve a 1.1 (0.8) 1.3 (0.84) 1.0 (0.50) 1.1 (0.9) 0.36 
a Presented as median (interquartile range); b Presented as number (%); c Mann-Whitney test for continuous variables with a non-




In summary, there were no significant differences in IMR values between tertiles of RHI measured 
on the first EndoPAT. RHI tertiles did not relate either to any baseline patient characteristics, 
including age, risk factors, blood test results on admission, coronary anatomy or procedural 




3.3.  Relation between RHI as a continuous variable on the first EndoPAT and IMR 
values  
 
3.3.1. RHI as a continuous variable and main baseline patient characteristics 
 
No significant associations were found between RHI and any baseline patient characteristics, 
including age, physical characteristics, risk factors, previous medication and blood tests on 
admission (Table 33, Table 34). 
 
Table 33 – Correlation between RHI on the first EndoPAT and baseline continuous variables 
Variables Correlation (R) p value a 
Physical characteristics   
   Age  0.110 0.402 
   BMI  -0.116 0.379 
   Waist circumference  -0.186 0.210 
Laboratory parameters on admission   
   Creatinine  (mg/dl) 0.120 0.360 
   NT-pro-BNP  (pg/mL) -0.123 0.376 
   hs-CRP (mg/dL) 0.007 0.960 
   Glucose (mg/dL) -0.036 0.795 
   HbA1c (%) 0.072 0.622 
a Spearmans’s rho  
 
Table 34 – RHI values on the first EndoPAT according to baseline categorical variables 
Variables 
Variable present? a 
p value b 
No  Yes 
Physical characteristics     
   Male gender  1.99±0.61 2.19±0.57 0.280 
Risk factors and previous coronary disease  
   Hypertension  (43/60) 2.16±0.53 2.15±0.60 0.91 
   Diabetes  (15/60) 2.17±0.59 2.09±0.56 0.62 
   Dyslipidaemia (30/60) 2.07±0.58 2.24±0.57 0.26 
   Active smoking (26/609) 2.27±0.52 1.99±0.62 0.06 
   Previous angina (9/60) 2.14±0.55 2.21±0.75 0.71 
   Previous revascularization (2/60) 2.16±0.58 1.83±0.18 0.42 
Previous medication     
   Aspirin (5/60) 2.15±0.58 2.18±0.73 0.92 
   ACEi/ARBs (23/60) 2.17±0.50 2.12±0.70 0.71 
   Beta-blockers (4/60) 2.18±0.59 1.70±0.23 0.11 
   Statins (9/60) 2.18±0.61 1.97±0.40 0.32 
a RHI presented as mean±standard deviation; b Independent t-test for continuous variables with a normal distribution.  Mann-





3.3.2. RHI as a continuous variable and angiography/angioplasty variables  
 
No significant associations were found between RHI and angiographic or primary PCI variables 
(Table 35, Table 36). 
 
Table 35 – Correlation between RHI on the first EndoPAT and angiography and P-PCI 
related continuous variables 
Variables Correlation (R) p value a 
   Pain-to-balloon time (min) -0.012 0.925 
   Door-to-balloon time (min) -0.132 0.313 
   Syntax score  -0.132 0.314 
   Area at risk scores   
          APPROACH score -0.140 0.287 
          BARI score -0.216 0.097 
a Pearson’s Correlation for continuous variables with a normal distribution; Spearmans’s 




Table 36 – RHI values on the first EndoPAT according to angiography and P-PCI categorical 
variables 
Variables  
Variable present? a 
p value b 
No  Yes  
Angiography     
   Culprit artery  = LAD (28/60) 2.11±0.50 2.20±0.66 0.57 
   Multivessel disease (25/60) 2.07±0.63 2.26±0.49 0.20 
   Initial TIMI flow 0-1 (50/60) 2.51±0.76 2.05±0.48 0.09 
Primary PCI     
   Mechanical aspiration (26/60) 2.15±0.51 2.16±0.67 0.96 
   Balloon pre-dilatation (35/60) 2.22±0.65 2.10±0.53 0.46 
   Stent implantation (57/60) 2.08±0.31 2.15±0.59 0.83 
   Balloon post-dilatation (37/60) 2.18±0.60 2.10±0.56 0.62 
   Abciximab use (14/60) 2.21±0.58 1.97±0.57 0.19 
a RHI presented as mean±standard deviation; b Independent t-test for continuous variables with a normal distribution.  Mann-













3.3.3.  RHI as a continuous variable and IMR   
 
There was no relation between RHI measured on the first EndoPAT and IMR or any of the 
invasive measurements performed (Table 37). RHI values were similar in patients with and 





Table 37 – RHI on the first EndoPAT and invasive hemodynamic continuous variables 
Variables Correlation (R) p value a 
IMR 0.128 0.328 
Coronary flow reserve  -0.110 0.410 
Basal SBP  -0.022 0.875 
Basal DBP -0.219 0.109 
Hyperaemic  SBP  0.093 0.500 
Hyperaemic  DBP -0.054 0.695 
Aortic pressure  -0.011 0.934 
Distal pressure  0.007 0.958 
a Pearson’s Correlation for continuous variables with a normal distribution; Spearmans’s 
rho for continuous variables without a normal distribution 
 
 
Table 38 – RHI values on the first EndoPAT according to IMR thresholds 
Variables  
Variable present? 
p value b 
No  Yes 
   IMR < 24 (median) (30/60) 2.16±0.58 2.14±0.58 0.89 
   IMR < 40  (21/60) 2.18±0.68 2.10±0.34 0.64 




In summary, there was no relation between RHI as a continuous variable measured on the first 
EndoPAT and IMR measured immediately after P-PCI. RHI did not relate either to any baseline 
patient characteristics, including age, risk factors, blood tests on admission, coronary anatomy or 






4. Primary outcome – IMR and RHI values on the second EndoPAT 
 
4.1. IMR values in patients with and without endothelial dysfunction (RHI<1.67) on 
the second EndoPAT  
 
Endothelial dysfunction, as evaluated by an RHI<1.67, was present in 16/38 patients (42.1%) in 
the second EndoPAT evaluation. In the following pages, the main patient characteristics according 
to the presence of endothelial dysfunction will be shortly described, followed by the IMR analysis.  
 
4.1.1. Main characteristics of patients according to the presence of endothelial 
dysfunction (RHI<1.67) 
 
Table 39 summarizes the main characteristics of patients with and without endothelial 
dysfunction (RHI<1.67) on the second EndoPAT evaluation.  
 
Table 39 – Main characteristics of patients according to the presence of endothelial 




Endothelial dysfunction (RHI<1.67) 
p value c 
No (n=22) Yes  (n=16) 
Physical characteristics     
   Age (years) a 60.0±13.7 60.1±12.4 59.8±15.7 0.94 x 
   Male gender b 29 (76.3) 18 (81.8) 11 (68.8) 0.58 d 
   BMI a 27.2±4.0 27.4±4.5 27.1±3.3 0.82 x 
   Waist circumference a 100.0±11.5 101.1±12.6 98.5±9.9 0.55 x 
Risk factors and previous coronary disease b 
   Hypertension  26 (68.4) 16 (72.7) 10 (62.5) 0.50 x 
   Diabetes  12 (31.6) 8 (36.4) 4 (25.0) 0.46 x 
   Dyslipidaemia 19 (50.0) 11 (50.0) 8 (50.0) 1.00 x 
   Active smoking 13 (34.2) 9 (40.9) 4 (25.0) 0.31 x 
   Previous angina 7 (18.4) 6 (27.3) 1 (6.3) 0.22 d 
   Previous revascularization 2 (5.3) 1 (4.5) 1 (6.3) 0.61 d 
Previous medication b     
   Aspirin 3 (7.9) 2 (9.1) 1 (6.3) 0.73 d 
   Clopidogrel 0 (0.0) - - - 
   ACEi/ARBs 13 (34.2) 10 (45.5) 3 (18.8) 0.11 x 
   Beta-blockers 1 (2.6) 1 (4.5) 0 (0.0) 0.85 d 
   Nitrates 0 (0.0) - - - 
   Statins 4 (10.5) 2 (9.1) 2 (12.5) 0.89 d 
a Presented as mean±standard deviation; b Presented as number (%); c Independent t-test for continuous variables, Chi-Square for 





There were no significant differences in physical characteristics, risk factors or previous 
medication between the two groups.   
Blood tests on admission were also similar between both populations (Table 40), except for hs-
CRP, which showed a tendency for higher values in patients with endothelial dysfunction.  
 
Table 40 – Laboratory results on admission according to the presence of endothelial 




Endothelial dysfunction (RHI<1.67) 
p value c 
No (n=22) Yes  (n=16) 
Creatinine (mg/dL) b  0.88 (0.32) 0.87 (0.54) 0.90 (0.19) 0.67 
NT-pro-BNP (pg/mL) b 158.5 (305.0) 154 (365) 163 (250) 0.95 
hs-CRP (mg(dL) b 0.57 (0.71) 0.29 (0.45) 0.81 (0.98) 0.06 
Glucose (mg/dL) b 136.0 (63.0) 131.0 (60.0) 145.5 (81.8) 0.51 
HbA1c (%)b 5.8 (1.3) 5.7 (1.4) 5.9 (2.1) 0.69 
a Presented as mean±standard deviation; b Presented as median (interquartile range); c Independent t-test for continuous variables 
with a normal distribution, Mann-Whitney test for continuous variables with a non-normal distribution.  
 
4.1.2. Angiography and angioplasty variables according to the presence of 
endothelial dysfunction (RHI<1.67) 
 
There were no significant differences in ischemic (pain-to-balloon) time between patients with 
and without endothelial dysfunction, although there was a trend for lower door-to-balloon 
times in patients with endothelial dysfunction.  
Patients with endothelial dysfunction had a prevalence of multivessel disease that was almost 
twice the one observed in patients without endothelial dysfunction (68.8% vs. 36.4%), although 
this difference was not statistically significant (p=0.10). Syntax score also tended to be higher 
in patients with endothelial dysfunction (Table 41).  
There was a clear trend towards higher area-at-risk, both measured by APPROACH and BARI 
scores (p=0.08 and 0.07, respectively) in patients with RHI<1.67. These patients also showed a 
trend for worse initial TIMI score (TIMI 0-1: 93.8% vs. 72.7% in patients without endothelial 
dysfunction).  
Finally, treatment options (use of mechanical aspiration, stent implantation technique and use 






Table 41 – Ischemic times and angiographic characteristics according to the presence of 




Endothelial dysfunction (RHI<1.67) 
p value d 
No (n=22) Yes  (n=16) 
Pain-to-balloon time (min)c 209 (173) 209 (186) 211 (167) 0.94 
Door-to-balloon time (min) c 75 (52) 79 (46) 57 (44) 0.06 
Culprit artery b     
       Left anterior descending 21 (53.3) 11 (50.0) 10 (62.5) 
0.89 f        Left circumflex 7 (18.4) 5 (22.7) 2 (12.5) 
       Right coronary artery 10 (26.3) 6 (27.3) 4 (25.0) 
Multivessel disease b 19 (50.0) 8 (36.4) 11 (68.8) 0.10 f 
SYNTAX score c 17.8±6.2 16.8±6.2 19.0±6.0 0.29 
Area at risk scores a     
       APPROACH score 27.8 (3.0) 28.1 (5.0) 29.7 (10.0) 0.08 
       BARI score 28.5 (6.0) 26.7 (7.0) 30.2 (10.0) 0.07 
Initial TIMI flow 0-1 b 31 (81.6) 16 (72.7) 15 (93.8) 0.22 
a Presented as mean±standard deviation; b Presented as number (%); c Presented as median (interquartile range); d Independent 
t-test for continuous variables with a normal distribution, Mann-Whitney test for continuous variables with a non-normal 
distribution, Chi-Square for categorical variables; E Yates correction 
 
 
Table 42 – Angioplasty treatment options according to the presence of endothelial 




Endothelial dysfunction (RHI<1.67) 
p value b 
No (n=22) Yes  (n=16) 
Mechanical aspiration 16 (42.1) 9 (40.9) 7 (43.8) 0.86 
Balloon pre-dilatation 21 (55.3) 13 (59.1) 8 (50.0) 0.58 
Stent implantation 36 (94.7) 20 (90.9) 16 (100.0) 0.61 
Balloon post-dilatation 24 (63.2) 14 (63.6) 10 (62.5) 0.94 
Abciximab treatment 9 (23.7) 4 (18.2) 5 (31.5) 0.58 
Mechanical aspiration 16 (42.1) 9 (40.9) 7 (43.8) 0.86 
a Presented as number (%); b Chi-Square test, with Yates correction 
 
 
4.1.3. IMR according to the presence of endothelial dysfunction (RHI<1.67) 
 
There was a clear trend towards higher values of IMR in patients with endothelial dysfunction 
on the second EndoPAT evaluation: median values (IQR) 40.5 (54.4) vs. 22.0 (26.0) in patients 
without endothelial dysfunction (p=0.09) (Figure 22, Table 43). The prevalence of 
microvascular coronary damage, either defined as an IMR >24 (median value) or an IMR >40 
(value published in the literature as prognostic marker in STEMI patients), was almost 2 times 
higher in patients with endothelial dysfunction, although differences did not reach statistical 
significance (Table 43). Other invasive variables, including coronary flow reserve (CFR) values, 




Table 43 – Invasive hemodynamic measurements according to the presence of endothelial 




Endothelial dysfunction (RHI<1.67) 
p value d 
No (n=22) Yes  (n=16) 
IMR c 23.4 (35.2) 22.0 (26.0) 40.5 (54.4) 0.09 
   IMR < 24 (median) b 18 (47.4) 8 (36.4) 10 (62.5) 0.11 
   IMR < 40 b 14 (36.8) 6 (27.3) 8 (50.0) 0.15 
Coronary flow reserve c 1.00 (0.70) 1.10 (0.60) 1.00 (0.90) 0.92 
Basal SBP a 112.0±31.3 113.0±26.3 110.4±38.8 0.81 
Basal DBP a 61.3±14.0 59.0±14.0 65.0±13.7 0.22 
Hyperaemic  SBP a 92.8±22.0 96.1±19.3 87.8±25.4 0.28 
Hyperaemic  DBP a 51.7±12.1 52.7±11.1 50.1±13.8 0.56 
Aortic pressure a 75.7±25.1 74.7±20.3 77.2±31.7 0.72 
Distal pressure a 64.6±14.9 67.1±14.3 60.9±15.5 0.24 
a Presented as mean±standard deviation; b Presented as number (%); c Presented as median (interquartile range); d Independent 
t-test for continuous variables with a normal distribution.  Mann-Whitney test for continuous variables with a non-normal 
distribution. Chi-Square for categorical variables. 
 
 
Figure 22 – Boxplot of IMR values according to the presence of endothelial dysfunction 
(RHI<1.67) on the second EndoPAT evaluation 
 
In summary, the presence of endothelial dysfunction (defined as an RHI<1.67) on the second 
EndoPAT was associated with a trend for higher IMR values measured immediately after P-PCI. 
These patients also tended to have more severe coronary artery disease, higher areas-at-risk and 




4.2. IMR values according to RHI tertiles on the second EndoPAT  
 
According to the defined protocol, RHI in the second endothelial dysfunction was divided in 
tertiles: 
 Tertile 1 (n=13): RHI< 1.62  
 Tertile 2 (n=13): RHI 1.62 – 1.96 
 Tertile 3 (n=12): RHI> 1.96 . 
In the following pages, main patient characteristics according to RHI tertiles will be shortly 
described, followed by the IMR analysis in these groups. 
 
4.2.1. Main characteristics of patients according to tertiles of RHI  
 
Table 44 summarizes the main characteristics of patients according to RHI tertiles on the 
second EndoPAT evaluation.  There was a trend towards more male patients and more 
previous use of ACEi/ARBs for higher tertiles of RHI. There were no significant differences in 
any of the other variables, including physical characteristics, risk factors and other previous 
pharmacological treatment. Blood tests  on admission (Table 45) were also similar. 
 











Tertile 3  
(n=12) 
Physical characteristics 
   Age (years) a 60.0±13.7 62.8±14.4 54.8±13.6 62.6±12.3 0.25 x 
   Male gender b 29 (76.3) 8 (61.5) 10 (76.9) 11 (91.7) 0.41 d 
   BMI a 27.2±4.0 26.3±3.2 28.9±3.9 26.4±4.5 0.17 x 
   Waist circumference a 100.0±11.5 96.8±10.6 102.8±12.9 100.0±10.8 0.50 x 
Risk Factors and previous coronary disease b 
   Hypertension  26 (68.4) 8 (61.5) 9 (69.2) 9 (75.0) 0.93 d 
   Diabetes  12 (31.6) 3 (23.1) 7 (53.8) 2 (16.7) 0.24 d 
   Dyslipidaemia 19 (50.0) 7 (53.8) 5 (38.5) 7 (58.3) 0.58 x 
   Active smoking 13 (34.2) 3 (23.1) 6 (46.2) 4 (33.3) 0.69 d 
   Previous angina 7 (18.4) 1 (7.7) 2 (15.4) 4 (33.0) 0.51 d 
   Previous revascularization 2 (5.3) 1 (7.7) 0 (0.0) 1 (8.3) 0.94 d 
Previous medication b 
   Aspirin 3 (8.1) 1 (7.7) 0 (0.0) 2 (16.7) 0.64 d 
   ACEi/ARBs 13 (35.1) 2 (15.4) 5 (38.5) 6 (50.0) 0.43 d 
   Beta-blockers 1 (2.7) 0 (0.0) 0 (0.0) 1 (8.3) 0.88 d 
   Statins 4 (10.8) 1 (7.7) 3 (23.1) 0 (0.0) 0.46 d 
a Presented as mean±standard deviation; b Presented as number (%); c One-way ANOVA for continuous variables, Chi-Square 















Tertile 3  
(n=12) 
Creatinine (mg/dL) b  0.91±0.28 0.87±0.16 0.95±0.32 0.90±0.34 0.72 
NT-pro-BNP (pg/mL) b 158.5 (305) 163.0 (204.0) 299.0 (290.0) 103.0 (434.8) 0.94 
hs-CRP (mg(dL) b 0.57 (0.71) 0.60 (0.99) 0.95 (0.72) 0.29 (0.14) 0.12 
Glucose (mg/dL) b 136.0 (63.0) 136.0 (108.5) 169.0 (132.5) 122.0 (43.8) 0.29 
HbA1c (%)b 6.6 (1.3) 5.8 (0.9) 6.3 (4.3) 5.7 (0.6) 0.37 
a Presented as mean±standard deviation; b Presented as median (interquartile range); c One-way ANOVA for continuous variables 
with a normal distribution, Kruskal-Wallis test for continuous variables with a non-normal distribution.  
 
 
4.2.2. Angiography and angioplasty variables according to RHI tertiles 
 
There were no significant differences in pain-to-balloon or hospital-to-balloon times in RHI 
tertiles groups. There was a clear trend towards more complex coronary disease in lower 
tertiles of RHI: multivessel disease was present in 75.0% of patients in the lower tertile, as 
compared to 30.8% in patients in the upper tertile. Syntax score also tended to be higher in 
lower tertiles of RHI (Table 46).  
 
Table 46 – Ischemic times and angiographic characteristics according RHI tertiles on the 










Tertile 3  
(n=12) 
Pain-to-balloon time (min)c 209 (173) 257 (173) 235 (185) 247 (155) 0.69 
Door-to-balloon time (min)c 75 (52) 55 (44) 63 (51) 82 (45) 0.52 
Culprit artery b      
       Left anterior descending  21 (55.5) 9 (69.2) 8 (61.5) 4 (33.3) 
0.61 e        Left circumflex 7 (18.4) 1 (7.7) 3 (23.1) 3 (25.0) 
       Right coronary  10 (26.3) 3 (23.1) 2 (15.4) 5 (41.7) 
Multivessel disease b 19 (50.0) 9 (75.0) 6 (46.2) 4 (30.8) 0.08 
Syntax score c 17.8±6.1 20.4±5.7 17.0±6.0 15.8±6.4 0.15 
Area at risk scores 
       APPROACH score c 27.8 (3.0) 29.7 (10.0) 29.7 (10.0) 27.7 (8.0) 0.07 
       BARI score a 29.1±6.7 31.1±7.4 31.4±5.3 24.5±5.1 0.011 
Initial TIMI flow 0-1 b 31 (81.6) 12 (92.3) 10 (76.9) 9 (75.0) 0.79 e 
a Presented as mean±standard deviation; b Presented as number (%); c Presented as median (interquartile range); d One-way 
ANOVA for continuous variables with a normal distribution, Kruskal-Wallis test for continuous variables with a non-normal 





The area-at-at risk evaluated by the BARI score was significantly lower in patients in the third 
tertile (higher values) of RHI and a similar trend was found when the APPROACH score was 
used (p=0.07). Initial unfavourable TIMI flow (0-1) was also more prevalent in the lowest RHI 
tertile, although the difference was not statistically significant (Table 46). Finally, treatment 
options (use of mechanical aspiration, stent implantation technique or use of abciximab) was 
similar between the 3 groups (Table 47). 
 











Tertile 3  
(n=12) 
Mechanical aspiration 16 (42.1) 5 (38.5) 5 (38.5) 6 (50.0) 0.80 x 
Balloon pre-dilatation 21 (55.3) 7 (53.8) 6 (46.2) 8 (66.7) 0.58 x 
Stent implantation 36 (94.7) 13 (100.0) 12 (92.3) 11 (91.7) 0.94 c 
Balloon post-dilatation 14 (36.8) 4 (30.8) 7 (53.8) 3 (25.0) 0.52 c 
Abciximab 9 (23.7) 5 (38.5) 2 (15.4) 2 (16.7) 0.59 c 
a Presented as number (%); b Chi-Square test; c Yates correction 
 
 
4.2.3. IMR according to RHI tertiles 
 
IMR median values were lower in the third tertile of RHI, although this difference was not 
statistically significant. The number of patients with coronary microvascular dysfunction 
(IMR>24 or IMR>40) also decreased from the first to the third tertile of RHI. CRF were similar 
between groups (Table 48). 
 











Tertile 3  
(n=12) 
IMR a 23.4 (35.2) 39.0 (43.4) 23.8 (42.5) 19.5 (30.6) 0.64 x 
   IMR < 24 (median) b 18 (47.4) 8 (61.5) 6 (46.2) 4 (33.3) 0.37 x 
   IMR < 40 b 14 (36.8) 6 (46.2) 5 (38.5) 3 (25.0) 0.78 c 
Coronary flow reserve a 1.1 (0.8) 1.3 (0.84) 1.0 (0.50) 1.1 (0.9) 0.36 x 
a Presented as median (interquartile range); b Presented as number (%); c Mann-Whitney test for continuous variables with a non-
normal distribution. Chi-Square for categorical variables 
 
In summary, there was a trend for lower IMR values in third tertile of RHI measured on the 
second EndoPAT. These patients also had lower areas-at-risk and a trend to less complex 




4.3.  Relation between RHI as a continuous variable on the second EndoPAT and 
IMR values  
 
4.3.1. RHI as a continuous variable and main baseline patient characteristics 
 
Male patients had significantly higher RHI values on the second EndoPAT evaluation (Table 49).  
 
Table 49 – Correlations between RHI on the second EndoPAT and baseline continuous 
variables 
Variable Correlation (R) p value a 
Physical characteristics   
   Age  -0.006 0.970 
   BMI  0.033 0.970 
   Waist circumference  0.132 0.470 
Admission laboratory parameters   
   Creatinine  (mg/dl) 0.030 0.258 
   NT-pro-BNP  (pg/mL) -0.193 0.259 
   hs-CRP (mg/dL) 0.249 0.131 
   Glucose (mg/dL) -0.107 0.528 
   HbA1c (%) 0.008 0.965 
a Spearmans’s rho  
 
Table 50 – RHI values on the second EndoPAT according to baseline categorical variables 
Variable 
Variable present? a 
p value b 
No  Yes 
Physical characteristics     
   Male gender (29/38) 1.43±0.53 2.00±0.56 0.024 
Risk factors and previous coronary disease  
   Hypertension  (26/38) 1.84±0.46 1.88±0.67 0.87 
   Diabetes  (12/38) 1.92±0.68 1.76±0.38 0.46 
   Dyslipidaemia (19/38) 1.84±0.65 1.89±0.56 0.78 
   Active smoking (13/38) 1.86±0.70 1.87±0.37 0.99 
   Previous angina (7/38) 1.84±0.64 1.98±0.41 0.58 
   Previous revascularization (2/38) 1.89±0.59 1.50±0.99 0.38 
Previous medication     
   Aspirin (3/38) 1.85±0.53 2.16±1.35 0.40 
   ACEi/ARBs (13/38) 1.72±0.49 2.16±0.71 0.042 
   Statins (9/38) 1.71±0.10 1.89±0.64 0.57 
a RHI presented as mean±standard deviation; b Independent t-test for continuous variables with a normal distribution.  Mann-





No significant associations were found between RHI and any other baseline patient 
characteristics, including age, physical characteristics, risk factors and blood tests on admission 
(Table 49, Table 50). However, diabetic patients and patients with previous coronary 
revascularization tended to have lower RHI values.  
Patients treated previously with ACEi/ARBs had significantly higher RHI values, and those 
treated previously with statins and aspirin also showed a trend for higher RHI values (Table 50). 
 
4.3.2. RHI as a continuous variable and angiography/angioplasty variables  
 
There were no significant associations between RHI measured on the second EndoPAT and 
ischemic times. RHI tended to be lower in patients with multivessel disease, lower initial TIMI 
flow and LAD as the culprit artery (Table 51, Table 52).   
 
Table 51 – Correlations between RHI on the second EndoPAT and angiography and P-PCI 
related continuous variables 
Variable Correlation (R) p value a 
   Pain-to-balloon time (min) -0.107 0.523 
   Door-to-balloon time (min) 0.263 0.111 
   Syntax score  -0.241 0.144 
   Area at risk scores   
          APPROACH score -0.426 0.008 
          BARI score -0.361 0.026 
a Pearson’s Correlation for continuous variables with a normal distribution; Spearmans’s 




Table 52 – RHI values on the second EndoPAT according to angiography and P-PCI 
categorical variables 
Variable  
Variable present? a 
p value b 
No  Yes 
Angiography    
   Culprit artery  = LAD (21/38) 2.02±0.51 1.74±0.65 0.15 
   Multivessel disease (20/38) 2.00±0.61 1.71±0.58 0.13 
   Initial TIMI flow 0-1 (29/38) 2.05±0.43 1.81±0.64 0.30 
Primary PCI     
   Mechanical aspiration (16/38) 1.79±0.61 1.96±0.60 0.40 
   Balloon pre-dilatation (21/38) 1.84±0.52 1.89±0.68 0.79 
   Stent implantation (36/38) 2.71±1.24 1.82±0.54 0.21 
   Balloon post-dilatation (14/38) 1.80±0.58 1.98±0.65 0.39 
   Abciximab use (9/38) 1.90±0.68 1.76±0.25 0.57 
a RHI presented as mean±standard deviation; b Independent t-test for continuous variables with a normal distribution.  Mann-




There was a significant negative correlation between both area-at-risk-scores and RHI, 
suggesting that patients with higher areas at risk had lower RHI values on the second EndoPAT 
evaluation (Table 51). 
 
 
4.3.3.  RHI as a continuous variable and IMR   
 
There was no relation between RHI measured on the second EndoPAT and IMR or any of the 
invasive measurements performed (Table 53). However, there was a trend for lower RHI values 
in patients with coronary microvascular dysfunction, according to the IMR cut-offs of 24 and 




Table 53 – RHI on the second EndoPAT and invasive hemodynamic continuous variables 
Variable Correlation (R) p value a 
IMR -0.090 0.593 
Coronary flow reserve  0.018 0.917 
Basal SBP  0.016 0.925 
Basal DBP -0.227 0.184 
Hyperaemic  SBP  0.200 0.250 
Hyperaemic  DBP 0.037 0.833 
Aortic pressure  0.181 0.298 
Distal pressure  -0.030 0.862 
a Pearson’s Correlation for continuous variables with a normal distribution; Spearmans’s 
rho for continuous variables without a normal distribution 
 
 
Table 54 – RHI values on the second EndoPAT according to IMR thresholds 
Variable  
Variable present? 
p value b 
No  Yes 
   IMR < 24 (median) (18/38) 1.92±0.59 1.81±0.62 0.56 
   IMR < 40  (14/38) 1.92±0.68 1.77±0.45 0.48 
a Presented as mean±standard deviation; b Mann-Whitney test for continuous variables with a non-normal distribution 
 
 
In summary, there was a trend for lower RHI values in patients with coronary microvascular 
dysfunction (increased IMR). RHI values correlated with male gender and previous treatment with 
ACEi/ARBs and tended to be lower in diabetic and previously revascularized patients. Additionally, 
RHI values on the second EndoPAT correlated with the area-at-risk and tended to be lower in 




5. Secondary outcome – Extent of myocardial infarction and 
microvascular reperfusion according to RHI on the first EndoPAT  
 
5.1. Impact of the presence of endothelial dysfunction (RHI<1.67) on the first 
EndoPAT on the extent of myocardial infarction 
 
The extent of infarction was evaluated by: 
 The area under the curve and the peak values of 7 evaluations of troponin I in the first 48 
hours after the P-PCI, 
 The area of infarction in the contrast enhanced cardiac magnetic resonance,  
 And, indirectly, by echocardiography parameters, including left ventricular volumes and 
ejection fraction, wall motion score index and global longitudinal strain, both on the initial 
and follow-up (3 month) echocardiograms.  
 
5.1.1. Endothelial dysfunction and troponin release 
 
The peak values and the area under the curve of the 7 values of troponin I in the first 48 hours, 
are presented in Table 55. Both total values and values indexed to the area-at-risk scores 
(APPROACH and BARI) are shown, in patients with and without endothelial dysfunction 
(RHI<1.67) on the first EndoPAT evaluation. There were no significant differences in these 
populations.  
 
Table 55 – Impact of endothelial dysfunction (RHI<1.67, measured on first EndoPAT) on 
Troponin I release 
Variable a, b 
Total Population 
(n=60) 
Endothelial Dysfunction (RHI<1.67) 
p value c 
No (n=49) Yes  (n=11) 
   TnIpeak 117±82 117±87 115±55 0.96 
   TnIpeak (APPROACH) 34±27 33±29 35±19 0.82 
   TnIpeak (BARI) 33±25 32±26 36±20 0.62 
   TnIpeak (2 scores) 33±26 33±27 36±19 0.72 
   TnIAUC 1938±1283 1951±1376 1883±787 0.88 
   TnIAUC (APPROACH) 565±441 564±472 574±275 0.94 
   TnIAUC (BARI) 548±405 541±43 584±282 0.75 
   TnIAUC (2 scores) 557±421 552±449 579±278 0.85 
a Presented as mean±standard deviation; b Peak value and area under the curve (AUC) of 7 troponin I (TnI, in mg/dL) 
measurements performed in the first 48 hours after the primary angioplasty; total values and values indexed to the 




5.1.2. Endothelial dysfunction and echocardiography parameters 
 
There were no significant differences in 2D, Doppler or 2D speckle tracking imaging 
measurements in the first echocardiogram between patients with and without endothelial 
dysfunction on the first EndoPAT (Table 56). Likewise, all measurements were similar in the 
second echocardiogram in patients with and without RHI<1.67 (Table 57). 
 
Table 56 – Impact of endothelial dysfunction (RHI<1.67, measured on first EndoPAT) on the 
first echocardiogram parameters 
Variable a, b Total population 
Endothelial dysfunction (RHI<1.67) 
p value c 
No Yes  
2D measurements  (n=60) (n=49) (n=11)  
   LVEdV (ml) a 105.8±24.2 107.5±24.0 95.7±24.4 0.27 
   LVEsV (ml) a 54.7±12.7 55.6±12.9 49.5±11.1 0.28 
   LVEF (%)a 47.9±6.7 47.9±6.8 47.8±5.9 0.96 
   Wall motion score index b 1.41 (0.35) 1.41 (0.35) 1.53 (0.18) 0.78 
   Left atria volume (ml/m2) a 34.8±12.2 35.7±12.9 30.6±7.2 0.32 
Doppler measurements  (n=40) (n=34) (n=7)  
   E/A ratio a 1.00±0.34 0.99±0.34 1.06±0.36 0.68 
   E/e’ ratio  a 9.00±2.71 8.91±2.85 9.58±1.55 0.61 
2D speckle tracking imaging (n=40) (n=34) (n=7)  
   Global longitudinal strain a -13.54±2.28 -13.38±2.30 -14.7±1.96 0.23 
a Presented as mean±standard deviation; b Presented as median (interquartile range); c Independent t-test for continuous variables 
with a normal distribution.  Mann-Whitney test for continuous variables with a non-normal distribution. LVEdV – left ventricular 
end diastolic volume; LVEsV – left ventricular end systolic volume; LVEF – left ventricular ejection fraction; WMSI – wall motion 
score index.  
 
Table 57 – Impact of endothelial dysfunction (RHI<1.67, measured on first EndoPAT) on the 3 
month echocardiogram parameters 
Variable a, b Total population 
Endothelial dysfunction (RHI<1.67) 
p value c 
No Yes  
2D measurements  (n=54) (n=43) (n=11)  
   LVEdV (ml) a 109.7±26.4 111.1±28.5 103.8±13.9 0.44 
   LVEsV (ml) a 52.9±18.8 54.2±20.4 47.6±8.8 0.32 
   LVEF (%)a 52.6±7.1 52.2±7.4 54.2±5.2 0.43 
   Wall motion score index b 1.24 (0.35) 1.24 (0.35) 1.29 (0.24) 0.93 
   Left atria volume (ml/m2) a 39.1±15.4 40.4±16.7 34.3±7.2 0.25 
Doppler measurements  (n=51) (n=40) (n=11)  
   E/A ratio a 1.20±0.56 1.21±0.54 1.15±0.66 0.75 
   E/e’ ratio  a 8.92±3.29 8.83±3.51 9.29±2.30 0.69 
2D speckle tracking imaging (n=40) (n=40) (n=11)  
   Global longitudinal strain a -15.77±3.11 -15.80±3.36 -15.68±2.11 0.91 
a Presented as mean±standard deviation; b Presented as median (interquartile range); c Independent t-test for continuous variables 
with a normal distribution.  Mann-Whitney test for continuous variables with a non-normal distribution. LVEdV – left ventricular 
end diastolic volume; LVEsV – left ventricular end systolic volume; LVEF – left ventricular ejection fraction; WMSI – wall motion 





When the 2 echocardiograms were compared in patients with and without endothelial 
dysfunction, improvements in left ventricular ejection fraction, wall motion score index, E/A 
ratio and global longitudinal strain were seen in both groups. However, these changes were 
only significant in the group with RHI>1.67, since the group with endothelial dysfunction was 
very small (only 5 to 7 patients, depending on the parameters evaluated). 
 
Table 58 – Baseline and 3 month echocardiographic parameters according to the presence of 
endothelial dysfunction (RHI<1.67) on the first EndoPAT evaluation 
 RHI > 1.67 RHI < 1.67 
Echo parameters Echo1 Echo2 P valuec Echo1 Echo2 P valuec 
2D measurements  n=38   n=7  
   LVEdV (ml) a 107.2±24.8 111.4±29.7 0.26 95,7±24.4 101.0±12.9 0.75 
   LVEsV (ml) a 55.0±12.8 54.2±20.8 0.37 49.5±11.1 46.5±9.6 0.67 
   LVEF (%)a 48.4±6.1 52.3±6.7 0.001 47.8±5.9 54.0±6.8 0.12 
   WMSI b 1.41 (0.37) 1.24±0.35 <0.001 1.53 (0.18) 1.29 (0.24) 0.05 
   Left atria (ml/m2) a 35.1±12.5 41.3±17.6 0.007 30.6±7.2 32.3±7.5 0.80 
Doppler measurements   n=31   n=6  
   E/A' ratio a 0.98±0.34 1.18±0.54 0.007 1.06±0.36 0.96±0.22 0.25 
   E/e’ ratio a  8.90±3.02 8.87±3.83 0.68 9.58±1.55 8.96±1.87 0.50 
2D speckle tracking imaging  n=30   n=5  
   Global longitudinal strain a -13.7±2.1 -15.6±3.3 0.001 -14.7±2.0 -16.1±1.8 0.08 
a Presented as mean±standard deviation; b Presented as median (interquartile range); C p-value for the comparison between the 
first and the second echo only in patients with 2 evaluations; Paired samples T-Test for variables with normal distribution and 
Wilcoxon test for variables with non-normal distribution. LVEdV – left ventricular end diastolic volume; LVEsV – left ventricular 
end systolic volume; LVEF – left ventricular ejection fraction; WMSI – wall motion score index.  
 
 
5.1.3. Endothelial dysfunction and contrast enhanced cardiac magnetic resonance 
 
Forty nine patients of the 60 patients had ceCMR performed during the index admission (Error! 
Reference source not found.). Of these, 10 (20.4%) had endothelial dysfunction, as defined by 
an RHI<1.67.  
There were no significant differences between patients with and without endothelial 
dysfunction in left ventricular volumes, left ventricular ejection fraction or wall motion score 
index (Table 59). 
Accordingly, the presence of transmural necrosis and the total and percent infarct mass were 





Table 59 – Impact of endothelial dysfunction (RHI<1.67, measured on first EndoPAT) on the 




Endothelial Dysfunction (RHI<1.67) 
p value d 
No (n=39) Yes  (n=10) 
LVEdV (ml) a 142,8±29.2 144.3±31.0 137.0±20.8 0.49 X 
LVEsV (ml) a 66.3±21.8 66.4±22.9 65.7±17.7 0.92 X 
LVEF (%)a 53.6±8.7 53.9±8.7 52.4±9.3 0.62 X 
Wall motion score index a 1.42±0.29 1.41±00.30 1.46±0.23 0.64 X 
Oedema mass b 19.6 (14.4) 19.1 (15.6) 23.6 (14.4) 0.76 X 
Transmural necrosis c 23 (46.9) 18 (46.2) 5 (50.0) 0.89 e 
Infarct mass     
    Total b 14.7 (12.6) 11.7 (9.8) 19.9 (11.9) 0.11 X 
    Percent b 12.6 (14.4) 11.6 (12.9) 20.3 (14.5) 0.08 X 
       Indexed to APPROACH 3.7 (4.5) 3.1 (3.9) 5.6 (5.5) 0.08 X 
       Indexed to BARI 3.8 (4.3) 3.0 (3.6) 5.5 (5.1) 0.07 X 
Salvage mass b 4.5 (10.4) 5.4 (11.5) 3.1 (7.6) 0.19 X 
a Presented as mean±standard deviation; b Presented as median (interquartile range); c  Presented as number (%); d Independent 
t-test for continuous variables with a normal distribution, Mann-Whitney test for continuous variables with a non-normal 
distribution, Chi-Square for categorical variables; e Yates correction 
 
 
In summary, the presence of endothelial dysfunction (RHI<1.67) on the first EndoPAT was not 
related to larger infarctions (measured by troponin release or by ceCMR). There was an 
improvement in echocardiogram parameters, both in patients with and without endothelial 




5.2. Impact of the presence of endothelial dysfunction (RHI<1.67) on the first 
EndoPAT on microvascular reperfusion 
 
Microvascular reperfusion was evaluated by: 
 ST elevation and deviation resolution on the ECGs performed immediately after and 
90 and 180 minutes after the coronary revascularization. 
 Angiographic indicators, including corrected TIMI frame count and TIMI myocardial 
perfusion grade. 
 Microvascular obstruction, evaluated by contrast enhanced cardiac magnetic 
resonance.  
 
5.2.1. Endothelial dysfunction and ST resolution on the ECG 
 
The residual total ST elevation and deviation and the percentage of resolution of these ST 
changes are presented in Table 60 and in Figure 23 and Figure 24, according to the presence 
of endothelial dysfunction (RHI<1.67) on the first EndoPAT evaluation. 
 
 
Figure 23 – ST elevation and deviation resolution (median values) according to the presence 
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Resolution of Total ST Elevation Resolution of Total ST Deviation Resolution of ST derivation with
max elevation





Figure 24 – ST residual changes (median values) according to the presence of endothelial 
dysfunction (RHI<1.67) on the first EndoPAT evaluation 
 
Table 60 – ECG ST resolution and residual changes according to the presence of endothelial 




Endothelial dysfunction (RHI<1.67) 
p value d 
No (n=49) Yes  (n=11) 
Immediately post-angioplasty ECG a 
   Total ST elevation b 3.3 (6.0) 3.5 (6.0) 2.5 (6.0) 0.96 
           % Resolution  74.5 (39.0) 74.0 (42.0) 77.0 (37.0) 0.83 
   Total ST deviation b 4.8 (6.0) 4.5 (6.0) 6.0 (7.0) 0.44 
           % Resolution  73.5 (44) 73.0 (48.0) 74.0 (34.0) 0.92 
   ST at derivation with max elevation) b 1.0 (2.0) 1.0 (2.0) 1.0 (2.0) 0.88 
           % Resolution  68.0 (47.0) 67.0 (51.0) 75.0 (25.0) 0.95 
90 minutes post-angioplasty ECG a 
   Total ST elevation b 1.5 (4.0) 1.5 (5.0) 1.5 (4.0) 0.77 
           % Resolution  79.5 (32.0) 78.0 (34.0) 86.0 (25.0) 0.70 
   Total ST deviation b 2.0 (4.0) 2.0 (5.0) 2.5 (3.0) 0.65 
           % Resolution  82.5 (33.0) 82.0 (36.0) 90.0 (26.0) 0.89 
   ST at derivation with   max elevation  b 0.5 (2.0) 0.5 (2.0) 0.5 (1.0) 0.55 
           % Resolution  77.5 (34.0) 75.0 (37.0) 83.0 (31.0) 0.64 
180 minutes post-angioplasty ECG a 
   Total ST elevation b 1.5 (3.0) 1.0 (4.0) 1.5 (3.0) 0.70 
           % Resolution  84.5 (23.0) 84.0 (26.0) 86.0 (12.0) 0.78 
   Total ST deviation b 1.5 (4.0) 1.0 (5.0) 2.0 (4.0) 0.31 
           % Resolution  88.0 (26.0) 88.0 (28.0) 92.0 (28.0) 0.60 
   ST at derivation with max elevation b 0.5 (2.0) 0.5 (2.0) 0.5 (1.0) 0.80 
           % Resolution  83.0 (33.0) 83.0 (33.0) 85.0 (31.0) 0.61 
   QS waves present 37 (61.7) 30 (61.2) 7 (63.6) 0.85 e 
a  Values expressed as median (interquartile range);  b Values expressed in mV; c values expressed as n(%); d Mann-Whitney test 









PostPCI 90 min 180 min PostPCI 90 min 180 min PostPCI 90 min 180 min
Residual total ST elevation Residual total ST deviation Residual ST elevation max ST
derivation




There were no significant differences in any of the ECG parameters evaluated, immediately 
after the P-PCI, at 90 minutes or at 180 minutes. The presence of Q waves in the final ECG was 
also similar in the two groups (Table 60). 
 
5.2.2. Endothelial dysfunction and angiographic indicators of microvascular 
reperfusion 
 
Corrected TIMI frame count and TIMI myocardial perfusion grade results according to the 
presence of endothelial dysfunction on the first EndoPAT evaluation are presented in Table 61. 
There were no significant differences on either parameters.  
 
Table 61 – Angiographic indicators of microvascular reperfusion according to the presence of 




Endothelial dysfunction (RHI<1.67) 
p value  
No (n=49) Yes  (n=11) 
 Corrected TIMI frame count a 17.0 (7.0) 18.0 (8.0) 14.0 (8.0) 0.27 c 
 TMPG  2-3 b 49 (81.7) 38 (77.6) 11 (100.0) 0.24 d  
a data presented as median (interquartile range); b data presented as n(%); c Mann-Whitney test; d Chi-Square test, with Yates 
correction. 
 
5.2.3. Endothelial dysfunction and microvascular obstruction on the ceCMR 
 
There were no significant differences in the number of patients with microvascular obstruction 
and in the mass of microvascular obstruction between patients with and without RHI<1.67 
(Table 62). 
 
Table 62 – Microvascular obstruction on the ceCMR according to the presence of endothelial 




Endothelial dysfunction (RHI<1.67) 
p value c 
No (n=39) Yes  (n=10) 
Microvascular obstruction      
   MVO present a 13 (26.5) 10 (25.6) 3 (30.0) 0.90 e 
   Mass of MVO b 5.7 (4.0) 6.1 (8.5) 5.4 (-) 0.57 X 
a Presented as number (%); b Presented as median (interquartile range); c  Mann-Whitney test for continuous variables with a non-





In summary, the presence of endothelial dysfunction (RHI<1.67) on the first EndoPAT was not 
related to non-invasive (ST resolution) and invasive (cTFC and TMPG) indicators of 
microcirculatory reperfusion. Likewise, endothelial dysfunction was not related with 





6. Secondary outcome – Extent of myocardial infarction and 
microvascular reperfusion according to RHI on the second  
EndoPAT 
 
6.1. Impact of the presence of endothelial dysfunction (RHI<1.67) on the second 
EndoPAT on the extent of myocardial infarction 
 
6.1.1. Endothelial dysfunction and Troponin release 
 
The peak values and the area under the curve of troponin I, according to the presence of 
endothelial dysfunction on the second EndoPAT evaluation are presented in Table 63. Both 
total values and values indexed to the area-at-risk scores (APPROACH and BARI) are presented, 
in patients with and without endothelial dysfunction (RHI<1.67) on the second EndoPAT 
evaluation. Patients with endothelial dysfunction had significantly higher values of both peak 
TnI and AUC of TnI, both total and indexed to the area-at-risk scores.  
 
Table 63 – Impact of endothelial dysfunction (RHI<1.67, measured on second EndoPAT) on 
Troponin I release 
Variable a, b 
Total population 
(n=38) 
Endothelial dysfunction (RHI<1.67) 
p value c 
No (n=22) Yes  (n=16) 
   TnIpeak 95 (96) 67 (81) 118 (186) 0.024 
   TnIpeak (APPROACH) 25 (32) 17 (20) 34 (56) 0.009 
   TnIpeak (BARI) 24 (31) 17 (22) 33 (47) 0.008 
   TnIpeak (2 scores) 24 (31) 17 (21) 33 (55) 0.009 
   TnIAUC 1293 (1580) 1076 (1042) 2305 (2486) 0.012 
   TnIAUC (APPROACH) 403 (522) 315 (303) 664 (1080) 0.008 
   TnIAUC (BARI) 383 (448) 314 (326) 618 (799) 0.007 
   TnIAUC (2 scores) 393 (482) 314 (300) 641 (984) 0.007 
a Presented as median (IQR); b Peak value and area under the curve (AUC) of 7 troponin I (TnI, in mg/dL) 
measurements performed in the first 48 hours after the primary angioplasty; total values and values indexed to the 
APPROACH, BARI or both are presented; c Mann-Whitney Test. 
 
6.1.2. Endothelial dysfunction and echocardiography parameters 
 
Patients with endothelial dysfunction had significantly higher end-systolic volumes, lower LVEF 




in WSMI, they also had higher values of global longitudinal strain (Table 64). These differences 
were no longer visible in the echocardiogram performed at 3 month (Table 65). 
 
Table 64 – Impact of endothelial dysfunction (RHI<1.67, measured on second EndoPAT) on 
the first echocardiogram parameters 
Variable  Total population 
Endothelial dysfunction (RHI<1.67) 
p value c 
No Yes  
2D measurements  (n=26) (n=15) (n=11)  
   LVEdV (ml) a 109.8±23.4 106.5±30.2 113.8±11.4 0.48 
   LVEsV (ml) a 55.9±12.6 51.1±12.3 61.7±10.9 0.047 
   LVEF (%)a 48.6±7.1 51.4±4.7 45.3±8.3 0.045 
   Wall motion score index b 1.44 (0.41) 1.35 (0.47) 1.77 (0.47) 0.006 
   Left atria volume (ml/m2) a 36.1±11.0 36.7±12.1 35.3±10.0 0.78 
Doppler measurements  (n=21) (n=11) (n=10)  
   E/A ratio a 1.10±0.40 1.17±0.40 0.97±0.0.39 0.30 
   E/e’ ratio  a 8.91±3.30 8.83±3.91 9.05±2.18 0.89 
2D speckle tracking imaging (n=21) (n=11) (n=10)  
   Global longitudinal strain a -13.16±2.35 -14.32±1.72 -11.89±2.35 0.014 
a Presented as mean±standard deviation; b Presented as median (interquartile range); c Independent t-test for continuous variables 
with a normal distribution.  Mann-Whitney test for continuous variables with a non-normal distribution. LVEdV – left ventricular 
end diastolic volume; LVEsV – left ventricular end systolic volume; LVEF – left ventricular ejection fraction; WMSI – wall motion 
score index.  
 
Table 65 – Impact of endothelial dysfunction (RHI<1.67, measured on second EndoPAT) on 
the 3 month Echocardiogram parameters 
Variable  Total Population 
Endothelial Dysfunction (RHI<1.67) 
p value c 
No Yes  
2D measurements  (n=30) (n=19) (n=11)  
   LVEdV (ml) a 109.7±28.1 103.9±29.8 119.7±22.4 0.14 
   LVEsV (ml) a 53.8±21.4 49.8±21.0 60.7±21.2 0.18 
   LVEF (%)a 52.2±7.9 53.2±7.6 50.5±8.3 0.37 
   Wall motion score index b 1.24 (0.40) 1.21 (0.35) 1.29 (0.66) 0.33 
   Left atria volume (ml/m2) a 40.6±15.4 42.2±16.9 38.0±12.7 0.46 
Doppler measurements  (n=29) (n=19) (n=10)  
   E/A ratio a 1.31±0.68 1.30±0.62 1.34±0.82 0.87 
   E/e’ ratio  a 8.96±3.93 9.13±4.19 8.59±3.51 0.74 
2D speckle tracking imaging (n=29) (n=19) (n=10)  
   Global longitudinal strain a -15.43±3.55 -15.95±3.01 -14.4±4.39 0.28 
a Presented as mean±standard deviation; b Presented as median (interquartile range); c Independent t-test for continuous variables 
with a normal distribution.  Mann-Whitney test for continuous variables with a non-normal distribution. LVEdV – left ventricular 
end diastolic volume; LVEsV – left ventricular end systolic volume; LVEF – left ventricular ejection fraction; WMSI – wall motion 
score index.  
 
When the 2 echocardiograms were compared, significant improvements in the wall motion 
score index were found in both patients with and without endothelial dysfunction. There was 




endothelial dysfunction. There were no other significant differences, independently of the 
presence of endothelial dysfunction.  
 
Table 66 – Baseline and 3 months echocardiographic parameters according to the presence of 
endothelial dysfunction (RHI<1.67) on the second EndoPAT evaluation 
 RHI > 1.67 RHI < 1.67 
Echo parameters Echo1 Echo2 P valuec Echo1 Echo2 P valuec 
2D measurements  n=15   n=11  
   LVEdV (ml) a 106.5±3..2 101.0±33.0 0.33 113.8±11.8 119.7±22.4 0.61 
   LVEsV (ml) a 51.1±12.3 48.3±22.3 0.24 61.7±10.9 60.7±21.1 1.00 
   LVEF (%)a 51.4±4.8 53.2±5.1 0.24 45.3±8.3 50.5±8.3 0.24 
   WMSI b 1.35 (0.47) 1.18 (0.35)  0.012 1.65 (0.47) 1.24 (0.74) 0.049 
   Left atria (ml/m2) a 36.7±12.1 43.8±18.8 0.16 35.3±10.0 38.0±12.7 0.16 
Doppler measurements   n=12   n=11  
   E/A' ratio a 1.14±0.40 1.24±0.43 0.61 0.97±0.39 1.34±0.82 0.08 
   E/e’ ratio a  9.0±4.1 8.2±4.7 0.37 9.1±2.2 8.6±3.5 0.72 
2D speckle tracking imaging  n=10   n=10  
   Global longitudinal strain a -14.3±1.8 -16.1±2.6 0.07 -11.9±2.3 -14.4±4.4 0.53 
a Presented as mean±standard deviation; b Presented as median (interquartile range); C p-value for the comparison between the 
first and the second Echo only in patients with 2 evaluations; paired samples T-Test for variables with normal distribution and 
Wilcoxon test for variables with non-normal distribution. LVEdV – left ventricular end diastolic volume; LVEsV – left ventricular 
end systolic volume; LVEF – left ventricular ejection fraction; WMSI – wall motion score index.  
 
 
6.1.3. Endothelial dysfunction and contrast enhanced cardiac magnetic resonance 
 
Contrast enhanced CMR was performed in 29 of the 38 patients with a second EndoPAT 
evaluation. Of these, 11 (37.9%) had endothelial dysfunction (RHI<1.67) (Table 67). 
Patients with endothelial dysfunction (RHI<1.67) had significantly lower left ventricular 
ejection fraction and higher wall motion score index, as compared to patients with RHI>1.67.  
There was a trend for more transmural necrosis (22.2% vs. 63.6%, p=0.06) and higher infarct 
mass (median value 10.1 vs. 17.5, p=0.08) in patients with RHI<1.67. The percent mass of 
infarct indexed to area-at-risk scores (APPROACH and BARI) also tended to be higher in patients 







Table 67 – Impact of endothelial dysfunction (RHI<1.67) measured on second EndoPAT on the 




Endothelial dysfunction (RHI<1.67) 
p value d 
No (n=18) Yes  (n=11) 
LVEdV (ml) a 138.6±26.9 139.2±26.5 137.5±28.9 0.87 
LVEsV (ml) a 63.5±21.0 59.3±19.4 70.4±22.6 0.17 
LVEF (%)a 53.9±8.4 56.6±8.1 49.5±7.2 0.025 
Wall motion score index a 1.37±0.33 1.28±0.31 1.53±0.32 0.05 
Oedema mass b 19.1 (19.0) 17.2 (14.1) 21.2 (28.6) 0.28 
Transmural necrosis c 12 (38.7) 4 (22.2) 7 (63.6) 0.06 e 
Infarct mass     
    Total b 11.6 (9.3) 10.1 (10.3) 17.5 (15.4) 0.08 
    Percent b 11.5 (13.7) 10.2 (7.6) 17.5 (21.8) 0.10 
       Indexed to APPROACH 3.2 (7.0) 2.7 (2.6) 4.9 (11.5) 0.10 
       Indexed to BARI 3.4 (5.8) 2.3 (2.7) 5.1 (11.5) 0.09 
Salvage mass b 5.0 (14.0) 5.0 (8.8) 4.7 (27.6) 0.87 
a Presented as mean±standard deviation; b Presented as median (interquartile range); c  Presented as number (%); d Independent 
t-test for continuous variables with a normal distribution, Mann-Whitney test for continuous variables with a non-normal 
distribution, Chi-Square for categorical variables; e Yates correction 
 
 
In summary, the presence of endothelial dysfunction (RHI<1.67) on the second EndoPAT was 
related with larger infarcts, as assessed by troponin I release and ceCMR. These patients also had 
lower LVEF and worse wall motion score index and GLS in the acute echocardiogram and in the 





6.2. Impact of the presence of endothelial dysfunction (RHI<1.67) on the second 
EndoPAT on microvascular reperfusion 
 
6.2.1. Endothelial dysfunction and ST resolution on the ECG 
 
The residual total ST elevation and deviation and the percentage of resolution of these ST 
changes are presented in Table 68 , in Figure 25 and in Figure 26, according to the presence of 
endothelial dysfunction (RHI<1.67) on the second EndoPAT evaluation. 
 
 
Figure 25 – ST elevation and deviation resolution (median values) according to the presence 
of endothelial dysfunction (RHI<1.67) on the second EndoPAT evaluation 
 
Although there was a tendency for higher resolution of ST elevation and deviation (particularly 
in post-PCI and 90 minutes ECGs) in patients without endothelial dysfunction, this difference 
was not statistically significant. 
Residual total ST elevation immediately after PCI and at 90 minutes was higher in patients with 
endothelial dysfunction and there was a trend for similarly worse results in residual ST 
deviation and residual ST elevation in these patients. 












PostPCI 90 min 180 min PostPCI 90 min 180 min PostPCI 90 min 180 min
Resolution of Total ST Elevation Resolution of Total ST Deviation Resolution of ST derivation with
max elevation





Figure 26 – ST residual changes (median values) according to the presence of endothelial 
dysfunction (RHI<1.67) on the second EndoPAT evaluation 
 
Table 68 – ECG ST resolution and residual changes according to the presence of endothelial 




Endothelial dysfunction (RHI<1.67) 
p value d 
No (n=49) Yes  (n=11) 
Immediately post-Angioplasty ECG a 
   Total ST elevation b 3.0 (6.0) 2.5 (5.0) 5.0 (12.0) 0.048 
           % Resolution  74.5 (39.0) 76.5 (41.0) 60.5 (72.0) 0.23 
   Total ST deviation b 4.8 (6.0) 4.5 (5.0) 5.8 (14.0) 0.22 
           % Resolution  67.8 (39.0) 70.5 (39.0) 59.0 (78.0) 0.39 
   ST at derivation with max elevation) b 1.0 (2.0) 0.8 (2.0) 1.3 (3.0) 0.06 
           % Resolution  67.0 (33.0) 70.0 (40.0) 67.0 (52.0) 0.15 
90 minutes post-Angioplasty ECG a 
   Total ST elevation b 1.8 (4.0) 1.3 (4.0) 3.0 (7.0) 0.036 
           % Resolution  77.0 (29.0) 78.5 (28.0) 69.0 (53.0) 0.07 
   Total ST deviation b 2.0 (5.0) 1.8 (5.0) 3.0 (7.0) 0.191 
           % Resolution  78.0 (30.0) 81.0 (31.0) 71.0 (59.0) 0.181 
   ST at derivation with   max elevation  b 1.0 (2.0) 0.5 (1.0) 1.3 (2.0) 0.07 
           % Resolution  69.0 (31.0) 73.0 (37.0) 67.0 (44.0) 0.19 
180 minutes post-Angioplasty ECG a 
   Total ST elevation b 1.3 (4.0) 1.0 (3.0) 2.8 (5.0) 0.30 
           % Resolution  85.5 (26.0) 81.5 (22.0) 83.5 (52.0) 0.67 
   Total ST deviation b 1.5 (5.0) 1.3 (4.0) 2.8 (5.0) 0.74 
           % Resolution  84.5 (32.0) 83.0 (32.0) 85.5 (54.0) 0.80 
   ST at derivation with max elevation b 0.5 (1.0) 0.5 (1.0) 1.3 (2.0) 0.20 
           % Resolution  81.0 (30.0) 80.5 (29.0) 81.0 (40.0) 0.65 
   QS waves present 24 (63.2) 13 (59.1) 11 (68.8) 0.54 
a Values expressed as median (interquartile range); b Values expressed in mV; c values expressed as n(%); d Mann-Whitney test for 
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Residual total ST elevation Residual total ST deviation Residual ST elevation max ST
derivation






6.2.2. Endothelial dysfunction and angiographic indicators of microvascular 
reperfusion 
 
Corrected TIMI frame count and TIMI myocardial perfusion grade results according to the 
presence of endothelial dysfunction on the second EndoPAT evaluation are presented in Table 
69. There was a trend toward higher values of cTFC and worse TMPG in patients with 
endothelial dysfunction, although it did not reach statistical significance.  
 
Table 69 – Angiographic indicators of microvascular reperfusion according to the presence of 




Endothelial dysfunction (RHI<1.67) 
p value c  
No (n=22) Yes  (n=16) 
 Corrected TIMI frame count a 17.0 (7.0) 16.4 (7.0) 19.5 (12.0) 0.07 x 
 TMPG 2-3 b 28 (73.7) 19 (86.4) 9 (56.3) 0.09 d 
a data presented as median (interquartile range); b data presented as n(%); c Mann-Whitney test; d Chi-Square test, with 
Yates correction. 
 
6.2.3. Endothelial dysfunction and microvascular obstruction on the ceCMR 
 
Only 8 patients with the second EndoPAT evaluation had microvascular obstruction on the 
ceCMR: 2 (11.1%) in the group with RHI<1.67 and 6 (54.5%) in the group with RHI>1.67 
(p=0.03). Likewise, the microvascular obstruction mass was higher in the group with RHI<1.67 
(median value 5.3 vs. 6.8), although the difference was not significant (Table 70). 
  
Table 70 - Microvascular obstruction on the ceCMR according to the presence of endothelial 




Endothelial Dysfunction (RHI<1.67) 
p value c 
No (n=18) Yes  (n=11) 
Microvascular obstruction      
   MVO present a 8 (27.6) 2 (11.1) 6 (54.5) 0.03 d 
   MVO mass b 6.1 (15.5) 5.3 (-) 6.8 (20.8) 0.29 
a Presented as number (%); b Presented as median (interquartile range); c  Mann-Whitney test for continuous variables with a non-
normal distribution, Chi-Square for categorical variables; d Yates correction 
 
 
In summary, there was a clear trend for worse angiographic and electrocardiographic indictors 
of microvascular reperfusion in patients with endothelial dysfunction on the second EndoPAT.  
The proportion of patients with MVO on the ceCMR was higher in patients with RHI<1.67 and 




7. Secondary outcome – Extent of myocardial infarction and 
microvascular reperfusion according to IMR values  
 
In order to evaluate the impact of IMR on the extent of myocardial necrosis and its relation to 
invasive and non-invasive indicators of coronary microvascular reperfusion, patients were divided 
into two groups, according to the median value of IMR measured (24). To simplify the presentation 
of results and its discussion, patients with an IMR above the median 24 value will be classified as 
having coronary microvascular damage, as opposed to those with IMR values below 24. Where 
indicated, IMR as a continuous variable was also evaluated.  In the following pages, the main 
patient characteristics according to IMR values will be shortly described, followed by the analysis 
of the impact of coronary microvascular damage.  
 
7.1. IMR and baseline characteristics 
 
7.1.1. IMR and patient’s main characteristics 
 
Patients with coronary microvascular dysfunction (IMR>24) were older (Table 71). In fact, there 
was a weak, but significant correlation between IMR and age (r=0.28, p=0.03).  
 




Coronary microvascular damage (IMR>24) 
p value c 
No (n=30) Yes  (n=30) 
Physical characteristics     
   Age (years) a 59.6±12.7 54.7±11.3 64.4±12.2 0.002 x 
   Male gender b 48 (80.0) 26 (86.7) 22 (73.3) 0.20 x 
   BMI a 27.5 ±4.0 27.4±4.4 27.6±3.7 0.79 x 
   Waist circumference a 99.2±12.2 96.5±12.0 102.3±12.0 0.11 x 
Risk Factors and previous coronary disease b 
   Hypertension  43 (71.7) 19 (63.3) 24 (80.0) 0.15 x 
   Diabetes  15 (25.0) 7 (23.3) 8 (26.7) 0.77 x 
   Dyslipidaemia 30 (50.0) 16 (53.3) 14 (46.7) 0.61 x 
   Active smoking 26 (43.3) 16 (53.3) 10 (33.3) 0.12 x 
   Previous angina 9 (15.0) 4 (13.3) 5 (16.7) 1.00 d 
   Previous revascularization 2 (3.3) 1 (3.3) 1 (3.3) 0.49 d 
Previous medication b     
   Aspirin 5 (8.3) 3 (10.0) 2 (6.7) 0.96 x 
   ACEi/ARBs 23 (38.3) 12 (40.0) 11 (36.7) 0.87 x 
   Beta-blockers 4 (6.7) 3 (10.0) 1 (3.33) 0.63 d 
   Statins 9 (15.0) 3 (10.0) 6 (20.0) 0.44 d 
a Presented as mean±standard deviation; b Presented as number (%); c Independent t-test for continuous variables, Chi-Square for 





There were no significant differences in gender, other physical characteristics or risk factors. 
NT-pro-BNP levels tended to be higher in patients with an IMR>24 and there was a weak but 
significant correlation between these 2 variables (r=0.33, p=0.015). Likewise, glucose and 
HbA1c levels on admission were higher in patients with IMR>24, and significant correlations 
were found between these laboratory tests and IMR (r=0.34, p=0.009 and r=0.67, p<0.001, 
respectively). Finally, there was a trend for higher values of hs-CRP in patients with coronary 
microvascular damage (Table 72). 
 




Coronary microvascular damage (IMR>24) 
p value c 
No (n=30) Yes  (n=30) 
Creatinine (mg/dL) b  0.90 (0.31) 0.89 (0.17) 0.94 (0.44) 0.14 
NT-pro-BNP (pg/mL) b 137.5 (255.5) 93 (165.5) 167.5 (222.8) 0.055 
hs-CRP (mg(dL) b 0.44 (0.59) 0.33 (0.36) 0.49 (0.84) 0.09 
Glucose (mg/dL) b 133.5 (61.0) 122.0 (48.8) 141.5 (60.0) 0.046 
HbA1c (%)b 5.7 (1.1) 5.5 (0.6) 5.9 (3.5) 0.047 
a Presented as mean±standard deviation; b Presented as median (interquartile range); c Independent t-test for continuous variables 
with a normal distribution, Mann-Whitney test for continuous variables with a non-normal distribution.  
 
 
7.1.2. IMR and angiography/angioplasty variables 
 
There were no significant differences in ischemic (pain-to-balloon) or hospital-to-balloon times 
between patients with and without microvascular coronary damage (IMR>24). Main 
angiographic characteristics, including culprit artery, presence of multivessel disease and 
Syntax score were also similar in both groups (Table 73).  
Likewise, the area-at-risk, measured both by APPROACH and BARI scores, was similar. 
However, patients with an IMR>24 had a significantly higher prevalence of initial TIMI flow 0-
1 (93.3% vs. 73.3%, p=0.038).  
Treatment options, including the use of mechanical aspiration and stent implantation 
technique were similar in patients with and without IMR>24 (Table 74). However, patients with 
lower IMR values were more likely to have received abciximab during the P-PCI procedure 











Coronary microvascular damage (IMR>24) 
p valued 
No (n=30) Yes  (n=30) 
Pain-to-balloon time (min)c 209 (148) 206 (107) 225 (163) 0.19 
Door-to-balloon time (min) c 78 (45) 78 (34) 79 (59) 0.89 
Culprit artery b     
       Left anterior descending 28 (46.7) 14 (46.7) 14 (46.7) 
0.94        Left circumflex 13 (21.7) 6 (20.6) 7 (23.3) 
       Right coronary artery 19 (31.7) 10 (33.3) 9 (30.0) 
Multivessel disease b 25 (41.7) 15 (50.0) 20 (66.7) 0.19 
Syntax score c 15.5 (10.0) 16.9 (10.0) 14.8 (8.0) 0.21 
Area at risk scores a     
       APPROACH score 27.8 (2.0) 27.8 (3.0) 27.8 (3.0) 0.48 
       BARI score 28.0±6.3 27.2±6.5 28.0±6.3 0.95 
Initial TIMI flow 0-1 b 50 (83.3) 22 (73.3) 28 (93.3) 0.038 
a Presented as mean±standard deviation; b Presented as number (%); c Presented as median (interquartile range); d Independent 
t-test for continuous variables with a normal distribution, Mann-Whitney test for continuous variables with a non-normal 
distribution, Chi-Square for categorical variables; E Yates correction 
 
 




Coronary microvascular damage (IMR>24) 
p valueb 
No (n=30) Yes  (n=30) 
Mechanical aspiration 26 (43.3) 14 (46.7) 12 (40.0) 0.60 
Balloon pre-dilatation 35 (58.3) 15 (50.0) 20 (66.7) 0.19 
Stent implantation 57 (95.0) 28 (93.3) 29 (96.7) 1.00 
Balloon post-dilatation 23 (38.3) 12 (40.0) 11 (36.7) 0.79 
Abciximab treatment 14 (23.3) 11 (36.7) 3 (10.0) 0.015 
a Presented as number (%); b Chi-Square test 
 
 
7.1.3. Multivariable analysis of IMR predictors 
 
Since there were several relevant differences in the populations with and without 
microvascular coronary damage and in order to clarify the independent predictors of IMR, 
multivariable analysis was performed, using IMR as a continuous variable. Variables statistically 
significant on the univariate analysis were included in the regression model: age, initial TIMI 
flow, admission glucose, admission HbA1c and abciximab treatment.  Since glucose levels and 
HbA1c are interdependent variables, 2 different models were used, with these 2 blood tests. 






Table 75 – Multivariable analysis of IMR predictors 
Variable Hazard Ratio (95% CI) P value 
Model 1 (with admission glucose levels) 
   Glucose (mg/dL) 0.32 (0.03-0.19) 0.012 
   Age (years) 0.28 (0.07-1.10)  0.026 
   Initial TIMI flow 0-1 0.17 (-6.9-32.5) 0.20 
   Abciximab treatment -0.15 (-25.2-6.3) 0.23 
Model 2 (with admission HbA1c levels) 
   HbA1c (%) 0.55 (0.47-11.4) <0.001 
   Age (years) 0.32 (0.21-1.19) 0.006 
   Initial TIMI flow 0-1 0.18 (-4.0-32.0) 0.13 
   Abciximab treatment -0.05 (-19.5-12.3) 0.65 
 
In Model 1, age and glucose levels at admission were the only independent predictors of IMR. 
When other clinically relevant variables (gender, previous diabetes, mechanical aspiration, 
culprit artery and ischemic time) where added to the model in a stepwise approach, age 
(HR=0.31, p=0.022) and glucose levels (HR=0.34, p=0.022) kept their independent relation with 
IMR. Importantly, this was true for glucose levels even after adding previous diabetes history 
to the model.  
In Model 2, age and HbA1c were the only independent predictors of IMR. Again, when other 
clinically relevant variables (gender, previous diabetes, mechanical aspiration, culprit artery 
and ischemic time) where added to the model in a stepwise approach, age (HR=0.35, p=0.004) 
and HbA1c levels (HR=0.61, p<0.001) kept their independent relation with IMR. 
 
 
In summary, IMR values were associated with age and with admission glucose and HbA1c levels. 
Higher IMR values were also observed in patients with initial TIMI flow 0-1 and in patients who 
were not treated with abciximab, but these associations were not significant in the multivariable 








7.2. Relation between IMR and the extent of myocardial infarction 
 
7.2.1. IMR and Troponin release 
 
The peak values and the area under the curve of troponin I, according to the presence of 
microvascular coronary damage (IMR>24) are presented in Table 76.  
Patients with an IMR>24 had significantly higher values of both peak TnI and AUC of TnI, either 
total or indexed to the area-at-risk scores. IMR significantly correlated with peak TnI and AUC 
of TnI (r=0.508, and r=0.490, respectively; p<0.001 for both), and those correlations were even 
stronger when TnI release was indexed to area-at-risk scores (r=0.551 and r=0.530, for 
APPROACH score; r=0.523 and r=0.503, for BARI score; p<0.001 for all analysis). 
 
Table 76 –Troponin I values according to median IMR  
Variable a, b 
Total Population 
(n=60) 
Coronary microvascular damage (IMR>24) 
p value c 
No (n=30) Yes  (n=30) 
   TnIpeak 117±82 91±59 142±93 0.013 
   TnIpeak (APPROACH) 34±27 25±19 42±32 0.014 
   TnIpeak (BARI) 33±25 25±18 40±29 0.025 
   TnIpeak (2 scores) 33±26 25±18 41±30 0.018 
   TnIAUC 1938±1283 1459±898 2418±1438 0.003 
   TnIAUC (APPROACH) 565±441 407±274 724±517 0.004 
   TnIAUC (BARI) 548±405 410±275 687±468 0.004 
   TnIAUC (2 scores) 557±421 408±274 706±490 0.005 
a Presented as mean±standard deviation; b Peak value and area under the curve (AUC) of 7 troponin I (TnI, in mg/dL) 
measurements performed in the first 48 hours after the primary angioplasty; total values and values indexed to the 
APPROACH, BARI or both are presented; c Independent t-test. 
 
 
7.2.2. IMR and echocardiography parameters 
 
There were no significant differences in 2D and Doppler measurements in patients with 
coronary microvascular dysfunction (IMR>24), compared to patients with lower IMR. However, 
global longitudinal strain was lower in these patients (-14.60±1.37, vs. –12.80±2.54, p=0.013, 
Table 77).  
In the 3 month follow-up echocardiogram, patients with IMR<24 showed significant reductions 
in end-systolic left ventricular volumes and significant improvements in left ventricular ejection 
fraction, Doppler measurements (E/A ratio and E/e’ ratio), wall motion score index and global 




Table 77 – First (acute) echocardiogram parameters according to median IMR  
Variable a, b Total Population 
Coronary microvascular damage (IMR>24) 
p value c 
No  Yes   
2D measurements  (n=47) (n=22) (n=25)  
   LVEdV (ml) a 105.8±24.2 102.5±23.9 108.6±24.5 0.43 
   LVEsV (ml) a 54.7±12.7 51.5±12.0 57.5±12.9 0.13 
   LVEF (%)a 47.9±6.7 49.4±6.6 46.5±6.6 0.17 
   Wall motion score index b 1.41 (0.35) 1.49±0.23 1.54±0.23 0.49 
   Left atria volume (ml/m2) a 34.8±12.2 34.7±13.6 35.0±11.3 0.95 
Doppler measurements  (n=40) (n=17) (n=23)  
   E/A ratio a 1.00±0.34 1.03±0.35 0.97±0.34 0.60 
   E/e’ ratio  a 9.00±2.71 9.01±3.34 8.99±2.12 0.98 
2D speckle tracking imaging (n=40) (n=17) (n=23)  
   Global longitudinal strain a -13.54±2.28 -14.60±1.37 -12.80±2.54 0.013 
a Presented as mean±standard deviation; b Presented as median (interquartile range); c Independent t-test for continuous variables 
with a normal distribution.  Mann-Whitney test for continuous variables with a non-normal distribution. LVEdV – left ventricular 
end diastolic volume; LVEsV – left ventricular end systolic volume; LVEF – left ventricular ejection fraction; WMSI – wall motion 
score index.  
 
Table 78 – Second (3 month) echocardiogram parameters according to median IMR  
Variable a, b Total Population 
Coronary microvascular damage (IMR>24) 
p value c 
No Yes  
2D measurements  (n=54) (n=29) (n=25)  
   LVEdV (ml) a 109.7±26.4 104.2±20.5 116.3±31.3 0.10 
   LVEsV (ml) a 52.9±18.8 47.7±13.2 59.4±22.6 0.025 
   LVEF (%)a 52.6±7.1 54.6±6.5 50.1±7.1 0.024 
   Wall motion score index b 1.24 (0.35) 1.21±0.18 1.43±0.25 <0.001 
   Left atria volume (ml/m2) a 39.1±15.4 38.1±15.3 40.3±15.8 0.60 
Doppler measurements  (n=52) (n=28 (n=24)  
   E/A ratio a 1.20±0.56 1.25±0.51 1.14±0.63 0.05 
   E/e’ ratio  a ±3.83 7.81±2.58 10.34±3.59 0.006 
2D speckle tracking imaging (n=51) (n=28) (n=23)  
   Global longitudinal strain a -15.77±3.11 -16.81±1.86 -14.50±3.83 0.007 
a Presented as mean±standard deviation; b Presented as median (interquartile range); c Independent t-test for continuous variables 
with a normal distribution.  Mann-Whitney test for continuous variables with a non-normal distribution. LVEdV – left ventricular 
end diastolic volume; LVEsV – left ventricular end systolic volume; LVEF – left ventricular ejection fraction; WMSI – wall motion 
score index.  
 
 
In the comparison of the two echocardiogram examinations according to the presence of 
coronary microvascular damage (Table 79), IMR clearly selected patients with different 
evolutions:  
 Patients with IMR<24 evolved with significantly reductions in end-systolic left 
ventricular volumes, improvement in left ventricular ejection fraction and in E/e’ ratio. 
Additionally, they showed important and very significant improvements in wall motion 
score index and global longitudinal strain. Finally, they tended to show lower left atria 




 On the contrary, patients with IMR>24 significantly increased their end-diastolic left 
ventricular volumes, with no significant improvement in LVEF. They also had a 
significant increase in left atria volumes and a significant worsening in E/e’ ratio. Their 
wall motion score index improved, although the magnitude and the statistical 
significance of this improvement was much lower than the one observed in patients 
with IMR<24. Additionally, they showed no improvement in global longitudinal strain.  
 
Table 79 – Baseline and 3 months echocardiographic parameters according to median IMR  
 IMR < 24 IMR > 24 
Echo parameters Echo1 Echo2 P valuec Echo1 Echo2 P valuec 
2D measurements  n=22   n=23  
   LVEdV (ml) a 102.5±23.9 101.2±20.3 0.78 108.3±26.0 118.3±32.1 0.043 
   LVEsV (ml) a 51.5±12.0 45.3±11.5 0.01 56.8±12.8 60.7±23.0 0.29 
   LVEF (%)a 49.4±6.6 55.4±5.1 0.001 47.3±5.2 49.7±6.8 0.13 
   WMSI b 1.41 (0.32) 1.12 (0.12) <0.001 1.41 (0.35) 1.35 (0.41) 0.010 
   Left atria (ml/m2) a 34.7±13.6 37.9±16.8 0.08 34.0±10.3 41.4±16.6 0.026 
Doppler measurements   n=18   n=19  
   E/A' ratio a 1.01±0.34 1.14±0.33 0.08 0.97±0.35 1.14±0.64 0.13 
   E/e’ ratio a  9.0±3.3 7.3±2.7 0.005 9.0±2.3 10.6±3.7 0.03 
2D speckle tracking imaging  n=16   n=19  
   Global longitudinal strain a -14.6±1.4 -17.2±1.3 <0.001 -13.3±2.4 -14.4±3.6 0.10 
a Presented as mean±standard deviation; b Presented as median (interquartile range); C p-value for the comparison between the 
first and the second Echo only in patients with 2 evaluations; Paired samples T-Test for variables with normal distribution and 
Wilcoxon test for variables with non-normal distribution. LVEdV – left ventricular end diastolic volume; LVEsV – left ventricular 
end systolic volume; LVEF – left ventricular ejection fraction; WMSI – wall motion score index.  
 
 
7.2.3. IMR and contrast enhanced cardiac magnetic resonance 
 
Of the 49 patients that did the ceCMR, 20 (40.8%) had an IMR above the median value of 24, 
and 15 (30.6%) above the reported prognostic value of 40.  
IMR correlated with infarction mass (r=0.70, p<0.001) and percent infarct mass (r=0.54, 
p<0.001). Additionally, IMR also correlated with wall motion score index (r=0.42, p=0.003) and 
salvage mass (r=0.35, p=0.014). 
When patients were stratified according to the mean IMR value for the global population, the 
ones with lower IMR (<24) had also significant lower wall motion score index (1.34±0.31 vs. 
1.53±0.23, p=0.026). Their ejection fraction was slightly higher, but the difference was not 










Coronary microvascular damage (IMR>24) 
p value d 
No (n=29) Yes  (n=20) 
LVEdV (ml) a 142.8±29.2 141.3±23.2 144.9±36.7 0.68 
LVEsV (ml) a 66.3±21.8 65.0±18.3 68.2±26.5 0.62 
LVEF (%)a 53.6±8.7 54.2±9.0 52.8±9.0 0.59 
Wall motion score index a 1.42±0.29 1.34±0.31 1.53±0.23 0.026 
Oedema mass b 19.6 (14.4) 18.4 (13.6) 22.5 (26.9) 0.25 
Transmural necrosis c 23 (46.9) 8 (27.6) 15 (75.0) 0.001 
Infarct mass     
    Total b 14.7 (12.6) 11.4 (10.9) 17.6 (15.0) 0.031 
    Percent b 12.6 (14.4) 11.6 (12.1) 17.0 (15.4) 0.035 
       Indexed to APPROACH 3.7 (4.5) 3.2 (3.2) 4.9 (6.8) 0.050 
       Indexed to BARI 3.8 (4.3) 3.3 (3.1) 5.1 (5.2) 0.044 
Salvage mass b 4.5 (10.4) 5.4 (9.7) 3.9 (11.7) 0.59 
a Presented as mean±standard deviation; b Presented as median (interquartile range); c  Presented as number (%); d Independent 
t-test for continuous variables with a normal distribution, Mann-Whitney test for continuous variables with a non-normal 
distribution, Chi-Square for categorical variables; e Yates correction. 
 
On the contrary, patients with higher IMR (>24) had more frequently transmural infarctions 
and higher total and percent infarct masses, as compared with patients to lower IMR.  
 
In summary, the presence of coronary microvascular damage (IMR>24) was associated with larger 
infarcts, as measured by troponin I release and ceCMR. Patients with lower IMR values had a 
significantly better evolution in all echocardiogram parameters, with an improvement in left 





7.3. Relation between IMR and microvascular reperfusion 
 
7.3.1. IMR and ST resolution on the ECG 
 
The percentage of resolution of ST elevation and deviation resolution is presented in Table 
81 and in Figure 27, according to the presence of coronary microvascular damage (IMR>24). 
The ST residual changes are presented in Figure 28. 
 
 
Figure 27 – ST elevation and deviation resolution (median values) according to the presence 
of coronary microvascular dysfunction (IMR>24) 
 
Patients with IMR<24 had significantly better ST resolution of both total ST elevation and 
deviation and significantly less ST residual elevation and deviation in ECGs performed 
immediately after the PCI and at 90 and 180 minutes. They also showed a trend for better 
results in ST elevation resolution and residual changes in the lead with maximum ST elevation 
before the P-PCI.  
The presence of Q waves was numerically higher in patients with IMR>24, but the difference 
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Figure 28 – ST residual changes (median values) according to the presence of coronary 
microvascular dysfunction (IMR>24) 
 
Table 81 – ECG ST resolution and residual changes according to the presence of coronary 




Coronary microvascular damage (IMR>24) p 
valued 
No (n=30) Yes  (n=30) 
Immediately post-angioplasty ECG a 
   Total ST elevation b 3.3 (6.0) 1.8 (4.0) 4.8 (11.0) 0.016 
           % Resolution  74.5 (39.0) 79.0 (33.0) 52.5 (79.0) 0.02 
   Total ST deviation b 4.8 (6.0) 3.0 (5.0) 6.5 (11.0) 0.035 
           % Resolution  73.5 (44.0) 79.5 (34.0) 54.0 (53.0) 0.046 
   ST at derivation with max elevation) b 1.0 (2.0) 0.75 (2.0) 1.3 (3.0) 0.037 
           % Resolution  68.0 (47.0) 75.0 (40.0) 63.5 (56.0) 0.051 
90 minutes post-angioplasty ECG a 
   Total ST elevation b 1.5 (4.0) 1.0 (3.0) 3.0 (7.0) 0.008 
           % Resolution  79.5 (32.0) 86.5 (29.0) 75.5 (36.0) 0.014 
   Total ST deviation b 2.0 (4.0) 1.3 (3.0) 4.8 (8.0) 0.015 
           % Resolution  82.5 (33.0) 90.0 (26.0) 78.0 (46.0) 0.042 
   ST at derivation with   max elevation  b 0.5 (2.0) 0.50 (1.0) 1.0 (2.0) 0.047 
           % Resolution  77.5 (34.0) 84.5 (37.0) 69.0 (28.0) 0.077 
180 minutes post-angioplasty ECG a 
   Total ST elevation b 1.5 (3.0) 0.8 (3.0) 2.5 (5.0) 0.022 
           % Resolution  84.5 (23.0) 90.0 (23.0) 81.5 (40.0) 0.048 
   Total ST deviation b 1.5 (4.0) 1.0 (3.0) 2.8 (5.0) 0.049 
           % Resolution  88.0 (26.0) 92.5 (24.0) 83.0 (37.0) 0.086 
   ST at derivation with max elevation b 0.5 (2.0) 0.5 (1.0) 0.5 (1.0) 0.117 
           % Resolution  83.0 (33.0) 88.0 (33.0) 81.0 (30.0) 0.162 
   QS waves present 37 (61.7) 16 (53.3) 21 (70.0) 0.18 
a Values expressed as median (interquartile range); b Values expressed in mV; c values expressed as n(%); d Mann-Whitney test for 
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7.3.2. IMR and angiographic indicators of microvascular reperfusion 
 
Corrected TIMI frame count and TIMI myocardial perfusion grade results according to the 
presence coronary microvascular damage are presented in Table 82. Patients with IMR>24 had 
higher cTFC values (Table 82) and IMR significantly correlated with cTFC (r=0.64, p<0.001). 
 
Table 82 – Angiographic indicators of microvascular reperfusion according to the presence 




Coronary microvascular damage (IMR>24) 
p value  
No (n=30) Yes  (n=30) 
 Corrected TIMI frame count a 17.0 (7.0) 14.0 (7.0) 20.0 (10.0) <0.001 c 
 TMPG 2-3 b 49 (81.7) 28 (93.3) 21 (70.0) 0.019 d 
a data presented as median (interquartile range); b data presented as n(%); c Mann-Whitney test; d Chi-Square test. 
 




Figure 29 – Corrected TIMI frame count, according to the presence of coronary 





7.3.3. IMR and microvascular obstruction on the ceCMR 
 
IMR strongly correlated with microvascular obstruction as measured on the ceCMR (r=0.91, 
p<0.0001, Figure 30), 
 
 
Figure 30 – Correlation between IMR and microvascular obstruction on the ceCMR 
 
Patients with IMR>24 were more likely to have microvascular obstruction on the ceCMR (45.0% 
vs. 13.8%, p=0.015) and their microvascular obstruction mass was significantly larger (Table 
83). 
 




Coronary microvascular damage (IMR>24) 
p value c 
No (n=29) Yes  (n=20) 
Microvascular obstruction      
   MVO present a 13 (26.5) 4 (13.8) 9 (45.0) 0.015 
   Mass of MVO b 5.7 (4.0) 2.9 (2.9) 6.4 (11.5) 0.006 
a Presented as number (%); b Presented as median (interquartile range); c  Mann-Whitney test for continuous variables with a non-




The receiver operating characteristics (ROC) analysis of IMR to predict microvascular 
obstruction (Figure 31) showed an AUC of 0.723 (CI 95% 0.500-0.896, p=0.018). The optimal 
cutoff values of IMR for predicting microvascular obstruction was 33 (sensitivity of 69.2% and 
specificity of 80.6%). 
 
 
Figure 31 – Receiver operating characteristics (ROC) curve of IMR to predict microvascular 
obstruction 
 
In summary, patients with IMR<24 showed significantly better ST resolution and significantly 
better angiographic indicators of microcirculatory reperfusion (cTFC and TMPG). Likewise, they 
had significantly lower microvascular obstruction in the ceCMR. IMR and microvascular 






8. Summary of the results 
 
1.1. Primary endpoint: IMR values and first EndoPAT 
 
1.1.1. IMR values in patients with and without RHI<1.67  
 
 There were no significant differences in IMR values in patients with and without 
RHI<1.67 on the first EndoPAT evaluation: median 16.0 (IQR 37.3) vs. median 24.0 (IQR 
31.2), p=0.17. 
 RHI values in the first EndoPAT evaluation were higher than expected (2.15±0.58) and 
only 11 patients (18.3%) had endothelial dysfunction as defined by an RHI<1.67. 
 With the exception of active smoking and previous beta-blocker, therapy RHI values 
<1.67 were not related to any baseline patient characteristics, including age, risk factors, 
blood tests on admission, coronary anatomy or procedural aspects of the P-PCI. 
 
1.1.2. IMR values according to RHI tertiles  
 
 There were no significant differences in IMR values according to RHI tertiles: median 
19.4 (IQR 35.0), median 40.5 (IQR 31.2) and median 23.3 (IQR 30.3), respectively for 
tertiles 1, 2 and 3.  
 RHI tertiles did not relate either to any baseline patient characteristics, including age, 
risk factors, blood tests on admission, coronary anatomy or procedural aspects of the P-
PCI. 
 
1.1.3. Additional analysis: IMR values according to RHI as a continuous variable  
 
 There was no significant relation between IMR values and RHI values measured on the 
first EndoPAT, evaluated as a continuous variable. 
 RHI as a continuous variable did not relate either to any baseline patient characteristics, 
including age, risk factors, blood tests on admission, coronary anatomy or procedural 







1.2. Primary endpoint: IMR values and second EndoPAT 
 
1.2.1. IMR values in patients with and without RHI<1.67  
 
 RHI values in the second EndoPAT were lower (1.87±0.60) and more patients had RHI 
values <1.67 (n=16, 42%) 
 There was a clear trend towards higher values of IMR in patients with RHI<1.67: median 
40.5 (IQR 54.4) vs. median 22.0 (IQR 26.0), p=0.09. The prevalence of microvascular 
coronary damage, either defined as an IMR >24 (median value) or an IMR >40 (value 
published in the literature as prognostic marker in STEMI patients) was almost 2 times 
higher in patients with RHI<1.67, although differences did not reach statistical 
significance. 
 Patients with RHI<1.67 also tended to have more severe coronary artery disease 
(multivessel disease, higher areas-at-risk and worse initial TIMI flow. Likewise, their 
values hs-PCR on admission tended to be higher. 
 There were no other significant differences between groups in baseline patient’s 
characteristic, other blood tests on admission or procedural aspects of the P-PCI. 
 
1.2.2. IMR values according to RHI tertiles  
 
 There was a trend for lower IMR values in the third tertile of RHI:  19.5 (IQR 30.6), 
compared to median 39.0 (IQR 43.4) and median 23.8 (IQR 42.5), respectively in tertiles 
1 and 2 (p=0.64). The proportion of patients with microvascular damage (defined as an 
IMR above the median value of 24) also tended to increase with RHI tertiles:  38.5% vs. 
53.8% vs. 66.7% (p=0.37). 
 Patients in the higher tertile of RHI tended to have less severe coronary artery disease 
(less multivessel disease and lower SYNTAX scores) and had lower areas-at-risk 
(significant difference for the BARI score).  
 There were no other significant differences between groups in baseline patient’s 
characteristic, blood tests on admission or procedural aspects of the P-PCI. 
 
1.2.3. Additional analysis: IMR values according to RHI as a continuous variable  
 
 There was a tendency for lower RHI values in patients with higher IMR results 
 RHI values were higher in male patients and in patients with previous treatment with 
ACEi/ARBs;  




 Additionally, RHI values on the second EndoPAT correlated with the area-at-risk and 
tended to be lower in patients with more complex coronary artery disease.  
 
1.3. Secondary endpoint: Extent of myocardial infarction and microvascular 
reperfusion according to RHI values on the first EndoPAT  
 
1.3.1. Extent of microvascular infarction  
 
 The presence of RHI<1.67 on the first EndoPAT was not related to larger infarctions 
(measured by troponin release or by ceCMR).  
 There was an improvement in echocardiogram parameters, both in patients with and 
without endothelial dysfunction, between the first and the follow-up exams.  
 
1.3.2. Microvascular reperfusion 
 
 The presence of RHI<1.67 on the first EndoPAT was not related to non-invasive (ST 
resolution) or invasive (cTFC and TMPG) indicators of microcirculatory reperfusion. 
 Likewise, endothelial dysfunction was not related to microvascular obstruction on the 
ceCMR 
 
1.4. Secondary endpoint: Extent of myocardial infarction and microvascular 
reperfusion according to RHI values on the second EndoPAT  
 
1.4.1. Extent of microvascular infarction  
 
 The presence of RHI<1.67 on the second EndoPAT was related to larger infarcts, as 
evaluated by the troponin I release and ceCMR.  
 These patients also had lower LVEF and worse wall motion score index and GLS in the 
acute echocardiogram and in the ceCMR, although these differences were not present 









1.4.2. Microvascular reperfusion 
 
 The presence of RHI<1.67 on the second EndoPAT was related to higher residual ST 
elevation on the post-PCI and 90 minutes ECGs; there was also a trend for lower ST 
resolution in these patients.  
 There was a clear trend for worse cTFC and TMPG values in patients with RHI<1.67 on 
the second EndoPAT evaluation. 
 The proportion of patients with MVO on the ceCMR was higher in patients with RHI<1.67 
and there was a trend for higher MVO mass in these patients. 
 
1.5. Secondary endpoint: Extent of myocardial infarction and microvascular 
reperfusion according to IMR values 
 
1.5.1. Extent of microvascular infarction  
 
 IMR values were associated with age and with admission glucose and HbA1c levels. 
Higher IMR values were also observed in patients with initial TIMI flow 0-1 and in 
patients who were not treated with abciximab, but these associations were not 
significant in the multivariate analysis. Finally, patients with higher IMR also had higher 
values of NT-pro-BNP. 
 The presence of coronary microvascular damage (IMR>24) was associated with larger 
infarcts, as measured by troponin I release.  
 IMR correlated with infarction mass, percent infarct mass, wall motion score index and 
salvage mass as measured in the ceCMR. Patients with higher IMR (>24) had more 
frequently transmural infarctions and higher total and percent infarct masses.  
 Patients with lower IMR values had a significantly better evolution in all echocardiogram 
parameters, with an improvement in left ventricular dimensions, function and dynamics, 
which was not seen in patients with an IMR>24. 
 
 
1.5.2. Microvascular reperfusion 
 
 Patients with IMR<24 showed significantly better ST resolution and significantly better 
angiographic indicators of microcirculatory reperfusion (cTFC and TMPG).  
 Likewise, they had significantly lower microvascular obstruction in the ceCMR. IMR and 
























1. Main findings of the study 
 
The main findings of this study were: 
1. First EndoPAT: 
 RHI values measured acutely after primary PCI in patients with STEMI were higher 
than expected. 
 RHI was not related to IMR values or any other variables.  
 An RHI<1.67 was not related to larger infarcts. 
 An RHI<1.67 was not related to microcirculatory reperfusion/obstruction. 
 
2. Second EndoPAT:  
 RHI values tended to relate to IMR values. Higher RHI values also tended to relate 
to larger myocardial area-at-risk, more severe coronary artery disease, worse 
initial TIMI flow and higher baseline hs-PCR values.  
 An RHI<1.67 was related to larger infarcts, lower LVEF and worse WMSI. 
 An RHI<1.67 was associated with more MVO and worse indirect indicators of 
microvascular reperfusion. 
 
3. Index of microcirculatory resistance: 
 IMR was independently associated with age and admission glucose metabolism 
blood tests (glucose and HbA1).   
 IMR values were strongly related to microvascular obstruction. Patients with 
higher IMR values had significantly better indirect indicators of microvascular 
reperfusion.  
 IMR values were related to larger infarcts. 
 Patients with an IMR<24 had significantly less left ventricular remodelling in the 
follow-up echocardiogram. 
 
The discussion of these results will be organized in the following sections: 
 Section 2: Patient inclusion and validity of the sample. 
 Section 3:  First EndoPAT results 
 Section 4: Second EndoPAT results 








2. Patient inclusion and validity of the sample 
 
Our study included 60 patients, approximately 11% of the total population of STEMI patients 
admitted to our hospital during the study period.  
Although this seems like a very low inclusion rate, it is important to compare it to other similar 
published studies. Unfortunately, of all published studies using IMR in STEMI patients (Table 84), 
only one presents the inclusion flow diagram according to the CONSORT recommendations for 
transparent reporting of trials246 and the STROBE statement for observational studies247, as we 
did.  In the study mentioned, by Ahn and colleagues248, the inclusion rate over 30 months was 
even lower (7.6%). Three other studies reported the rate of inclusion (ranging from 15.6% to 
58.7%), but they did not follow the abovementioned recommendations for data reporting (Table 
84).  
 














28 NR NR 62.2 287±138 Mean 39± 26 
Median 32 
Lim (2009)249 40 NR NR 54±12 346±274 Mean 34±24 
Sezer 
(2010)250 
35 NR NR 58.4±9.3 210±145 Mean 28.7±10.3 
McGeoch 
(2010) 251 
53 NR NR 58 (32-83) 258 (132-420) Median 35  
(IQR 24-63) 
Yoo (2012)252 34 NR NR 57±4 194±123 NR b 
Payne 
(2012)253 








88 29 months 150 (58.7%) 67±13 345±193 Median 33  
(IQR 8-170) 
Anh (2014)255 40 15 months 256 (15.6%) NR b NR b NR b 
Cuculi 
(2014)256 
82 12 months NR 62±12 209±163 Mean 42.8±30.0 
Patel 
(2015)173 
34 NR 131 (23.1%) 61.0±10.6 174 (114-276) Median 28.6  
(IQR 20.0-43.5 
Park (2016)257 89 47 months NR 54±10 NR b Mean 26.5±16.7 
Palmer 
(2016)258 
31 NR NR 60±10 138±161 Median 24  
(IQR 23-45) 
Ahn (2016)248 40 30 months 529 (7.6%) 56±9 276±116 Mean 33±19 
Baptista 60 36 months 543 (11.0%) 59.6±12.7 209 (IQR 148) Median 24 
(IQR 33). 
a multicentric registry; b Reported only for subgroups, not for the total population; NR: not reported; c Ischemic time: time between 






Regarding this issue, there are some important points that deserve mention: 
 First of all, including acute STEMI patients in trials (particularly observational trials, in 
which additionally procedures will not bring any gains to the patient) is difficult. Patients 
are often under extreme stress and the process of informed consent is severely 
constrained. In this setting, pushing for an equivocal informed consent should not be 
done.259–262 
 Secondly, even though measuring IMR is a safe procedure to perform immediately after 
P-PCI180, it still implies introducing a new guide-wire into the culprit coronary artery and 
administrating adenosine. As such, all patients with hemodynamic, rhythm or conduction 
disturbances need to be excluded.  In our cohort, in addition, all patients had TIMI 3 flow 
at the end of the procedure. Although the later was not necessary (a TIMI flow <3 was not 
an exclusion criteria), usually patient with final compromised flow have ongoing pain and 
often some hemodynamic and rhythm instability and it is understandable that operators 
chose not to include these patients. 
 Finally, most research studies performed with IMR are relatively complex and require at 
least one more diagnostic test to be performed (MPE, ceCMR, PET, etc.). More complex 
trials imply more contra-indications and limitations for patient inclusion.    
 
Still, it has to be acknowledged that this is a selected population, younger and probably healthier 
than the general population of patients admitted with acute STEMI. Mean age in our study 
(59.6±12.7 years), for instance, although numerically superior to most other published studies 
(Table 84), was significantly lower than the mean age of the total population of patients admitted 
to our hospital in the same period, but not included in the study (N=484; 63.6±13.4, p=0.029).  
While it is plausible to argue that results in such selected cohorts should not be extrapolated to 
the global population of STEMI patients, it is also fair to acknowledge that the consistent results 
observed in IMR studies were obtained even though more severe patients were excluded. As such, 
results would eventually have been even more meaningful if those more severe patient had been 
included.  Despite these selection issues, the mean age and the median ischemic time in our cohort 
are within the intervals of values reported in the previous trials (Table 84).  
Additionally, the main epidemiological characteristics of the included cohort of patients is similar 
to other recent STEMI studies, both performed in single centres, and reported in the Portuguese 
National Interventional Cardiology Registry. Likewise, there are apparently no significant 
differences, when comparing these results to a recent large international registry (Table 85). 









Table 85 – Comparison of patient’s main characteristics in contemporary national and 













No. of patients 60 223 607 3.524 24.449 
Inclusion Selected Consecutive Consecutive  Consecutive Consecutive 
Age (years) 60±13 60±12 62±13 65±12 61±13 
Male Gender  80% 76% 76% 74% 78% 
   BMI 27.5±4.0 NR NR NR 29.1±6.1 
Risk Factors      
   Diabetes 25.0% 17.0% 21.9% 32.5% 20.7% 
   Hypertension 71.7% 56.0% 62.0% NR 65.3% 
   Dyslipidaemia  50.0% 50.0% 51.1% NR 65.0% 
   Current smoker 43.3% 56.0% 45.0% NR 42.7% 
Primary PCI      
   Ischemic time a 209 (IQR 148) 270 (-) NR NR NR 
   Stent used 95.0% NR NR 92.2% 90.6% 
   Mechanical thrombectomy 43.3% NR NR 46.7% 39.2% 
   IIb/IIIa inhibitors 23.3% NR NR 23.6% 42.8% 
a Ischemic time: time between symptom onset and the first balloon dilation (“pain-to-balloon” time); NR: not reported 
 
 
3. First EndoPAT results  
 
3.1. Implications of the RHI results in the first EndoPAT evaluation 
 
This was the first study ever to measure peripheral endothelial function in the acute phase 
(immediately after primary PCI) of ST elevation myocardial infarction patients. 
Reactive hyperemia index (RHI) results on this first EndoPAT evaluation were clearly higher than 
expected, even if outlier results (5 extreme high and 1 extreme low) are not considered.  
In fact, when comparing these results to other published studies using EndoPAT in patients with 
coronary artery disease, the values we reported in the first EndoPAT evaluation (2.15±0.58) are 
the highest and the number of patients with endothelial dysfunction (18.3%, defined as an 
RHI<1.67) is the lowest (Table 86), even though the other studies were performed either in stable 





Table 86 – Values of RHI reported in studies performed with EndoPAT in patients with 












362 PCI 24 hours 
RHI 1.82±0.48 
45.0% patients had an RHI<1.67 
Baptista (2013)19 231 
Diagnostic 
angiography 
NR (not acute) RHI 2.10+/-0.63 
Yamamoto 
(2014)268 
86 STEMI, P-PCI 
3 weeks 
 
RHI 1.70 (1.46-2.14) in patients with restenosis vs.  
RHI 1.87 (1.65-2.19) in patients without restenosis 
8 months 
RHI 1.75 (1.46-2.06) in patients with restenosis vs. 
RHI 2.12 (1.61-2.45) in patients without restenosis 
Kandhai-Ragunath 
(2014)269 
71 STEMI. P-PCI 4-6 weeks 
RHI 1.90±0.58 
47.9% patients had an RHI<1.67 
Baptista (2016)18 58 STEMI, P-PCI 5th-7th day 
RHI median 1.78 (IQR 0.74) 
43.1% patients had an RHI<1.67 
Levi (2016)270 30 STEMI, P-PCI 48-72h 
RHI 1.91±0.3 in patients with no reflow 
RHI 2.09±0.11 in patients with normal flow 
Current study  
   
   First EndoPAT  60 STEMI, P-PCI 1h 
RHI 2.15±0.58 (2.08±0.42 after exclusion of outliers) 
18.3% patients had  RHI<1.67 
   Second EndoPAT  38 STEMI, P-PCI 24h 
RHI 1.87±0.60 
42.1% patients had an RHI<1.67 
NR: not reported; RHI: reactive hyperemia index; STEMI: ST elevation myocardial infarction: P-PCI: primary percutaneous coronary 
intervention. 
 
The presence of endothelial dysfunction in patients with acute coronary syndromes has been 
repeatedly demonstrated (Table 87):  
 Elbaz and colleagues evaluated invasively the endothelial function in non-culprit arteries 
in patients with NST-ACS using intracoronary infusion of acetylcholine and found that 81% 
of patients had a blunted response to this endothelium-dependent vasodilator.271   
 Spiro and colleagues used flow-mediated dilation and low flow-mediated constriction to 
demonstrate that endothelial function is significantly more compromised in patients with 
ACS than in patients with stable coronary artery disease, both before and after 
angioplasty.272   
 More recently, Careri evaluated endothelial function in the first 12 hours both in stable 
and NST-ACS patients, and showed that flow-mediated dilation is significantly lower in 
acute patients.132  
 Finally, we also demonstrated that patients with STEMI treated with P-PCI have a high 




This endothelial dysfunction was associated with a worse prognosis, using different techniques 
and at different times after the symptoms onset (from 12 hours to several days or weeks). 
Importantly, the absence of late (2 to 3 months) recovery of this endothelial dysfunction was also 
associated with a dire outcome (Table 87).  
In the face of all this evidence, how do we explain the results obtained in our first endothelial 
function evaluation?  
As previously stated, endothelial function testing is particularly challenging in acute patients, for 
several reasons: in addition to the unpredictable nature of the acute event onset, the unstable 
condition and the pain, anxiety and fear patients usually experience, most of the times it is not 
possible to comply with several recommendations for endothelial function evaluation (including 
fasting state, morning exam, avoidance of caffeine or smoking, etc.).199. Additionally, patients 
were evaluated after an arterial puncture (for the urgent angiography) and several venous 
punctures (both for blood tests and for drugs administration).  
All these factor might have influenced the results. However, another important phenomenon may 
have occurred: as explained in the Introduction (section 7.1, page 66) and in the Methods (section 
3.9, page 95), the RHI is calculated as the ratio between hyperaemic and baseline pulse volume 
analysis (PAT ratio) normalized for the same ratio in the contralateral arm. If the presence of 
peripheral vasoconstriction (likely to occur in acute patients273,274), the  normalization using a 
constricted control arm may have led to an increase in the ratio of reactive hyperemia, thus 
explaining the unexpected high values of RHI found in our study. Importantly, this initial 
vasoconstriction usually normalizes in the first 24 hours in stable patients.273 
The low prevalence of endothelial dysfunction (defined as an RHI<1.67) in our cohort could 
eventually also be explained by the fact that this threshold (defined for stable populations) does 
not apply in acute patients. That was the reason why we initially planned an analysis based on 
tertiles of RHI and the motive that led us to perform the unplanned analysis using RHI as a 
continuous variable.  
However, independently of the analysis performed (RHI as dichotomous variable using the 1.67 
threshold; RHI divided in tertiles; or, RHI as a continuous variable), RHI values in the first EndoPAT 
evaluation did not relate to any baseline patient characteristics, including age, risk factors (except 
a trend for lower values in active smokers) or previous pharmacological treatment. Likewise, we 
did not find any significant relations between the first and the second EndoPAT evaluations.  































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.2. IMR, microvascular obstruction and extent of infarction according to RHI on 
the first EndoPAT  
 
We found no relation between RHI on the first EndoPAT (analysed as a dichotomous variable, in 
tertiles or as a continuous variable) and IMR.  Likewise, we found no relation of RHI and any of the 
measures of necrosis extension or any of the indicators of microvascular obstruction.  
Three explanations can justify these findings: 
 The first one would be that endothelial function is not involved in the acute mechanisms 
that occur in STEMI patients. If this was the case, we could hypothesize that microvascular 
coronary dysfunction and the consequent myocardial infarction extent are only related to 
non-endothelial dependent factors (including distal embolization of thrombi and debris, 
and/or other unknown factors). A large amount of evidence argues against this 
hypothesis: i) even though peripheral endothelial function was never evaluated acutely in 
STEMI patients, coronary endothelial dysfunction has been clearly demonstrated in NST-
ACS patients in the acute angiography271 and peripheral endothelial dysfunction was also 
demonstrated in ACS patients before PCI;272 ii) patients with endothelial dysfunction 
measured with EndoPAT have an higher risk for events129,275–278, so it would be at least 
expectable to find a high percentage of STEMI patients with endothelial dysfunction, even 
if it did not relate to IMR or other indicators of coronary microvascular dysfunction; iii) if 
non-endothelial dependent factors, including distal embolization during P-PCI, prevailed 
as the main contributors for coronary microvascular dysfunction, it would be expectable 
that strategies targeted to that complication (like thrombectomy and distal protection 
devices) would improve indicators of coronary microvascular damage, but that is not the 
case73–75, iv) thromboembolic distal embolization by itself results in the release of 
vasoactive factors279, implying that some degree of endothelial dysfunction would be 
expectable in these STEMI patients. 
 The second explanation could be that peripheral endothelial function evaluated with 
EndoPAT does not reflect coronary endothelial function in STEMI patients. This is also 
unlikely, since a good correlation between coronary and peripheral endothelial function 
was shown with several different techniques195,206,208, including EndoPAT207, in stable 
patients and there is no reason to suppose that this would be different in STEMI patients. 
Our results with the second EndoPAT, although performed 24 hours after the first one, 
also argue against this hypothesis (see below). 
 Finally, the third possible explanation is that EndoPAT measurements in the acute phase 
are not valid. For all the reasons described in the previous section, this seems to be the 
more plausible explanation for the observed results. It implies, therefore, that EndoPAT 
cannot be used to evaluate peripheral endothelial function in the acute phase of STEMI, 





4. Second EndoPAT results  
 
4.1. RHI results in the second EndoPAT evaluation 
 
On the second EndoPAT evaluation (38 patients), values were significantly lower (1.87±0.60, 
p=0.006; Table 15) as compared to the first EndoPAT evaluation and, importantly, they were 
similar to the values reported by Schoenenberger and colleagues (1.82±0.48) in the only study 
published that also measured RHI 24 hours after P-PCI in STEMI patients.267  
Accordingly, the percentage of patients with an RHI<1.67 in this second evaluation (42.1%) is very 
consistent with the results observed in all studies that reported this information in the 
acute/subacute phase of ACS: 47.9% in the study by Yamomoto et al268, 43.1% in our pilot study18 
and 45.0% in the study by Schoenenberger et al267 (Table 87).  
It is also important to underscore that the values of RHI on the second EndoPAT evaluation did 
not correlate with the values on the first EndoPAT (r=0.260, p=0.131). Among patients with 
endothelial dysfunction (RHI<1.67) on the first EndoPAT, half evolved to normal endothelial 
function on the second one. On the other hand, 44.8% patients with a normal endothelial function 
on the first EndoPAT ended up with endothelial dysfunction (RHI<1.67) on the second evaluation.  
The second EndoPAT evaluation was performed in a much calmer situation, still in the Coronary 
Care Unit, but with much less stress involved. Medication known to affect endothelial function 
(like statins and anti-platelets) was given to all patients studied. Importantly, the time of the day 
was not the same for all measurements, since it depended on the hour of the primary angioplasty. 
Accordingly, the patients could be or not on a fasting state.  
Still, the fact that this second EndoPAT results are apparently not related to the first ones and the 
consistency of the results when compared to other similar studies suggests that the problems of 
validity discussed for the first evaluation are not confirmed in the second one.  
This is further reinforced by the observation that patients with previous (before the current event) 
ACEi/ARBs treatment had higher RHI values, with a similar trend observed in patients previously 
treated with statins and beta-blockers. Similarly, there was a trend for lower RHI values in patients 
with known diabetes and previous coronary revascularization. All these observations are in 








4.2. IMR, microvascular obstruction and extent of infarction according to RHI on 
the second EndoPAT  
 
4.2.1. IMR, microvascular obstruction and extent of infarction 
 
The prevalence of microvascular coronary damage, either defined as an IMR >24 (median 
value) or an IMR >40 (value published in the literature as prognostic marker in STEMI 
patients) was almost 2 times higher in patients with endothelial dysfunction (RHI<1.67), 
although differences did not reach statistical significance. The number of patients with 
IMR>24 or IMR>40 also decreased from the first to the third tertile of RHI. Likewise, there 
was a clear trend towards higher values of IMR in patients with endothelial dysfunction: 
median values (IQR) 40.5 (54.4) vs. 22.0 (26.0) in patients without endothelial dysfunction 
(p=0.09). 
In accordance to the IMR results, the presence of endothelial dysfunction (RHI<1.67) also 
tended to relate with electrocardiographic (particularly residual ST elevation after P-PCI) and 
angiographic (cTFC and TMPG) indicators of microvascular reperfusion.   
Altogether, these data suggest a higher damage of coronary microvasculature in patients 
with endothelial dysfunction evaluated on the second EndoPAT, which is confirmed by the 
results of the ceCMR: patients with an RHI<1.67 had an almost 5 times higher probability 
(11.1% vs. 54.5%, p=0.03) of having microvascular obstruction on the ceCMR, and tended to 
have higher obstruction masses.  
Endothelial dysfunction was also clearly related to the extension of the infarct: patients with 
an RHI<1.67 had significantly higher values of both peak TnI and AUC of TnI, either total or 
indexed to the area-at-risk scores. Correspondingly, they had a 3 times higher risk of 
transmural necrosis (22.2% vs. 63.6%, p=0.06) and a clear tendency to higher total and 
percent infarct masses in the ceCMR. In line with these results, they also had lower left 
ventricular ejection fractions and higher (worse) wall motion score indexes, both in the initial 
echocardiogram and in the ceCMR. 
To our knowledge, this is the first study reporting the association of early (24 hours) 
measured peripheral endothelial dysfunction with microvascular coronary damage and with 
myocardial infarction extension in patients with STEMI.   
 
4.2.2. Endothelial dysfunction: cause, consequence or both?  
 
The fact that patients with endothelial dysfunction had a tendency for more severe coronary 
artery disease (the prevalence of multivessel disease was almost two times higher in patients 




in these patients) is in accordance with our previous work19 and suggests that at least the 
severity of previous coronary artery disease is related to endothelial dysfunction. We also 
found a trend for lower initial TIMI flow in patients with endothelial dysfunction, which his in 
agreement with a recent study by Kandhai-Ragunat and colleagues. These authors 
documented lower RHI values (although measured 4 to 6 weeks after the STEMI) in patients 
with an occluded artery before the P-PCI, as compared to patients with a patent artery 
(2.08±0.34 vs. 1.75±0.35; p<0.007),269 suggesting that endothelial dysfunction may be 
involved in microvascular reperfusion in STEMI patients.  
However, we also found a significant negative correlation between both area-at-risk scores 
and RHI. The area-at-at risk evaluated by the BARI score was significantly lower in patients in 
the third tertile (higher values) of RHI and there was a trend for lower RHI in patients that 
had the LAD as culprit artery. Both larger areas-at-risk and the LAD as culprit artery are 
associated with larger infarctions, implying that the documented lower RHI values may 
indirectly measure the extension of the infarction, as opposed to being part of the 
pathophysiological process that caused it. Indeed our finding that patients with endothelial 
dysfunction in the first 24 hours after STEMI have larger infarcts and lower ejection fraction 
are in line with the evidence of neuro-humoral activation in patients with heart failure. In 
fact, it was already demonstrated that the reduction in stroke volume produces a lower 
endothelial shear stress, which causes a dysregulation in NO synthase isoforms gene 
expression281,282, eventually leading to a reduced NO bioavailability.283 Furthermore, there is 
an additional reduction in NO bioavailability caused by direct NO destruction by reactive 
oxygen species, mainly driven by an increase in angiotensin II and aldosterone activity, and 
purine metabolism.284  
While we cannot infer from our results whether the endothelial dysfunction was a cause or a 
consequence of the severity of the myocardial infarction, it is reasonable to conclude that 
peripheral endothelial dysfunction in these patients may be a marker of the severity of the 
myocardial disease and, therefore, of its systemic consequences, which makes it useful to 
assess the effectiveness of therapy and predict events, independently of its exact 
pathophysiological role.  
In fact, in patients with acute myocardial infarction, early treatment with statins, currently 
known to reduce events, was initially evaluated through its beneficial effect in the endothelial 
function.285,286 Likewise, in heart failure patients, peripheral endothelial function has been 
described as a tool to predict the response to cardiac resynchronization therapy, and 
endothelial dysfunction improvement after CRT correlated with functional improvement287, 
being related to an increase in cardiac output288, likely mediated by shear-stress.289  
In summary, albeit demonstrating the exact role of endothelial dysfunction in STEMI patients 
is not possible at this point, we demonstrated that its measurement early after primary PCI 
is feasible and related both with the extent of infarct and microvascular obstruction, which 
makes it a valuable tool both for identifying high risk patients and for testing new 





5. IMR results 
 
5.1. IMR and microvascular obstruction  
 
IMR strongly correlated with all other indirect indicators of microvascular reperfusion. Regarding 
ECG, patients with IMR<24 had significantly better ST resolution of both total ST elevation and 
deviation and significantly less ST residual elevation and deviation in ECGs performed immediately 
after the PCI and at 90 and 180 minutes. They also showed better results in ST elevation resolution 
and residual changes in the lead with maximum ST elevation before the P-PCI.  
Most studies performed with IMR did not report this and some of the ones that did it248,250,290 
could not find significant differences in ECG parameters between patients with and without 
microvascular obstruction. However, it must be acknowledge that the classic thresholds of 50 or 
70% in ST resolution were derived from thrombolytic trials in which, in fact, a significant 
percentage of patients did not reperfuse the culprit artery. In the primary-PCI era, a normal flow 
(TIMI 3) is almost always obtained and therefore the vast majority of patients evolves with 
significant ST resolution in the first hours after the procedure – in our cohort, 68.3% and 81.7% 
had an ST resolution higher than 70% respectively at 90 and 180 min after the P-PCI.  While we 
must accept that a consensus is still lacking about which leads to analyse, the optimal timing of 
electrocardiogram analysis, and whether standard ECG or continuous ECG monitoring is 
preferable, ECG may still have his role in identifying patients with microvascular obstruction, being 
an easy and inexpensive exam to perform. 
Concerning the angiographic indicators, corrected TIMI frame count was significantly higher in 
patients with IMR>24 and there was a significant correlation between IMR and cTFC (r=0.64, 
p<0.001), Likewise, a TIMI myocardial perfusion grade 2-3 was significantly less frequent in 
patients with IMR>24. Strangely, of the 6 studies that evaluated the role of IMR in predicting MVO, 
only 1 reported these data – Carrick  et al found significantly higher cTFC in lower tertiles of IMR 
and a significantly higher percentage of patients with TMPG 2/3 in the lower tertiles290, in line with 
our results. Likewise, in the largest cohort with IMR published to date, there were significant 
associations with both variables.64 
These ECG and angiographic results suggest that IMR is a good predictor of microvascular 
obstruction, which was confirmed in the ceCMR: IMR strongly correlated with microvascular 
obstruction (r=0.91, p<0.0001), patients with an IMR>24 were much more likely to have 
microvascular obstruction on the ceCMR (45.0% vs. 13.8%, p=0.015) and their microvascular 
obstruction mass was significantly higher.   
These results confirm those previously published by others (Table 4) and support the feasibility of 






5.2. IMR and infarct extension  
 
Patients with an IMR>24 had significantly higher values of both peak TnI and AUC of TnI, and IMR 
was significantly correlated with both, particularly when those measurements were indexed to 
the area-at-risk scores.  
Previous studies reported similar results, but only with peak CK (Fearon et al238; r=0.61, p=0.005) 
or peak TnI (Mcgeoch et al; r=0.52, p=0.01251). Others have shown that when patients are divided 
into groups according to IMR values, those in the higher IMR groups also have higher mean 
CK249,252,257 or TnI257 values. 
However, evidence suggests that peak CK and peak TnI are weak predictors of the extension of 
myocardial necrosis, particularly when these measurements are performed only in the first 24 
hours after admissio291. Among the studies that evaluated IMR, our study is the first to 
systematically measure TnI values in the first 48 hours after primary PCI, establishing a curve of 
TnI release and calculating both its area under the curve and peak values. We obtained results 
similar to the ones previously published, reinforcing the consistency of IMR measurements in 
STEMI patients.  
The cardiac biomarker results were confirmed by the ceCMR evaluation: IMR correlated with 
infarction mass (r=0.70, p<0.001) and percent infarct mass (r=0.54, p<0.001). Additionally, IMR 
also correlated with wall motion score index (r=0.42, p=0.003) and salvage mass (r=0.35, p=0.014). 
Again, these results confirm those in three recently published studies, also performed with 
ceCMR251,253,290 and a fourth that used SPECT.250 
Taken together, these results confirm IMR as a valuable tool for predicting myocardial infarction 
extension in STEMI patients treated with P-PCI. 
 
5.3. IMR and left ventricular remodelling  
 
We confirmed the results of others (Table 3), showing that patients with IMR<24 have less left 
ventricular remodelling in the follow up echocardiogram (with significant reductions in end-
systolic left ventricular volumes and significant improvements in left ventricular ejection fraction, 
Doppler measurements [E/A ratio and E/e’ ratio] and wall motion score index), when compared 
to patients with IMR>24.  
Additionally, we showed for the first time that baseline (in the acute echocardiogram) global 
longitudinal strain (GLS) was lower in patients with lower IMR (-14.60±1.37, vs. –12.80±2.54, 
p=0.013). We recently published this analysis in a subset of the final cohort of patients56 and the 
results were confirmed in the final cohort. In our study, IMR evaluated immediately after P-PCI 
correlated with GLS evaluated in the first 24 hours after infarction. However, there was no relation 
between IMR and the conventional echocardiographic parameters, evaluated at the same time, 




myocardium evaluation after infarction has been extensively reported: Sjøli et al. evaluated a 
population of patients with STEMI by echocardiography and CMR and concluded that LV global 
strain is a more precise and reproducible diagnostic predictor of large infarcts when compared to 
LVEF.292 Global strain after STEMI has been reported to be well associated with echocardiographic 
WMSI, CMR-determined infarct size, and LVEF measured by CMR, SPECT, standard 
echocardiography and contrast echocardiography; additionally, it was found to be the best 
predictor of low LVEF, measured by the gold standard CMR293. To the best of our knowledge, this 
study is the first to report the association between IMR and strain after STEMI. In stable coronary 
artery disease, IMR was already correlated with strain in evaluation of LV contractile reserve on 
dobutamine echocardiography.294 In STEMI patients, Park et al. found myocardial strain to be well 
correlated with coronary flow reserve (CFR), as determined by intracoronary measurement after 
P-PCI in anterior STEMI, and suggested its utility in predicting myocardial functional recovery, non-
invasively.295 Laøgstrup et al. on the other hand, reported that the magnitude of myocardial 
deformation correlates with the severity of alterations in microcirculation, detected by CFR, 
assessed by transthoracic echocardiography. They also demonstrated longitudinal global and 
regional strain to be a significantly better tool than WMSI to investigate LV dysfunction after acute 
myocardial infarction.296 In the present study, the IMR was able to independently predict 
myocardial deformation, evaluated immediately after infarction by GLS, which is considered to be 
a very sensitive and informative parameter of infarction extension and functional recovery. This 
association between IMR and GLS was not only present initially, but persisted at 3 months, when 
the relationship of IMR with LVEF and WMSI also manifested.  
Importantly, the association between IMR and GLS was independent of the area-at-risk and the 
NT-pro-BNP values on admission, suggesting that IMR has an additional value in predicting left 
ventricular recovery in these patients56. 
 
5.4. Predictors of IMR 
 
Patients with coronary microvascular dysfunction (defined as having an IMR higher than the mean 
value 24) were older and there was a weak, but significant correlation between IMR and age 
(r=0.28, p=0.03). This result is similar in three recent studies (Table 88), but discordant from the 
results from the largest multicentric study, published by Fearon et al64. However, in this last 
dataset, mean age was significantly lower, which may indicate a more selected population (Table 
84). Similarly to other studies published, there were no significant differences in IMR according to 
gender and other physical characteristics or risk factors, including diabetes.  
We found no significant differences in ischemic (pain-to-balloon) or hospital-to-balloon times 
between patients with and without microvascular coronary damage (IMR>24). Once again, this 
result is similar to that reported by most studies that evaluated this aspect (Table 88). 
Patients with an IMR>24 had a significantly higher prevalence of initial TIMI flow 0-1 (93.3% vs. 




Importantly, treatment options, including the use of aspiration thrombectomy catheters and 
IIb/IIIa inhibitors, were similar in patients with or without IMR>24 (IIb/IIIa inhibitors were more 
often used in patients with lower IMR, but that difference was not significant on the multivariable 
analysis), in accordance with the majority of studies that reported on this question (Table 88) 
 













Bonello (2010)297 45 + - + a + a NR 
Sezer (2010)250 35 - - NR NR NR 
Fearon (2013)64 253 - - - NR NR 
Baek (2015)298 113 + + - - - 
Carrick (2016) 259 Trend  - - - NR 
Park (2016)257 89 + - - - NR 
Ahn (2016)248 40 NR NR + Trend NR 
Baptista 60 + - - - ++ 
a Univariate analysis, b p=0.057 
 
Glucose and HbA1c levels on admission were higher in patients with IMR>24, and significant 
correlations were found between these laboratory tests and IMR (r=0.34, p=0.009 and r=0.67, 
p<0.001, respectively). The impact of both admission glucose and HbA1c was still significant after 
adjusting for other variables, including history of diabetes.  
Admission glucose levels were clearly confirmed as an independent prognostic marker of both in-
hospital and long-term outcome, regardless of diabetic status.299,300 The exact deleterious 
mechanisms of hyperglycaemia are not completely understood: hyperglycaemia during STEMI is 
probably caused by an inflammatory and adrenergic response to ischemic stress, when 
catecholamines are released and glycogenolysis induced. Although the pathophysiological 
mechanisms involved have not yet been fully elucidated, it is believed that hyperglycaemia is 
associated with an increase in free fatty acids (which induce cardiac arrhythmias), insulin 
resistance, chemical inactivation of nitric oxide and the production of oxygen reactive species 
(with consequent microvascular and endothelial dysfunction), a prothrombotic state, and vascular 
inflammation. It is also related to myocardial metabolic disorders, leading to thrombosis, 
extension of the damaged area, reduced collateral circulation, and ischemic preconditioning301.  
Several studies have demonstrated that high admission glucose levels in STEMI patients treated 
with P-PCI are related with different indicators of microvascular coronary dysfunction, including 
ECG ST resolution302, angiographic markers (like cTFC and TMPG)303 and CFR measured by 
echocardiography.304,305 Admission glucose levels are also significantly higher in patients with 
microvascular obstruction in ceCMR.306,307  
Likewise, the prognostic impact of admission HbA1c was also demonstrated in STEMI patients.308–
310 Glycosylated haemoglobin (HbA1c) is an established marker of long-term glycaemic control in 
patients with diabetes mellitus, and elevated HbA1c levels in such patients are associated with an 




appears to be also predictive for cardiovascular disease and mortality in patients without diabetes 
mellitus, regardless of fasting glucose levels, indicating that long-term glycometabolic 
derangement also poses a risk for cardiovascular events.311 However, both HbA1c and glucose 
levels probably reflect different patient populations, and their association with outcome is 
probably due to different mechanisms.  
To the best of our knowledge, this is the first study to identify a significant relation between 
glucose levels on admission and microvascular coronary dysfunction as evaluated by IMR. 
Regarding HbA1c, only one other study reported its relation with IMR. In this study, as opposed 
to our findings, there was no difference in HbA1c between tertiles of IMR298 . Our results, however, 
show an unequivocal and significant relation between these 2 variables and IMR.  
Although not surprising, this was not a planned endpoint of our study. However, we plan to 
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This study has several limitations, which should be taken into account when interpreting the 
results. 
 Firstly, the inclusion rate was very low and the cohort included represents only 11% of the 
population of patients with STEMI in the period in which recruitment occurred. Although 
the majority of patients was excluded due to predefined exclusion criteria, a significant 
number (n=99) of patients was not included due to unknown reasons or to the operator’s 
decision. Although this limitation was also described in the only study that reported 
inclusion rate as extensively as we did, it must still be acknowledged that this is a highly 
selected population. However, as noted in the discussion, the patients selected appear to 
be the ones with less risk. Patients with more severe clinical presentation, more prolonged 
ischemic times and hemodynamic instability probably would have larger infarcts and more 
severe microvascular obstruction, which would likely increase the diagnostic ability of IMR 
and EndoPAT.  
 Secondly, the EndoPAT exams were not performed according to the recommendations for 
endothelial function evaluation: patients were not fasting, coffee or tea consumption was 
not excluded and the morning hour of the exam was not respected. However, measuring 
endothelial function in the acute phase was exactly the purpose of the study and we did 
acknowledge that the acute measurement probably is not valid exactly because of these 
technical constraints. The second EndoPAT evaluation, on the other hand, was performed 
in a much less stressful situation and the results are in accordance with previous published 
studies, suggesting it is feasible, even though recommendations for performing the exam 
were not followed strictly. Importantly, all the operators performing the EndoPAT 
evaluation were highly trained in this procedure, having participated in several previous 
studies.  
 Thirdly, the number of patients with the second EndoPAT evaluation is small. In fact, this 
evaluation was not initially planned and it was only decided when we realized that the 
first EndoPAT values were probably not valid. Probably some of the tendencies described 
would be statistically significant if the cohort was larger. 
 Fourthly, imaging exams (both ceCMR and echocardiograms) are not available for all 
patients. This is a limitation that is difficult to overcome. In studies which reported 
inclusion rate according to recent recommendations, authors faced the same problem, 
for several reasons: some patients refuse to perform follow-up exams, while others do 
the exams but technical issues prevent its interpretation. However, in spite of this 
limitation, results with bot echocardiogram and ceCMR were very consistent.  
 
Our study also has some important strengths:  
 We have one of the largest single-centre databases in IMR evaluation in STEMI patient in 
the world, systematically evaluating all indirect indicators of microvascular reperfusion: 
ECGs were performed before and after reperfusion (including at 90 and 180 minutes) for 
all patients and cTFC and TMPG were also registered in all cases. Most of the studies 
performed in this area are very inconsistent in reporting these data, as highlighted in the 
discussion.  
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 The evaluation of myocardial infarction by troponin release was also much more 
comprehensive: blood samples were collected at predetermined times in all patients for 
the first 48 hours allowing for a precise evaluation of both peak and area under the curve 
values for the estimation of infarction extent. None of the studies already published 









































Conclusions and future perspectives 
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Coronary microvascular circulation remains a largely unknown territory in patients with ST 
elevation myocardial infarction, and this is an area where almost no scientific advances were made 
in the last years. 
The recent availability of new techniques for non-invasive measurement of endothelial 
dysfunction and for invasive assessment of the coronary microcirculation in this clinical setting 
offered new research opportunities in this field and led to the study presented on this thesis, 
which was designed with the intention of improving our knowledge on the role of endothelial 
dysfunction in patients with STEMI. Based on the data presented, the main conclusions of this 
study are: 
 
1. Reactive hyperemia index measurement with EndoPAT immediately after primary PCI in ST 
elevation myocardial infarction patients probably cannot be performed, due to the serious 
unavoidable technical pitfalls in the acute phase.  
Although we found no relation between this test and the index of microcirculatory resistance, 
other measures of microvascular coronary dysfunction or the extent of the myocardial 
infarction, the validity of these results is questionable. 
Other non-invasive tests available, like flow-mediated dilation, should also have the same 
pitfalls we found with EndoPAT, since they too depend on the baseline vasoconstrictor status 
and on all the factors that influence it in the acute phase of a coronary event. Invasive methods 
for testing coronary endothelial function, on the other hand, remain dependent on 
pharmacological stimuli and are not an option in acute patients. Therefore, evaluation of the 
endothelial function in the acute phase apparently is not feasible with the current technology.    
 
 
2. Reactive hyperemia index measurement with EndoPAT 24 hours after primary PCI in ST 
elevation myocardial infarction patients is feasible and related both to the extension of the 
infarct and to microvascular obstruction (including a tendency for lower IMR values in 
patients with higher RHI values).  
 
Despite the fact that measurement of RHI in this subacute phase is not able to differentiate if 
the endothelial dysfunction found is a cause or a consequence (or both!) of the myocardial 
infarction, these results are quite important, for several reasons: firstly, they prove that the 
coronary endothelial dysfunction previously documented in ACS patients with invasive 
methods is also measurable by an non-invasive peripheral technique in a subacute phase. 
Secondly, they confirm endothelial function having a central role in the pathophysiological 
processes occurring in STEMI patients. Thirdly, they suggest that RHI could eventually be used 
as a surrogate for coronary endothelial function in this setting, allowing research on the 






However, there is still a lot to be learned regarding the evolution of endothelial function in the 
first days, weeks and months in STEMI patients. It is particularly important to understand how 
the recovery of endothelial dysfunction impacts positively on left ventricular remodelling and 
on future events, since this may be an important target for present or future treatment 




3. The index of microcirculatory resistance measured immediately after primary PCI in ST 
elevation myocardial infarction patients predicts microvascular obstruction in the ceCMR 
and correlates both with infarct extension and myocardial salvage. It is also closely related 
to infarct extension measured by Troponin I release and to indirect indicators of 
microvascular coronary obstruction. 
 
Although this was not new, it was important to confirm the feasibility, safety and utility of 
measuring IMR in the acute phase of STEMI patients. Unfortunately, since this is an expensive 
technique, it will be difficult to implement it routinely in this population. However, measuring 
IMR in patients with clinical indication for a pressure-wire (i.e., patients with intermediate 
lesions in which the pressure-wire is to be used for fractional flow reserve evaluation), 
including patients with STEMI, may allow us to further increase our knowledge of this 
technique. Indeed, there are several ongoing trials trying to assess complete vs. differed 
revascularization of non-culprit arteries in STEMI patients, using pressure-wire to guide the 
decisions and I am currently involved in the design of a new one, using a non-hyperaemic 
technology.  
 
Likewise, measuring IMR in different clinical settings may be useful to the understanding of the 
role of microvascular coronary circulation in coronary disease. An example, is the currently 
ongoing SAVE-IT trial (which is evaluating the role of fractional flow reserve in orienting 
revascularization decisions in surgical valve patients with intermediate coronary lesions), 
which I helped to design and implement, and which includes a substudy with IMR evaluation 
in severe aortic stenosis patients.  
 
 
4. Age and glucose metabolic status (both acute, measured by glucose on admission, and 
previous, measured by HbA1c levels on adission) are independent predictors of IMR  
The impact of glucose metabolism on IMR was not an unexpected finding, considering all that 
is known about the impact of glucose levels (and, to a lesser extent, of HbA1 levels) in STEMI 
patients.  
However, despite the significant relation we found between these glucose metabolism 
indicators and IMR, the fact that all pharmacological approaches that tried to improve the 
outcomes of these patients failed is just another crude evidence of an irrefutable fact in 
coronary artery disease patients: we are still far from understanding what happens in the 
microcirculation. In order to further improve the outcomes of our patients, this is a limitation 
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Early peripheral endothelial dysfunction predicts myocardial infarct 
extension and microvascular obstruction in patients with ST elevation 
myocardial infarction  
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RESUMO 
Introdução e objectivos: o papel da disfunção endotelial (DE) em doentes com enfarte agudo do 
miocárdio com elevação do segmento ST (EAMcST) é mal compreendido. A tonometria arterial 
periférica (TAP) permite avaliar de forma não invasiva a função endotelial, mas nunca foi usada 
precocemente após intervenção coronária percutânea primária (ICP-P). O nosso objectivo foi 
avaliar a relação entre a DE avaliada por TAP, a presença de obstrução microvascular (OMV) e a 
extensão do enfarte (EE) em doentes com EAMcST. 
Métodos: a função endotelial foi avaliada pelo índice de hiperemia reactiva (IHR), obtido por TAP. 
A DE foi definida como um valor de IHR<1,67. A EE foi avaliada pela Troponina I (TnI) e por 
ressonância magnética cardíaca com contraste (RMCc). A OMV foi avaliada por RMCc e por 
indicadores indirectos electrocardiográficos e angiográficos. Foi ainda efectuado um 
ecocardiograma nas primeiras horas. 
Resultados: foram incluídos 38 doentes (idade média 60,0±13,7 anos, 29 homens). Os valores 
médios de IHR foram 1,87±0,60 e 16 (42,1%) tinham DE. Os valores máximos (mediana 118/IIQ 
186 vs. 67/81, p=0,024) e a área sob a curva de TnI (mediana 2305/IIQ 2486 vs. 1076/1042, 
p=0,012) foram significativamente superiores nos doentes com DE, que também mostraram uma 
tendência para mais enfartes transmurais (63,6% vs. 22,2%, p=0,06) e maiores massas de enfarte 
na RMCc (mediana 17,5/IIQ15,4 vs. 10,1/10,3, p=0.08). Os doentes com RHI<1,67 mostraram 
valores de fracção de ejecção do ventrículo esquerdo (FEVE) significativamente menores e valores 
do índice de motilidade segmentar (IMS) significativamente maiores, por ecocardiografia e por 
RMCc. A presença de OMV na RMCc foi mais frequente nos doentes com DE (54,5% vs. 11,1%, 
p=0,03), observando-se uma tendência semelhante nos marcadores electrocardiográficos e 
angiográficos de reperfusão microvascular. 
Conclusões: A presença de DE avaliada por TAP 24 horas após ICP-P em doentes com EAMcST 
associa-se a enfartes maiores, menor FEVE, maior IMS e maior prevalência de OMV. 
 
PALAVRAS CHAVE 
Enfarte Agudo do miocárdio; intervenção coronária percutânea primária; função endotelial; 
tonometria arterial periférica; índice de hiperémia reactiva  




Background and Objectives: The role of endothelial dysfunction (ED) in patients with ST elevation 
myocardial infarction (STEMI) is poorly understood. Peripheral arterial tonometry (PAT) allows the 
non-invasive evaluation of endothelial function, but was never evaluated early after primary 
percutaneous coronary intervention (P-PCI). Our purpose was to evaluate the relation between 
ED evaluated by PAT and both the presence of microvascular obstruction (MVO) and infarct extent 
(IE) in STEMI patients. 
Methods: Endothelial function was evaluated by the reactive hyperemia index (RHI), measured by 
PAT. ED was defined as an RHI<1.67.  IE was evaluated by troponin I (TnI) release and contrast 
enhanced cardiac magnetic resonance (ceCMR). MVO was evaluated by ceCMR and by indirect 
angiographic and ECG indicators. An Echocardiogram was also performed in the first hours.  
Results: 38 patients were included (mean age 60.0±13.7 years, 29 males). Mean values of RHI 
were 1.87±0.60 and 16 patients (42.1%) had ED. Peak TnI (median 118/IQR 186 vs. 67/81, p=0.024) 
and AUC of TnI (median 2305/IQR2486 vs. 1076/1042, p=0.012) were significantly higher in 
patients with ED, which also had a trend for more transmural infarcts (63.6% vs. 22.2%, p=0.06) 
and larger infarct mass in the ceCMR (median 17.5/IQR15.4 vs. 10.1/10.3, p=0.08). Left ejection 
fraction (LVEF) was lower and wall motion score index (WMSI) was higher both in Echo and ceCMR 
in patients with ED. In the ceCMR, MVO was more frequent in patients with RHI<1.67 (54.5% vs. 
11.1%, p=0.03). ECG and angiographic indicators of MVO all showed a trend towards worse results 
if these patients. 
Conclusions: The presence of ED evaluated by PAT 24 hours after P-PCI in patients with STEMI is 
related with larger infarcts, lower LVEF, higher WMSI and higher prevalence of MVO. 
 
KEYWORDS 
Acute myocardial infarction; primary PCI; endothelial function; peripheral arterial tonometry; 
reactive hyperaemia index  
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LIST OF ABREVIATIONS 
ACS Acute coronary syndromes 
AUC Area under the curve 
ceCMR Contrast enhanced cardiac magnetic resonance 
cTFC Corrected TIMI frame count 
ED Endothelial dysfunction  
hs-CRP High sensitive C-reactive protein 
IE Infarct extension 
IMR Index of microvascular resistance 
IQR Interquartile range 
LVEF Left ventricle ejection fraction 
MVO Microvascular obstruction 
NO Nitric oxide 
NST-ACS Non-ST elevation acute coronary syndromes 
PAT Peripheral arterial tonometry 
P-PCI Primary percutaneous coronary intervention 
RHI Reactive hyperemia index 
RHI Reactive hyperemia index 
STEMI ST elevation myocardial infarction 
TMPG TIMI myocardial perfusion grade 
TnI Troponin I 


















Notwithstanding  all the improvements we have seen in primary angioplasty programs, with 
dramatic reductions in the time between symptom onset and the intervention, and despite a 
normal epicardial coronary artery flow is almost always achieved in a timely fashion after primary 
percutaneous coronary intervention (P-PCI) in patients with ST elevation myocardial infarction 
(STEMI), a significant proportion of patients (from 20% to 60%) has a poor outcome because of 
microvascular coronary damage.1,2  
The negative prognostic implications (both on the risk of left ventricle remodelling and on the risk 
of hard endpoints, including death) associated with coronary microvascular damage has been 
repeatedly confirmed, with several invasive and non-invasive indicators2–13. However, the precise 
mechanisms underlying coronary microcirculation dysfunction before and after the restoration of 
epicardial blood flow are largely unknown and likely to be multifactorial. Traditionally, coronary 
microvascular dysfunction in this setting is seen as a consequence of the primary epicardial event 
and/or of the coronary reperfusion, either pharmacological (thrombolysis) or mechanical (P-PCI). 
An alternative explanation is that either pre-existing or simultaneous coronary microvascular 
dysfunction may have by itself pathophysiological importance and contribute to the extension of 
the myocardial infarction, left ventricular remodelling and future events.14 Whatever theory 
concerning microvascular coronary dysfunction in patients with STEMI is correct (cause, 
consequence or both), endothelial function seems to be always at the core of the proposed 
mechanisms.  In fact, there is accumulating evidence that endothelial dysfunction (ED) is not just 
a risk factor and precursor of coronary artery disease, but it also plays a central role leading to 
acute coronary syndromes and STEMI.15 In patients with acute coronary syndromes, endothelial 
function, measured in the peripheral circulation, has been shown to be an independent predictor 
of events16, and subsequent normalization of endothelial function in these patients predicts a 
lower risk.17,18 Similarly, in patients with STEMI treated with P-PCI, peripheral ED was associated 
with larger infarctions as measured by troponin peak levels19 and endothelial function 
improvement six months after the event also correlated with lower end-diastolic left ventricular 
volumes.20  
It is therefore licit to speculate that previous ED or a blunted reaction of the endothelial 
mechanisms during STEMI may be a central component of coronary microvascular dysfunction in 
these patients and, as a consequence, a determinant of microvascular reperfusion, infarction 
extension and left ventricle remodelling. Ideally, this hypothesis would best be proved if 
endothelial function evaluation had been performed before the myocardial infarction, which 
evidently is not possible. Actually, most studies evaluating endothelial function in acute coronary 
syndrome patients were performed relatively late (several days or weeks) after the onset of the 
event19,21–25. As such, the worse results documented in patients with ED may just be a consequence 
of larger and more complicated infarcts. Assuming peripheral endothelial function (which is much 
more easy to measure) as a surrogate of coronary endothelial function, we would expect, if the 
above theory is true, worse acute ED, worse microvascular reperfusion and worse left ventricle 
remodelling in patients with larger infarctions.  
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The purpose of this pilot study was to evaluate the relation between peripheral endothelial 
function evaluated early (24 hours after reperfusion) by peripheral arterial tonometry, the 
presence of MVO and the extent of myocardial infarction.  
 
METHODS 
Patients admitted with a first STEMI and treated with P-PCI, were prospectively included. The 
inclusion criteria were: chest pain lasting at least 20 minutes and ST-segment elevation of at least 
1 mm in two or more contiguous leads; pain-to-balloon time lower than 6 hours (or between 6 
and 12 hours if ongoing pain); P-PCI performed with success on the culprit lesion in a native 
coronary artery; age over 18 years; informed consent obtained. The exclusion criteria were: 
previous history of myocardial infarction; patients presenting with left bundle-branch block and 
patients with implanted pacemaker; cardiogenic shock; known myocardial diseases and severe 
left ventricular hypertrophy (> 15 mm); previous coronary artery bypass surgery; percutaneous 
revascularization in the last 3 months; contraindication to adenosine.; any serious non-cardiac 
disease associated with a life expectancy of less than 12 months. The institutional ethical 
committee approved the study, which was conducted in compliance with the Declaration of 
Helsinki.  
Primary PCI and adjuvant treatment were performed according to standard of care for patients 
with acute STEMI.  Endothelial function was evaluated 24 hours after the P-PCI by peripheral 
arterial tonometry (PAT). Infarct extension was evaluated by contrast enhanced cardiac magnetic 
resonance (ceCMR) and by the release of troponin I. MVO was evaluated by ceCMR and also by 
indirect indicators, including ST resolution in the ECG and angiographic indicators (corrected TIMI 
frame count, TIMI myocardial perfusion grade and the index of microcirculatory resistance). 
Additionally, an echocardiographic exam was performed in the first hours after P-PCI.  
 
Evaluation of endothelial function – peripheral arterial tonometry  
Endothelial function was evaluated by peripheral arterial tonometry (PAT), using EndoPAT 2000 
(Itamar Medical®, Caesarea, Israel).  The protocol was the same followed in previous studies.26 
Briefly, a complete digital peripheral arterial tonometry (PAT) endothelial function test includes 
three phases: baseline, occlusion, and hyperemia. A blood pressure cuff is placed on one upper 
arm (study arm), while the other arm serves as a control (control arm). A PAT probe is positioned 
on one finger of each hand and set by the computer to inflate to 10 mm Hg below diastolic 
pressure or 70 mm Hg (the lower value is selected). Recordings are taken simultaneously from 
both fingers throughout the study. The response in the control finger not experiencing hyperemia 
can be used to adjust for systemic effects. After baseline data acquisition, the blood pressure cuff 
is inflated on one arm to suprasystolic pressures for 5 minutes. During the occlusion period, signals 
are absent from the hyperaemic finger but continue from the control finger. After cuff release, 
pulse amplitude increases in the hyperaemic finger. The pulse amplitude recordings are digitized 
and analysed by an automated, proprietary algorithm. Average pulse amplitude is calculated for 
each 30-second intervals after cuff occlusion for up to 5 minutes. As a measure of reactive 
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hyperemia, the pulse amplitude tonometry is then calculated as the ratio of the average amplitude 
of the PAT signal over a 1-min time interval starting 1 min after cuff deflation divided by the 
average amplitude of the PAT signal of a 3.5-min time period before cuff inflation (baseline). 
Subsequently, PAT index values from the study arm are normalized to the control arm. All these 
data are analysed by a computer in an operator-independent manner, to get the reactive 
hyperemia index (RHI). ED was defined as an RHI<1.67, as previously described26.  
 
Contrast enhanced cardiac magnetic resonance 
Cardiac magnetic resonance was performed in a subset of patients on the 7-8th day post-MI27, 
using a 1.5-T magnetic resonance imaging system (Avanto, Siemens Medical System, Erlangen, 
Germany) equipped with a dedicated cardiac software package and 8 available independent 
radiofrequency receiver channels, cardiac coil, and vectorcardiogram. After the acquisition of 
localizing images, long- and short-axis cine images were obtained, using retrospectively ECG-gated 
breath-hold segmented K-space balanced steady-state free precession pulse sequence (trueFISP) 
technique. The short-axis cine scans of 6-mm slices were used to determine the left ventricular 
mass, volume, and function (in-plane resolution 1.6x1.6mm; gap 2mm). STIR technique, a triple-
IR black-blood turbo spin echo pulse sequence was used for oedema quantification (area at risk). 
A bolus of contrast medium (gadopentetate dimeglumine - Magnevist, Schering AG, Berlin, 
Germany) was injected at a dose of 0.2 mmol/kg.  Early enhancement images for MVO assessment 
were obtained by acquiring an inversion-recovery segmented gradient echo T1-weighted 
sequence with a high inversion time (approximately 500 ms), 2-4 min after gadolinium injection. 
Delayed enhancement images were then obtained by acquiring an inversion-recovery segmented 
gradient echo T1-weighted sequence, 10 to 15 min after the bolus. All post-processing and 
analyses of the area at risk, myocardial infarct size, and presence of MVO were performed using 
CVI 42 Version 5 Software (Circle Cardiovascular Imaging Inc, Calgary, Canada) by a cardiologist 
experienced in CMR and blinded to all clinical and invasive physiological data. Area at risk was 
manually quantified on short-axis STIR sequences slices, delineating higher intensity areas (no 
threshold definition) at each slice, with subsequent computation for mass estimation. Infarct size 
was also assessed manually by planimetry on each short-axis slice, delineating the hyperenhanced 
area, including areas of hypoenhancement surrounded by the hyperenhanced area, the latter 
being considered MVO. Infarct size, as a percentage of left ventricular mass, was computed from 
the sum of hyperenhanced pixels from each of the 10 short-axis images divided by the total 
number of pixels within the left ventricular myocardium multiplied by 100% (21)28. MVO mass was 
also manually quantified as the sum of hypoenhanced pixels at delayed enhancement sequences 
as better spacial resolution was found when compared for early enhancement sequences29.  
 
Cardiac biomarkers 
Troponin I (TnI) values were used to quantify the extent of the myocardial infarction. With that 
purpose, blood tests for TnI measurement (by sandwich chemiluminescent immunoassay based 
LOCI™ technology, with a Dimension Vista™ Intelligent Lab System, Siemens Healthcare 
Diagnostics™) were collected at admission, every 6 hours for the first 24 hours (i.e., 0, 6, 12, 18, 
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24), and every 12 hours thereafter until 48 hours after admission (i.e., 36 and 48 hours). Peak TnI 
values and the area under the curve (AUC) of TnI release were calculated, as previously 
described.30. In order to account for lesion location, these values (AUC of TnI and peak TnI values) 
were indexed to area-at-risk scores (BARI and modified APPROACH scores31). 
 
Angiographic indicators of MVO 
At the end of the primary PCI procedure, a final run of images of the culprit artery was registered, 
at 30 frames per second, in order to measure TIMI frame count and TIMI perfusion grade. If 
necessary, the view was adjusted, so that the culprit vessel territory was not superimposed. The 
duration of cine filming was prolonged at least 3 cardiac cycles, to make sure that the entire 
washout phase was included. These two measures of flow were analysed offline by a blinded 
operator to other evaluations of the patient.  
The corrected TIMI frame count (cTFC) was measured as the number of frames required for 
epicardial contrast to reach standardized distal landmarks, as previously described.32 The first 
frame used for TIMI frame counting was defined as the frame in which a column of dye touched 
both borders of the coronary artery and moved forward, and the last frame was defined as the 
frame in which dye begins to enter (but does not necessarily fill) a standard distal landmark in the 
artery. These frame counts were corrected for the longer length of the left anterior descending 
coronary artery by dividing the TFC by 1.7, to arrive at the corrected TIMI frame count (cTFC). 
TIMI myocardial perfusion grade (TMPG) was classified according to the standard definition33, in 
which grade 3 corresponds to normal entry and exit of dye from the microvasculature (with a 
ground-glass appearance (“blush”) or opacification of the myocardium in the distribution of the 
culprit lesion that clears normally, and is either gone or mildly or moderately persistent at the end 
of the washout phase), and grade 0 corresponds to the failure of the dye to enter the 
microvasculature.  
The index of microvascular resistance (IMR) was measured immediately after the P-PCI, as 
previously described:34,35 a coronary pressure 0.014 pressure-wire (Certus. St. Jude Medical) was 
calibrated outside the body, equalized to the pressure reading from the guide catheter with the 
pressure sensor positioned at the ostium of the guiding catheter (after intracoronary 
administration of 1-2 ml of nitroglycerin), and then advanced to the distal two-thirds of the culprit 
vessel. Maximal hyperaemia was induced using intravenous adenosine (140 μg/kg/min) via a 
central venous catheter. Approximately 3 millilitres of room-temperature saline were injected 
down the culprit vessel, and the hyperaemic transit times were recorded and automatically 
averaged, using the RadiAnalyzer™ Xpress (St. Jude Medical) console. Mean distal coronary 
pressures were recorded during peak hyperaemia. The IMR was calculated by multiplying the 








An echocardiogram was performed in the first hours, by an operator blinded to the EndoPAT, ECG 
and angiographic results, using a commercially available ultrasound system (Vivid 7 GE 
Healthcare). Measures were performed offline with EchoPAC version 113 GE Healthcare by two 
observers. Parameters were measured several times and then averaged. The echocardiographic 
quantification left ventricular ejection fraction was determined from four- and two-chamber 
views using a semiautomatic border detection based on feature tracking imaging.36 Left 
ventricular (LV) regional wall-motion analysis was performed with the calculation of the wall-
motion score index (WMSI) by 2D echocardiography, according to the European Society of 
Echocardiography Recommendations, using the 17-segment model on a 1–5 scale: 1-normal, 2-
hypokinesia, 3-akinesia, 4-dyskinesia, 5-aneurysmal. 37 Mitral inflow was obtained by pulsed-wave 
Doppler-echocardiography with the sample volume between mitral leaflet tips during diastole, 
and mitral annulus velocities were obtained from the media of septal and lateral annulus by tissue 
Doppler imaging. The ratio of early diastolic mitral inflow velocity to early diastolic mitral annular 
velocity (E/e´) was calculated. Left atria volumes were obtain by 2D echocardiography and indexed 
to body area. Global LV longitudinal strain (GLS) was assessed using speckle-tracking analysis with 
automated function imaging. Peak longitudinal strain was defined as the change in length of the 
myocardium from end-diastole to end-systole and expressed as a percentage: longitudinal strain 
(%) = (L end-systole - L end-diastole)/L end-diastole x 100%, where L is the length of the region of 
interest. GLS was obtained from 2D grey scale images of the apical four-chamber, two-chamber, 
and long-axis view with optimized frame rate (50–90 frames/sec). Software identified the 
endocardial border, and myocardial motion was automatically tracked in each imaging view. In 
segments with poor tracking, the observer readjusted the endocardial trace line until a better 
tracking was achieved. Mean of the peak systolic longitudinal strain values from the 17 LV 
segments were calculated to determine LV GLS.  
 
Statistical Analysis 
Continuous variables are presented as mean ± standard deviation (normal distribution) or as 
median and interquartile range (non-normal distribution); categorical variables are presented as 
frequencies.  All analyses of ED (i.e., RHI<1.67 vs. >1.67) were performed using independent 
sample T-Test for continuous variables with a normal distribution, Mann-Whitney Test, for 
continuous variables with a non-normal distribution and Chi-square for categorical variables (with 
Fisher correction when applicable). Analysis of RHI as continuous variables was performed using 
a Pearson’s correlation for continuous variables with a normal distribution and Spearmans’s rho 
correlation for continuous variables with a non-normal distribution. Statistical tests and 
corresponding p-values were two-sided and a p value <0.05 was considered as statistically 
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RESULTS 
Thirty eight patients were included (mean age 60.0±13.7 years, 29 males). Mean values of RHI 
were 1.87±0.60 and 16 patients (42.1%) had ED (RHI<1.67). 
Main characteristics of the population according to the presence of ED are presented in Table 1. 
The flow chart of the exams performed in the study is presented in Figure 1. 
There were no significant differences in physical characteristics, risk factors or previous 
medication between the two groups. Admission blood tests were also similar between both 
populations, except for hs-CRP, which showed a tendency for higher values in patients with ED. 
There were no significant differences in ischemic (pain-to-balloon) time between patients with 
and without ED, although there was a trend for lower door-to-balloon times in patients with 
RHI<1.67. Patients with ED had a prevalence of multivessel disease that was almost twice the one 
observed in patients without ED (68.8% vs. 36.4%), although this difference was not statistically 
significant (p=0.10). Syntax score also tended to be higher in patients with ED.  There was a clear 
trend towards higher area-at-risk, both measured by APPROACH and BARI scores (p=0.08 and 
0.07, respectively) and these two scores showed a weak, but significant inverse correlation with 
RHI (r=-0.426, p=0.008 and r=-0.361, p=0.026, respectively). RHI values tended to be lower in 
patients in which the left anterior descending artery (LAD) was the culprit vessel (1.74±0.65 vs. 
2.02±0.51 in other vessels, p=0.15). Patients with ED also showed a trend for worse initial TIMI 
score (TIMI 0-1: 93.8% vs. 72.7% in patients without ED). Finally, treatment options (use of 
mechanical aspiration, stent implantation technique and use of abciximab) were similar in patients 
with or without RHA<1.67 (Table 1).  
 
Extent of the infarction 
Both peak values of TnI and the AUC of TnI release were significantly higher in patients with ED 
(Figure 2). These differences were even more significant when troponin I values were indexed to 
the area-at-risk, both by the APPROACH and the BARI scores (Table 2).  
Left ventricular ejection fraction by echocardiography analysis was significantly lower and wall 
motion score index significantly higher in patients with ED (Figure 3). Likewise, global longitudinal 
strain was significantly higher in patients with an RHI<1.67, although there were no other 
significant differences in Doppler variables (Table 3). 
In the ceCMR, patients with ED had significantly lower left ventricular ejection fraction and higher 
wall motion score index, confirming the echocardiography results. There was a trend for more 
transmural necrosis (22.2% vs. 63.6%, p=0.06) and higher infarct mass (median value 10.1 vs. 17.5, 
p=0.08) in patients with RHI<1.67. The percent mass of infarct indexed to area-at-risk scores 
(APPROACH and BARI) also tended to be higher in patients with ED (Table 4). 
 
 




ECG resolution of ST elevation was numerically inferior immediately after PCI (median 60.5% [IQR 
72.0%] vs. 76.5% [IQR 41.0%]), and at 90 minutes after reperfusion (median 69.0% [IQR 53.0%] vs. 
78.5 [IQR 28.0]) in patients with ED, although these differences were not statistically significant 
(p=0.23 and 0.07, respectively).  However, residual total ST elevation was significantly higher in 
both ECGs performed immediately after the PCI (5.0 mV [12.0 mV, median vs. 2.5 mV [IQR 5.09 
mV], p=0.048) and at 90 minutes (median 3.0 mV [IQR 7.0 mV] vs. 1.3 mV [IQR 4.0 mV]) in patients 
with RHI<1.67. 
All angiographic measures of microvascular dysfunction after STEMI showed important trends 
towards worse results in patients with RHI<1.67: cTFC was higher (19.5 [12.0] vs. 16.4 [IQR7.0], 
p=0.07) and TMPG 2 or 3 was less frequent (56.3% vs. 86.4, p=0.09). Likewise, there was a clear 
trend towards higher values of IMR in patients with ED: median values 40.5 (IQR 54.4) vs. 22.0 
(IQR 26.0), p=0.09. The prevalence of microvascular coronary damage, defined as an IMR >24 
(median value) was almost 2 times higher in patients with ED (36.4% vs. 62.5%, p=0.11). 
Contrast enhanced CMR showed a significant higher proportion of patients with MVO when ED 
was present (11.1% vs. 54.5%, p=0.03). The MVO mass was higher in the group with RHI<1.67 
(median value 5.3 vs. 6.8), although the difference was not statistically significant.  
 
DISCUSSION 
To our knowledge, this is the first study reporting the association of early (24 hours) measured 
peripheral endothelial dysfunction with microvascular coronary damage and with myocardial 
infarction extension in patients with STEMI treated with P-PCI. 
The presence of ED in patients with ACS has been repeatedly demonstrated: Elbaz and colleagues 
evaluated invasively the endothelial function in non-culprit arteries in patients with NST-ACS using 
intracoronary infusion of acetylcholine and found that 81% of patients had a blunted response to 
this endothelium-dependent vasodilator.38  Spiro and colleagues used flow-mediated dilation and 
low flow-mediated constriction to demonstrate that endothelial function is significantly more 
compromised in patients with non-ST elevation acute coronary syndromes (NST-ACS), as 
compared to patients with stable coronary artery disease, both before and after angioplasty.39 
More recently, Careri evaluated endothelial function in the first 12 hours both in stable and NST-
ACS patients, and showed that flow-mediated dilation is significantly lower in acute patients.18 
Finally, we also demonstrated that patients with STEMI treated with P-PCI have a high prevalence 
of ED evaluated with PAT 3 to 5 days after the event.19. 
Importantly, peripheral endothelial function as been shown to relate closely with coronary 
microvascular dysfunction, with several different techniques40–42, including PAT43. However, the 
exact role of peripheral ED (as a surrogate for coronary ED) in the early phase after P-PCI was 
never investigated before. Indeed, peripheral endothelial function testing is particularly 
challenging in acute patients, for several reasons: in addition to the unpredictable nature of the 
acute event onset, the unstable condition and the pain, anxiety and fear patients usually 
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experience, most of the times it is not possible to comply with several recommendations for 
endothelial function evaluation (including fasting state, morning exam, avoidance of caffeine or 
smoking, etc.).44. Additionally, patients were evaluated after an arterial puncture (for the urgent 
angiography) and several venous punctures (both for blood tests and for drugs administration). 
Finally, the time of the day was not the same for all measurements (since it depended on the hour 
of the primary angioplasty) and, accordingly, the patients could be or not on a fasting state. 
Notwithstanding all these potential pitfalls, the RHI results we describe in this population are 
similar to the values reported by Schoenenberger and colleagues (1.82±0.48) in the only published 
study that also measured RHI 24 hours after P-PCI in STEMI patients.21 Accordingly, the percentage 
of patients with an RHI<1.67 (42.1%) is very consistent with the results observed in all studies that 
reported this information in the acute/subacute phase of ACS: 47.9% in the study by Yamomoto 
et al23, 43.1% in our pilot study19 and 45.0% in the study by Schoenenberger et al.21 
Patients with an RHI<1.67 had significantly higher values of both peak TnI and AUC of TnI, either 
total or indexed to the area-at-risk scores. Correspondingly, they had a 3 times higher risk of 
transmural necrosis and a clear trend to higher total and percent infarct masses in the ceCMR. In 
line with these results, they also had lower LVEF and higher (worse) WMSI, both in the initial 
echocardiogram and in the ceCMR.  
Similarly, patients with an RHI<1.67 had a clear trend towards worse electrocardiographic 
(particularly residual ST elevation after P-PCI) and angiographic (IMR, cTFC and TMPG) indicators 
of microvascular reperfusion. Altogether, these data suggest a higher damage of coronary 
microvasculature in patients with peripheral ED, which is confirmed by the results of the ceCMR: 
patients with an RHI<1.67 had an almost 5 times higher probability of having MVO on the ceCMR, 
and tended to have higher obstruction masses. 
The fact that patients with ED had a trend for more severe coronary artery disease (the prevalence 
of multivessel disease was almost two times higher in patients with ED and SYNTAX score also 
tended to be higher in these patients) is in accordance with our previous work22 and suggests that 
at least the previous severity of coronary artery disease is related with ED. We also found a trend 
for lower initial TIMI flow in patients with ED, which his in agreement with a recent study by 
Kandhai-Ragunat and colleagues. These authors documented lower RHI values (although 
measured 4 to 6 weeks after the STEMI) in patients with an occluded artery before the P-PCI, as 
compared with patients with a patent artery (2.08±0.34 vs. 1.75±0.35; p<0.007),24 suggesting that 
ED may be involved in microvascular reperfusion in STEMI patients.  
However, we also found a significant negative correlation between both area-at-risk scores and 
RHI and there was a trend for lower RHI in patients that had the LAD as culprit artery. Both larger 
areas-at-risk and the LAD as culprit artery are associated with larger infarctions, implying that the 
documented lower RHI values may translate the extension of the infarction, as opposed to being 
part of the pathophysiological process that caused it. Indeed our finding that patients with ED in 
the first 24 hours after STEMI have larger infarcts and lower ejection fraction are in line with the 
evidence of neuro-humoral activation in patients with heart failure. In fact, it was already 
demonstrated that the reduction in stroke volume produces a lower endothelial shear stress, 
which causes a dysregulation in nitric oxide (NO) synthase isoforms gene expression45,46, 
eventually leading to a reduced NO bioavailability.47 Furthermore, there is an additional reduction 
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in NO bioavailability caused by direct NO destruction by reactive oxygen species, mainly driven by 
an increase in angiotensin II and aldosterone activity, and purine metabolism.48  
While we cannot infer from our results if the ED was a cause or a consequence of the severity of 
the myocardial infarction, it is reasonable to conclude that peripheral ED in these patients may be 
a marker of the severity of the myocardial disease and, therefore, of its systemic consequences, 
which makes it useful to assess the effectiveness of therapy and predict events, independently of 
its exact pathophysiological role.  
In fact, in patients with acute myocardial infarction, early treatment with statins, currently known 
to reduce events, was initially evaluated through its beneficial effect in the endothelial 
function.49,50 Likewise, in heart failure patients, peripheral endothelial function has been described 
as tool to predict the response to cardiac resynchronization therapy, and ED improvement after 
CRT correlated with functional improvement51, being related to an increase in cardiac output52, 
likely mediated by shear-stress.53  
In summary, albeit demonstrating the exact role of ED in STEMI patients is not possible at this 
point, we demonstrated that its measurement early after primary PCI is feasible and related both 
with the extent of infarct and MVO, which makes it a valuable tool both for identifying high risk 
patients and for testing new pharmacological or device-based strategies. 
 
STUDY LIMITATIONS 
This study is limited by the small number of patients and larger studies will be necessary to confirm 
these results. Additionally, the EndoPAT exams were not performed according the 
recommendations for endothelial function evaluation: patients were not fasting, coffee or tea 
consumption was not excluded and the morning hour of the exam was not respected. However, 
measuring endothelial function at the acute phase was exactly the purpose of the study. 
Importantly, all the operators performing the EndoPAT evaluation were highly trained in this 
procedure, having participated in several previous studies. 
 
CONCLUSIONS 
The presence of ED evaluated by PAT at 24 hours after P-PCI in patients with STEMI is related with 
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Figure 1. Study flow chart 
Figure 2.  Area under the curve of and peak values of troponin I (determined from 7 scheduled 
blood tests in the first 48 hours after P-PCI), according to the presence of endothelial dysfunction 
(RHI<1.67) 
Figure 3. Left ventricular ejection fraction (mean ± standard deviation) and wall motion score 
index (median and interquartile range) evaluated by Echo, according to the presence of 
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TABLES 
Table 1. Baseline characteristics according to the presence of endothelial dysfunction (RHI<1.67). 
Variable Total Population 
(n=38) 
Endothelial Dysfunction (RHI<1.67) p value d 
No (n=22) Yes  (n=16) 
Physical characteristics     
   Age (years) a 60.0±13.7 60.1±12.4 59.8±15.7 0.94 x 
   Male gender b 29 (76.3) 18 (81.8) 11 (68.8) 0.58 e 
   BMI a 27.2±4.0 27.4±4.5 27.1±3.3 0.82 x 
   Waist circumference a 100.0±11.5 101.1±12.6 98.5±9.9 0.55 x 
Risk Factors and previous coronary disease b 
   Hypertension 26 (68.4) 16 (72.7) 10 (62.5) 0.50 x 
   Diabetes 12 (31.6) 8 (36.4) 4 (25.0) 0.46 x 
   Dyslipidemia 19 (50.0) 11 (50.0) 8 (50.0) 1.00 x 
   Active smoking 13 (34.2) 9 (40.9) 4 (25.0) 0.31 x 
   Previous angina 7 (18.4) 6 (27.3) 1 (6.3) 0.22 e 
   Previous revascularization 2 (5.3) 1 (4.5) 1 (6.3) 0.61 e 
Previous medication b     
   Aspirin / Clopidogrel 3 (7.9) 2 (9.1) 1 (6.3) 0.73 e 
   ACEi/ARBs 13 (34.2) 10 (45.5) 3 (18.8) 0.11 x 
   Beta-blockers 1 (2.6) 1 (4.5) 0 (0.0) 0.85 e 
   Statins 4 (10.5) 2 (9.1) 2 (12.5) 0.89 e 
Admission laboratory values 
   Creatinine (mg/dL) c 0.88 (0.32) 0.87 (0.54) 0.90 (0.19) 0.67 
   NT-pro-BNP (pg/mL)c 158.5 (305.0) 154 (365) 163 (250) 0.95 
   hs-CRP (mg(dL) c 0.57 (0.71) 0.29 (0.45) 0.81 (0.98) 0.06 
   Glucose (mg/dL) c 136.0 (63.0) 131.0 (60.0) 145.5 (81.8) 0.51 
   HbA1c (%)c 5.8 (1.3) 5.7 (1.4) 5.9 (2.1) 0.69 
Ischemic times     
   Pain-to-balloon time (min) c 209 (173) 209 (186) 211 (167) 0.94 
   Door-to-balloon time (min) c 75 (52) 79 (46) 57 (44) 0.06 
Angiographic characteristics     
   Culprit artery b     
       Left anterior descending 21 (53.3) 11 (50.0) 10 (62.5) 0.89 e 
       Left circumflex 7 (18.4) 5 (22.7) 2 (12.5) 
       Right coronary artery 10 (26.3) 6 (27.3) 4 (25.0) 
   Multivessel disease b 19 (50.0) 8 (36.4) 11 (68.8) 0.10 e 
   SYNTAX score c 17.8±6.2 16.8±6.2 19.0±6.0 0.29 
   Initial TIMI flow 0-1 b 31 (81.6) 16 (72.7) 15 (93.8) 0.22 
Area at risk scores c     
   APPROACH score 27.8 (3.0) 28.1 (5.0) 29.7 (10.0) 0.08 
   BARI score 28.5 (6.0) 26.7 (7.0) 30.2 (10.0) 0.07 
Angioplasty variables b     
   Mechanical aspiration 16 (42.1) 9 (40.9) 7 (43.8) 0.86 
   Balloon pre-dilatation 21 (55.3) 13 (59.1) 8 (50.0) 0.58 
   Stent implantation 36 (94.7) 20 (90.9) 16 (100.0) 0.61 
   Balloon post-dilatation 24 (63.2) 14 (63.6) 10 (62.5) 0.94 
   Abciximab treatment 9 (23.7) 4 (18.2) 5 (31.5) 0.58 
   Mechanical aspiration 16 (42.1) 9 (40.9) 7 (43.8) 0.86 
a Presented as mean±standard deviation; b Presented as number (%); c Presented as median (interquartile range); d Independent t-test 
for continuous variables with a normal distribution, Mann-Whitney test for continuous variables with a non-normal distribution, Chi-
Square for categorical variables; e Yate’s correction 
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Table 2. Troponin I release according to the presence of endothelial dysfunction (RHI<1.67) 
 
Variable a, b Total Population 
(n=38) 
Endothelial Dysfunction (RHI<1.67) p value c 
No (n=22) Yes  (n=16) 
Peak TnI values     
   TnIpeak 95 (96) 67 (81) 118 (186) 0.024 
   TnIpeak (APPROACH) 25 (32) 17 (20) 34 (56) 0.009 
   TnIpeak (BARI) 24 (31) 17 (22) 33 (47) 0.008 
   TnIpeak (2 scores) 24 (31) 17 (21) 33 (55) 0.009 
Area under the curve of TnI     
   TnIAUC 1293 (1580) 1076 (1042) 2305 (2486) 0.012 
   TnIAUC (APPROACH) 403 (522) 315 (303) 664 (1080) 0.008 
   TnIAUC (BARI) 383 (448) 314 (326) 618 (799) 0.007 
   TnIAUC (2 scores) 393 (482) 314 (300) 641 (984) 0.007 
a Presented as median (IQR); b Peak value  and area under the curve (AUC) of 7 troponin I (TnI, in mg/dL) measurements 
performed in the first 48 hours after the primary angioplasty; total values and values indexed to the APPROACH, BARI 
or both are presented; c Mann-Whitney Test 
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Table 3. Echocardiographic results according to the presence of endothelial dysfunction 
(RHI<1.67) 
 
Variable Total Population Endothelial Dysfunction (RHI<1.67) p value c 
No Yes 
2D measurements  (n=26) (n=15) (n=11)  
   LVTdV (ml) a 109.8±23.4 106.5±30.2 113.8±11.4 0.48 
   LVTsV (ml) a 55.9±12.6 51.1±12.3 61.7±10.9 0.047 
   LVEF (%)a 48.6±7.1 51.4±4.7 45.3±8.3 0.045 
   Wall motion score index b 1.44 (0.41) 1.35 (0.47) 1.77 (0.47) 0.006 
   Left atria volume (ml/m2) a 36.1±11.0 36.7±12.1 35.3±10.0 0.78 
Doppler measurements  (n=21) (n=11) (n=10)  
   E/A ratio a 1.10±0.40 1.17±0.40 0.97±0.0.39 0.30 
   E/e’ ratio  a 8.91±3.30 8.83±3.91 9.05±2.18 0.89 
2D speckle tracking imaging (n=21) (n=11) (n=10)  
   Global longitudinal strain a -13.16±2.35 -14.32±1.72 -11.89±2.35 0.014 
a Presented as mean±standard deviation; b Presented as median (interquartile range); c Independent t-test for continuous variables 
with a normal distribution.  Mann-Whitney test for continuous variables with a non-normal distribution. LVEdV – left ventricular end 
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Table 4. ceCMR results according to the presence of endothelial dysfunction (RHI<1.67) 
 
Variable Total Population 
(n=29) 
Endothelial Dysfunction (RHI<1.67) p value d 
No (n=18) Yes  (n=11) 
LVTdV (ml) a 138.6±26.9 139.2±26.5 137.5±28.9 0.87 
LVTsV (ml) a 63.5±21.0 59.3±19.4 70.4±22.6 0.17 
LVEF (%)a 53.9±8.4 56.6±8.1 49.5±7.2 0.025 
Wall motion score index a 1.37±0.33 1.28±0.31 1.53±0.32 0.05 
Edema mass b 19.1 (19.0) 17.2 (14.1) 21.2 (28.6) 0.28 
Transmural necrosis c 12 (38.7) 4 (22.2) 7 (63.6) 0.06 e 
Infarct mass     
    Total b 11.6 (9.3) 10.1 (10.3) 17.5 (15.4) 0.08 
    Percent b 11.5 (13.7) 10.2 (7.6) 17.5 (21.8) 0.10 
       Indexed to APPROACH 3.2 (7.0) 2.7 (2.6) 4.9 (11.5) 0.10 
       Indexed to BARI 3.4 (5.8) 2.3 (2.7) 5.1 (11.5) 0.09 
Salvage mass b 5.0 (14.0) 5.0 (8.8) 4.7 (27.6) 0.87 
Microvascular obstruction      
   MVO present c 8 (27.6) 2 (11.1) 6 (54.5) 0.03 e 
   MVO mass b 6.1 (15.5) 5.3 (-) 6.8 (20.8) 0.29 
a Presented as mean±standard deviation; b Presented as median (interquartile range); c  Presented as number (%); d Independent t-test 
for continuous variables with a normal distribution, Mann-Whitney test for continuous variables with a non-normal distribution, Chi-
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